Supplementary Information for

Isotopologues of Potassium 2,2,2-Trifluoroethoxide for Applications in Positron Emission Tomography and Beyond

Qunchao Zhao, Sanjay Telu*, Susovan Jana, Cheryl L. Morse, Victor W. Pike*

Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Building 10, Rm B3C346, 10 Center Drive, Bethesda, MD 20892, USA.

*Corresponding authors: sanjay.telu@nih.gov; pikev@mail.nih.gov

Contents

Supplementary Notes	S2
Supplementary Methods	S3
1. Optimization of 2,2,2-trifluoroethanol synthesis	S3
2. The synthesis of precursors and standards	S4
3. General HPLC methods	S48
4. Syntheses of [11C]fluoroform and [18F]fluoroform	S49
5. General procedure for producing [11C/18F]2,2,2-trifluoroethanol	S52
6. General procedure for radio-2,2,2-trifluoroethoxylation	S55
7. HPLC analysis of ¹¹ C- and ¹⁸ F- labeled products	S61
Supplementary Abbreviations	S243
Supplementary NMR spectra	S244
Supplementary References	S377

Supplementary Notes

Fluoroform was purchased from Sigma-Aldrich. Other commercially available chemicals, reagents, and solvents were purchased primarily from Sigma-Aldrich, Alfa Aesar, TCI, AmBeed, and Chemscene, and used as received. ¹H (400.13 MHz), ¹³C (100.62 MHz), and ¹⁹F (376.47 MHz) NMR spectra were recorded on an Avance 400 instrument (Bruker) at RT in deuterated solvents. All spectra are reported with chemical shifts in parts per million. NMR data are reported as follows: chemical shift (δ (ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, q = quint = quint, q = quint, q = quintdt = doublet of triplets, dq = doublet of quartets, qd = quartet of doublets, td = triplet of doublets, *tt* = triplet of triplets, *ddd* = doublet of doublet of doublets, *dtd* = doublet of triplet of doublets, tdd = triplet of doublet of doublets, m = multiplet, app = apparent), coupling constants (*J* in Hz), and integration. TMS ($\delta = 0$ ppm) was used as an internal standard for ¹H and ¹³C-NMR spectroscopy and 1,1,1-trifluorobenzene ($\delta = -62$ ppm) as internal standard for ¹⁹F-NMR spectroscopy. NMR data were processed using MestReNova. HRMS data (ESI-TOF) were obtained at the Bioorganic Chemistry Laboratory of NIDDK (NIH). Melting points were measured with a digital SMP20 (Stuart) melting point apparatus. Radiochemistry was performed in a lead-shielded hot-cell for protection of personnel from radiation. HPLC analyses were performed on Shimadzu HPLC systems. which were also coupled with UV absorbance and radioactivity detectors. The HPLC chromatograms were processed using GraphPad Prism 8. Flash chromatography was performed on silica gel; eluent compositions are reported as v/v.

Supplementary Methods

1. Optimization of 2,2,2-trifluoroethanol synthesis.

1.1. Optimization.

Paraformaldehyde (y mmol) and t-BuOK (z mmol), followed by DMF (3.0 mL) were added. to a round-bottomed flask equipped with a magnetic stirrer bar under argon. Then fluoroform (x mmol in DMF; 0.3 M) was added. The flask was capped loosely, and the contents stirred at RT for t h. The reaction was then quenched with water (0.5 mL). The yield of 2,2,2-trifluoroethoxide (δ –76.3 ppm) from fluoroform (δ –78.9 ppm) was determined by ¹⁹F NMR spectroscopy on the crude reaction mixture.

Supplementary Table 1. Optimization of the yield of 2,2,2-trifluoroethanol from the reaction of fluoroform with paraformaldehyde.

HCE . (CH O)	t-BuOK (z mmol)	Que	nched with water	- F 0\\\		
$HCF_3 + (CH_2O)_n$ x mmol y mmol		DMF, t, RT	-		➤ F ₃ C´ OH	
Entry	x	у	z	<i>t</i> (h)	Yield (%)	
1	0.9	0.3	0.3	2	41	
2	0.9	0.3	0.6	2	4	
3	0.9	0.3	0.9	2	trace	
4	0.6	0.3	0.3	2	21	
5	0.3	0.3	0.3	2	33	
6	0.15	0.3	0.3	2	68	
7	0.1	0.3	0.3	2	95	
8	0.1	0.4	0.3	2	75	
9	0.1	0.15	0.3	2	12	
10	0.1	0.1	0.3	2	12	
11	0.1	0.3	0.3	3	96	
12	0.1	0.3	0.3	1	91	
13	0.1	0.3	0.3	0.5	88	
14 ^a	0.1	0.3	0.3	3	2	
15 ^b	0.1	0.3	0.3	3	trace	
16 ^c	0.1	0.3	0.3	3	trace	
17 ^d	0.1	0.3	0.3	3	trace	
18 ^e	0.1	0.3	0.3	3	trace	

 $[^]at$ -BuONa as the base; b NaH as the base; c DMA as the solvent; d THF as the solvent; e DMSO as the solvent

1.2. One-pot 2,2,2-trifluoroethoxylation of 2-chloropyrimidine (1).

To a round-bottomed flask equipped with a magnetic stirrer bar was added paraformaldehyde (0.5 mmol) and t-BuOK (0.5 mmol), followed by DMF (3 mL) under

argon. A DMF solution (0.6 mL) of fluoroform (0.17 mmol; 0.3 M) was added and the solution was stirred at RT for 3 h. 2-Chloropyrimidine (0.5 mmol) in DMF (0.5 M) was then added and the reaction mixture was stirred either at RT or at 60 °C for another 2 h. The reaction was then quenched with water (0.5 mL). The yield of 2-(2,2,2-trifluoroethoxy)pyrimidine (1) (δ –73.8 ppm) was determined by ¹⁹F NMR spectroscopy on the crude reaction mixture.

HCF₃
$$\xrightarrow{\text{(CH}_2O)_n, \, ^t\text{BuOK}}$$
 [CF₃CH₂OK] $\xrightarrow{\text{1)}}$ RT, 2 h 2) Water quench 1 71% yield by ¹⁹F NMR

Supplementary Figure 1. One-pot 2,2,2-trifluoroethoxylation of 2-chloropyrimidine to give 1.

1.3. One-pot 2,2,2-trifluoroethoxylation of naphthalen-1-yl iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (2).

The procedure used for the 2,2,2-trifluoroethoxylation of 2-chloropyrimidine was used instead with naphthalen-1-yl iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (0.5 mmol). The yield of 1-(2,2,2-trifluoroethoxy)naphthalene (**2**) (δ –73.5 ppm) was determined by ¹⁹F-NMR spectroscopy.

HCF₃
$$\xrightarrow{\text{(CH}_2O)_n, \, ^t\text{BuOK}}$$
 $\text{[CF}_3\text{CH}_2\text{OK]}$ $\xrightarrow{\text{1) 60 °C, 2 h}}$ 2) Water quench $\text{63\% yield by }^{19}\text{F NMR}$

Supplementary Figure 2. One-pot 2,2,2-trifluoroethoxylation of naphthalen-1-yl iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide to give **2.**

2. The synthesis of precursors and standards.

2.1. General procedure 1 for the synthesis of heterocycle precursors and standards.

R
$$\stackrel{\mathsf{X}}{\longleftarrow}$$
 + F₃C $\stackrel{\mathsf{OH}}{\longrightarrow}$ OH $\stackrel{\mathsf{NaH}}{\longrightarrow}$ R $\stackrel{\mathsf{Het}}{\longrightarrow}$ O $\stackrel{\mathsf{CF}_3}{\longrightarrow}$ X = Cl, Br, NO₂, SO₂Me

Supplementary Figure 3. General procedure 1 for the synthesis of 2,2,2-trifluoroethyl heterocyclic ethers.

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (1 equiv.) and DMF (0.5 M) under argon. 2,2,2-Trifluoroethanol (2 equiv.) was then added dropwise, and the reaction mixture was stirred at RT for 5 min under argon. Precursor (1 equiv.) was then added and stirred vigorously at 80 °C for 30 min. After completion of the reaction, as assessed with TLC, the reaction mixture was cooled to RT, poured onto water, and extracted with DCM (2×25 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography using hexane-ethyl acetate to afford the corresponding 2,2,2-trifluoroethyl heterocyclic ether.

2-(2,2,2-Trifluoroethoxy)pyrimidine (1).

General procedure 1 with 2-chloropyrimidine on a 2.0 mmol scale $N \cap CF_3$ followed by flash chromatography (ethyl acetate/n-hexane,1: 4) gave 1 as a colorless oil (274 mg, 77% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.54 (d, J = 4.8 Hz, 2H), 7.04 (t, J = 4.8 Hz, 1H), 4.79 (q, J = 8.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.85 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.85, 159.70, 123.39 (q, J = 277.6 Hz), 116.52, 63.57 (q, J = 36.5 Hz). MS (ESI): 179.1 [M+H]⁺. HRMS (ESI) for $C_6H_6N_2OF_3$ [M+H]⁺: calc'd: 179.0432; found: 179.0430.

6-(2,2,2-Trifluoroethoxy)nicotinaldehyde (3).

General procedure 1 with 6-chloronicotinaldehyde on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 5) gave **3** as a pale-yellow solid (353 mg, 86% yield). Mp: 52–54 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 9.99 (s, 1H), 8.63 (d, J = 2.2 Hz, 1H), 8.14 (dd, J = 8.6, 2.2 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 4.85 (q, J = 8.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.77 (t, J = 8.3 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃): δ (ppm) 189.36, 165.30, 152.10, 138.70, 128.12, 123.51 (q, J = 277.4 Hz), 112.32, 62.91 (q, J = 36.3 Hz). MS (ESI): 206.0 [M+H]⁺. HRMS (ESI) for C₈H₇NO₂F₃ [M+H]⁺: calc'd: 206.0429; found: 206.0426.

5-Bromo-2-(2,2,2-trifluoroethoxy)pyridine (4).

General procedure 1 with 5-bromo-2-nitropyridine on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **4** as a colorless oil (342 mg, 67% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.19 (d, J = 2.4 Hz, 1H), 7.72 (dd, J = 8.7, 2.5 Hz, 1H), 6.78 (d, J = 8.7

Hz, 1H), 4.72 (q, J = 8.5 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.84 (t, J = 8.6 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 160.78, 147.49, 142.06, 123.73 (q, J = 277.5 Hz), 113.56, 112.93, 62.57 (q, J = 36.1 Hz). (Known compound).¹

4,6-Dimethyl-2-(2,2,2-trifluoroethoxy)nicotinonitrile (5).

General procedure 1 with 2-chloro-3-cyano-4,6-dimethylpyridine on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-Me N O CF₃ hexane, 1: 10) gave **5** as a white solid (201 mg, 87% yield). Mp: 54–56 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.80 (s, 1H), 4.85 (q, J = 8.4 Hz, 2H), 2.47 (s, 3H), 2.45 (s, 3H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm) –73.71 (t, J = 8.2 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 161.84, 160.71, 155.41, 123.39 (q, J = 277.6 Hz), 119.32, 114.09, 94.53, 62.64 (q, J = 36.6 Hz), 24.52, 20.26. MS (ESI): 231.1 [M+H]⁺. HRMS (ESI) for C₁₀H₁₀N₂OF₃ [M+H]⁺: calc'd: 231.0745; found: 231.0742.

3-Benzyl-6-bromo-2-(2,2,2-trifluoroethoxy)quinoline (6).

Ph on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 1: 20) gave **6** as a white solid (313 mg, 79% yield). Mp: 90–92 °C .¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.77 (d, J = 1.7 Hz, 1H), 7.70–7.56 (m, 3H), 7.37–7.28 (m, 2H), 7.26–7.21 (m, 3H), 4.88 (q, J = 8.5 Hz, 2H), 4.04 (s, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.46 (t, J = 8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 158.78, 143.58, 138.53, 136.91, 132.58, 129.45, 129.37, 128.83, 127.42, 126.91, 126.82, 123.95 (q, J = 277.3 Hz), 118.27, 62.71 (q, J = 36.1 Hz), 36.21. MS (ESI): 396.0 [M+H]⁺. HRMS (ESI) for C₁₈H₁₄NOF₃Br [M+H]⁺: calc'd: 396.0211; found: 396.0208.

6-Methoxy-1-(2,2,2-trifluoroethoxy)isoquinoline (7).

General procedure 1 with 1-chloro-6-methoxyisoquinoline on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave **7** as a white solid (473 mg, 92% yield). Mp: 80–82 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.16 (d, J = 9.1 Hz, 1H), 7.90 (d, J = 5.9 Hz, 1H), 7.19 (dd, J = 12.8, 4.0 Hz, 2H), 7.03 (d, J = 2.2 Hz, 1H), 4.92 (d, d = 8.6 Hz, 2H), 3.93 (d = 3.93 (d = 3.94 NMR (101 MHz, CDCl₃) d (ppm): 161.68, 158.62, 140.48, 139.96, 125.92, 124.09 (d = 277.3 Hz), 119.44, 116.22, 114.23, 104.86, 62.56 (d = 36.0 Hz), 55.63. MS

(ESI): 258.1 [M+H]⁺. HRMS (ESI) for C₁₂H₁₁NO₂F₃ [M+H]⁺: calc'd: 258.0742; found: 258.0740.

3-(2,2,2-Trifluoroethoxy)-1,2-benzisothiazole (8).

CF₃

General procedure 1 with 3-chloro-1,2-benzisothiazole on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 1: 10) gave **8** as a colorless oil (178 mg, 76% yield). ¹H NMR (400 MHz,

CDCl₃) δ (ppm): 7.97 (*d*, J = 8.1 Hz, 1H), 7.79 (*d*, J = 8.2 Hz, 1H), 7.56 (*t*, J = 7.6 Hz, 1H), 7.43 (*t*, J = 7.5 Hz, 1H), 4.95 (*q*, J = 8.3 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.91 (*t*, J = 8.3 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 160.95, 152.42, 129.29, 125.04, 124.54, 123.41 (*q*, J = 277.3 Hz), 123.24, 120.43, 65.00 (*q*, J = 36.5 Hz). MS (ESI): 234.0 [*M*+H]⁺. HRMS (ESI) for C₉H₇NOF₃S [*M*+H]⁺: calc'd: 234.0200; found: 234.0197.

tert-Butyl 2-(2,2,2-trifluoroethoxy)-7,8-dihydropyrido[4,3-*d*]pyrimidine-6(5*H*)-carboxylate (9).

Boc N CF₃ General procedure 1 with *tert*-butyl 2-(methylsulfonyl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave **9** as a white solid (301 mg, 90% yield). Mp: 65–67 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.24 (s, 1H), 4.75 (q, J = 8.4 Hz, 1H), 4.51 (s, 1H), 3.70 (t, J = 6.0 Hz, 1H), 2.86 (t, J = 5.9 Hz, 1H), 1.45 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.86 (t, J = 8.3 Hz); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 166.73, 162.33, 156.93, 154.65, 123.37 (q, J = 277.8 Hz), 122.14, 80.76, 63.49 (q, J = 36.3 Hz), 42.22, 40.85, 31.81, 28.48. MS (ESI): 334.2 [M+H]⁺. HRMS (ESI) for C₁₄H₁₉N₃O₃F₃ [M+H]⁺: calc'd: 334.1379; found: 334.1376.

4-Phenyl-2-(2,2,2-trifluoroethoxy)quinazoline (10).

General procedure 1 with methyl 2-chloro-3-quinolinecarboxylate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **10** as a white solid (273 mg, 90% yield). Mp: 86–88 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.07 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.84 (t, J = 7.6 Hz, 1H), 7.80–7.75 (m, 2H), 7.62–7.51 (m, 3H), 7.45 (t, J = 7.6 Hz, 1H), 5.00 (t, t = 8.5 Hz, 2H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm): –73.49 (t, t = 8.5 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 172.76, 160.39, 152.87,

136.65, 134.67, 130.57, 130.19, 128.75, 127.79, 127.50, 125.84, 123.63 (q, J = 277.7 Hz), 120.72, 63.69 (q, J = 36.2 Hz). MS (ESI): 305.1 [M+H]⁺. HRMS (ESI) for C₁₆H₁₂N₂OF₃ [M+H]⁺: calc'd: 305.0902; found: 305.0903.

4-(2,2,2-Trifluoroethoxy)furo[2,3-d]pyrimidine (11).

General procedure 1 with 4-chlorofuro[2,3-d]pyrimidine on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/petroleum ether, 1: 4) gave 11 as a colorless oil (193 mg, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.56 (s, 1H), 7.65 (d, J = 2.5 Hz, 1H), 6.88 (d, J = 2.5 Hz, 1H), 4.97 (q, J = 8.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.69 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 168.74, 162.29, 152.81, 143.81, 123.38 (q, J = 277.4 Hz), 104.80, 103.36, 62.86 (q, J = 36.7 Hz). MS (ESI): 219.0 [M+H]⁺. HRMS (ESI) for C₈H₆N₂O₂F₃ [M+H]⁺: calc'd: 219.0381; found: 219.0380.

3-Phenyl-6-(2,2,2-trifluoroethoxy)pyridazine (12)

General procedure 1 with 3-chloro-6-phenylpyridazine on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **12** as a white solid (132 mg, 52% yield). Mp: 132–134 °C.¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.99 (dd, J = 7.6, 1.5 Hz, 2H), 7.86 (d, J = 9.2 Hz, 1H), 7.64–7.39 (m, 3H), 7.18 (d, J = 9.2 Hz, 1H), 5.00 (q, J = 8.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.80 (t, J = 8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.64, 156.86, 135.88, 130.02, 129.22, 128.09, 126.87, 123.52 (q, J = 277.2 Hz), 117.86, 63.56 (q, J = 36.5 Hz). MS (ESI): 255.1 [M+H]⁺. HRMS (ESI) for C¹2H¹0N²OF₃ [M+H]⁺: calc'd: 255.0745; found: 255.0744.

2,4-Diphenyl-6-(2,2,2-trifluoroethoxy)-1,3,5-triazine (13).

General procedure 1 with 2-bromo-4,6-diphenyl-1,3,5-triazine on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, o N Ph 1: 20) gave 13 as a white solid (123 mg, 74% yield). Mp: 118–120 °C.

1H NMR (400 MHz, CDCl₃) δ (ppm): 8.69–8.56 (m, 4H), 7.66–7.58 (m, 2H), 7.58–7.47 (m, 4H), 5.02 (q, J = 8.3 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.33 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 174.24, 170.66, 135.23, 133.36, 129.39, 128.89, 123.24 (q, J = 277.8 Hz), 63.60 (q, J = 36.9 Hz). MS (ESI): 332.1 [M+H]⁺. HRMS (ESI) for C₁₇H₁₃N₃OF₃ [M+H]⁺: calc'd: 332.1011; found: 332.1005.

2,7-Bis(2,2,2-trifluoroethoxy)-1,8-naphthyridine (14).

F₃C O N O CF₃ General procedure 1 with 2-chloro-7-(2,2,2-trifluoroethoxy)-1,8-naphthyridine on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/petroleum ether, 1: 5) gave **14** as a white solid (110 mg, 67% yield). Mp: 165–167 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.04 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 4.97 (q, J = 8.5 Hz, 4H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.70 (t, J = 8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.30, 153.60, 139.96, 123.77 (q, J = 277.1 Hz), 116.71, 111.46, 63.05 (q, J = 36.1 Hz). MS (ESI): 327.1 [M+H]⁺. HRMS (ESI) for C₁₂H₉N₂O₂F₆ [M+H]⁺: calc'd: 327.0568; found: 327.0564.

4-Chloro-1-isobutyl-1*H*-imidazo[4,5-*c*]quinoline.

A dried round bottomed flask equipped with a stirrer bar was loaded with Imiquimod (1-isobutyl-1*H*-imidazo[4,5-*c*]quinolin-4-amine; 721 mg, 3.0 mmol, 1 equiv.), followed by concentrated hydrochloric acid (11 mL). The flask was cooled to 0 °C, and then a cold (0 °C) aqueous solution (10 mL) of NaNO₂ (3.45 g, 50 mmol, 16.7 equiv.) was added in three portions. The mixture was stirred at bath temperature for 30 min and then at RT for 2 h. Water (50 mL) and DCM (50 mL) were then added to the reaction mixture. The organic layer was separated off, washed with brine, dried (Mg₂SO₄), and concentrated in *vacuo*. The residue was purified by silica gel chromatography (ethyl acetate/DCM, 1: 1) to give the title compound as a white solid (343 mg, 44% yield). Mp: 140–142 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.09 (*dd*, *J* = 8.3, 1.2 Hz, 1H), 7.98 (*dd*, *J* = 8.1, 1.3 Hz, 1H), 7.86 (s, 1H), 7.59 (*dtd*, *J* = 15.0, 7.1, 1.4 Hz, 2H), 4.28 (*d*, *J* = 7.4 Hz, 2H), 2.27 (sept, *J* = 13.8, 6.9 Hz, 1H), 0.99 (*d*, *J* = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 144.28, 144.10, 135.26, 134.04, 130.12, 128.05, 126.99, 120.18, 117.75, 55.37, 28.91, 19.88. MS (ESI): 260.1 [*M*+H]†. HRMS (ESI) for C₁₄H₁₅N₃Cl [*M*+H]†: calc'd: 260.0955; found: 260.0950.

1-lsobutyl-4-(2,2,2-trifluoroethoxy)-1*H*-imidazo[4,5-c]quinoline (15).

General procedure 1 with 4-chloro-1-isobutyl-1*H*-imidazo[4,5-*c*]quinoline (prepared as described immediately above) on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 2: 1)

gave **15** as a white solid (179 mg, 55% yield). Mp: 136–138 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.98 (d, J = 8.4 Hz, 1H), 7.82 (s, 1H), 7.59 (ddd, J = 8.4, 7.2, 1.2 Hz, 1H), 7.53–7.41 (m, 1H), 5.13 (q, J = 8.6 Hz, 2H), 4.29 (d, J = 7.4 Hz, 2H), 2.32 (sept, J = 13.8, 6.9 Hz, 1H), 1.01 (d, J = 6.7 Hz, 6H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm): –73.12 (t, J = 8.8 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 153.44, 143.73, 142.82, 135.22, 128.98, 128.50, 127.72, 124.89, 123.94 (q, J = 277.6 Hz), 120.18, 117.15, 62.04 (q, J = 36.2 Hz), 55.21, 28.98, 19.90. MS (ESI): 324.1 [M+H] $^+$. HRMS (ESI) for C₁₆H₁₇N₃OF₃ [M+H] $^+$: calc'd: 324.1324; found: 324.1324.

9-(Tetrahydro-2*H*-pyran-2-yl)-6-(2,2,2-trifluoroethoxy)-9*H*-purine (16).

General procedure 1 with 6-chloro-9-(tetrahydro-2*H*-pyran-2-yl)-9*H*-purine on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 1: 2) gave **16** as a white solid (287 mg, 95% yield). Mp: 113–115 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.53 (s, 1H), 8.19 (s, 1H), 5.76 (*dd*, J = 10.1, 2.5 Hz, 1H), 5.27–4.85 (m, 2H), 4.16 (dd, J = 12.7, 2.9 Hz, 1H), 3.77 (td, J = 11.6, 2.7 Hz, 1H), 2.18–1.95 (m, 3H), 1.87–1.59 (m, 3H); ¹⁹F

NMR (376 MHz, CDCl₃) δ (ppm): -73.40 (t, J = 8.6 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 158.90, 152.32, 151.75, 141.12, 123.35 (q, J = 277.9 Hz), 121.36, 82.45, 69.03, 62.51 (q, J = 36.9 Hz), 32.01, 25.01, 22.92. MS (ESI): 303.1 [M+H]⁺. HRMS (ESI) for C₁₂H₁₄N₄O₂F₃ [M+H]⁺: calc'd: 303.1069; found: 303.1068.

tert-Butyl 3,6-dichloropicolinate.

To a dried round-bottomed flask equipped with a stirrer bar were added Clopyralid (3,6-dichloropicolinic acid; 960 mg, 5.0 mmol, 1 equiv.), *tert*-butanol (740 mg, 10.0 mmol, 2 equiv.), DCC (1.55 g, 7.5 mmol, 1.5 equiv.), and DMAP (916 mg, 7.5 mmol, 1.5 equiv.). DCM (30 mL) was then added. The reaction mixture was stirred for 12 h at RT and then water (50 mL) and DCM (50 mL) were added. The organic phase was washed with brine, dried (Mg₂SO₄), and concentrated *in vacuo*. The residue was purified with silica gel chromatography (ethyl acetate/n-hexane, 1: 20) to give the title compound (1.17 g, 92% yield) as a white solid. Mp: 61–63 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.69 (d, J =

8.5 Hz, 1H), 7.33 (d, J = 8.5 Hz, 1H), 1.61 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.89, 149.88, 149.19, 140.78, 128.41, 126.68, 84.47, 28.22. MS (ESI): 270.0 [M+Na]⁺. HRMS (ESI) for C₁₀H₁₁NO₂Cl₂Na [M+Na]⁺: calc'd: 270.0065; found: 270.0062.

tert-Butyl 3-chloro-6-(2,2,2-trifluoroethoxy)picolinate (17).

General procedure 1 with *tert*-butyl 3,6-dichloropicolinate (prepared as described immediately above) on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 20) afforded **17** as a colorless oil (128 mg, 41% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.66 (d, J = 8.8 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 4.75 (q, J = 8.5 Hz, 2H), 1.62 (s, 9H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.80 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.47, 159.39, 145.91, 141.53, 123.42 (q, J = 277.2 Hz), 123.34, 113.98, 83.67, 62.76 (q, J = 36.2 Hz), 28.07.

6-Bromo-2-methyl-3,4'-bipyridine-5-carbonitrile.

Phosphorus oxybromide (4.30 g, 15 mmol, 3 equiv.) was dissolved in anhydrous MeCN (15 mL). Milrinone (2-methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carbonitrile; 1.06 g, 5.0 mmol, 1 equiv.) and DMF (365 mg, 5.0 mmol, 1 equiv.) were added under argon and the resultant mixture was stirred at 85 °C for 12 h. The reaction mixture was cooled to RT, poured onto ice-water, and basified with saturated sodium carbonate solution until the pH was between 8 and 9. The mixture was extracted with DCM (2 × 15 mL), washed with brine, dried (Mg₂SO₄), and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate/n-hexane: 8: 1) to give the title compound as a white solid (692 g, 51% yield). Mp: 141–143 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.73 (d, J = 4.5 Hz, 2H), 7.75 (s, 1H), 7.24 (d, J = 4.5 Hz, 2H), 2.55 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.38, 150.63, 144.35, 142.46, 142.40, 133.91, 123.54, 115.67, 111.79, 23.77. MS (ESI): 274.0 [M+H]⁺. HRMS (ESI) for C₁₂H₉N₃Br [M+H]⁺: calc'd: 273.9980; found: 273.9976.

2-Methyl-6-(2,2,2-trifluoroethoxy)-3,4'-bipyridine-5-carbonitrile (18).

General procedure 1 with 6-bromo-2-methyl-3,4'-bipyridine-5-carbonitrile (prepared as described immediately above) on 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-

hexane, 8: 1) gave **18** as a white solid (112 mg, 76% yield). Mp: 135–137 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.70 (d, J = 5.8 Hz, 2H), 7.79 (s, 1H), 7.22 (d, J = 5.8 Hz, 2H), 4.92 (q, J = 8.3 Hz, 2H), 2.48 (s, 3H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm): –73.56 (t, J = 8.2 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 160.50, 159.27, 150.47, 145.21, 144.11, 129.48, 123.98, 123.19 (q, J = 277.8 Hz), 114.06, 94.77, 62.90 (q, J = 36.8 Hz), 23.63. MS (ESI): 294.1 [M+H]⁺. HRMS (ESI) for C₁₄H₁₁N₃OF₃ [M+H]⁺: calc'd: 294.0854; found: 294.0857.

6,7-Bis(2-methoxyethoxy)-4-(2,2,2-trifluoroethoxy)quinazoline (19).

CF₃ General procedure 1 with 4-chloro-6,7-bis(2-methoxyethoxy)quinazoline on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/petroleum ether, 9: 1) gave 19 as a white solid (123 mg, 65% yield). Mp: 93–95 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.60 (s, 1H), 7.33 (s, 1H), 7.23 (s, 1H), 4.94 (q, J = 8.4 Hz, 2H), 4.32–4.16 (m, 4H), 3.84 (m, 4H), 3.46–3.45 (m, 6H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm): –73.54 (t, t = 8.2 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 163.55, 155.64, 152.35, 149.83, 149.09, 123.54 (t, t = 277.3 Hz), 110.26, 107.89, 102.48, 70.80, 70.57, 68.90, 68.64, 62.57 (t, t = 36.5 Hz), 59.47, 59.44. MS (ESI): 377.2 [t = t +

2-Fluoro-5-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)pyridine.

A mixture of 2-fluoropyridine-5-boronic (845 mg, 6.0 mmol, 1.2 equiv.), 2-(4-fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene (2.04 g, 5.0 mmol, 1 equiv.), Pd(PPh₃)₄ (289 mg, 0.25 mmol, 5 mol%), K₂CO₃ (2.07 g, 15 mmol, 3 equiv.) in 1,4–dioxane (25 mL) and water (5 mL) was degassed for 15 min under argon. The reaction mixture was then heated at 100 °C overnight. The reaction mixture was cooled to RT and diluted with DCM (300 mL). The organic layer was washed with water (200 mL), dried (Mg₂SO₄), filtered, and concentrated. The residue was purified by silica gel chromatography (ethyl acetate/*n*-hexane, 1: 10) to give the title compound as a white solid (1.12 g, 59% yield). Mp: 118–

120 °C.¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.41 (d, J = 2.4 Hz, 1H), 7.95 (td, J = 8.1, 2.6 Hz, 1H), 7.56–7.44 (m, 2H), 7.43–7.33 (m, 2H), 7.29 (d, J = 7.8 Hz, 1H), 7.11–6.93 (m, 4H), 6.72 (d, J = 3.6 Hz, 1H), 4.20 (s, 2H), 2.39 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –70.83 (d, J = 6.0 Hz, 1F), –111.96 to –121.23 (m, 1F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.96 (d, J = 83.7 Hz), 161.54 (d, J = 91.6 Hz), 145.85 (d, J = 14.7 Hz), 142.97, 141.96, 139.73 (d, J = 7.7 Hz), 139.32, 136.77, 134.85, 134.78 (d, J = 4.8 Hz), 131.50, 130.92 (d, J = 3.2 Hz), 128.21, 127.32 (d, J = 8.0 Hz), 126.33, 125.67, 122.91, 115.92 (d, J = 21.7 Hz), 109.54 (d, J = 37.5 Hz), 34.34, 19.41. MS (ESI): 378.1 [M+H]†. HRMS (ESI) for C₂₃H₁₈NF₂S [M+H]†: calc'd: 378.1128; found: 378.1123.

5-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-2-(2,2,2-trifluoroethoxy) pyridine (20).

General procedure 1 with 2-fluoro-5-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4methylphenyl)pyridine (prepared described immediately above) on 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **20** as a white solid (201 mg, 88% yield). Mp: 98–100 °C ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.25 (d, J = 2.0 Hz, 1H), 7.74 (dd, J = 8.5, 2.2 Hz, 1H), 7.38 (dd, J = 8.5, 5.3 Hz, 2H), 7.33–7.22 (m, 2H), 7.22–7.13 (m, 1H), 6.93 (dd, J =14.7, 6.0 Hz, 3H), 6.82 (d, J = 8.6 Hz, 1H), 6.62 (d, J = 3.3 Hz, 1H), 4.71 (g, J = 8.6 Hz, 2H), 4.09 (s, 2H), 2.28 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.78 (t, J = 8.6 Hz, 3F), -103.87 to -127.09 (m, 1F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 162.33 (d, J =246.9 Hz), 161.21, 144.67, 143.16, 141.93, 139.20, 138.22, 136.18, 135.60, 131.69, 131.42, 130.98 (d, J = 3.2 Hz), 128.01, 127.33 (d, J = 7.9 Hz), 126.31, 125.44, 123.96 (g, J = 277.6 Hz), 122.92, 115.93 (d, J = 21.7 Hz), 111.14, 62.40 (q, J = 35.8 Hz), 34.38, 19.39. MS (ESI): 458.1 [M+H]+. HRMS (ESI) for C₂₅H₂₀NOF₄S [M+H]+: calc'd: 458.1202; found: 458.1208.

N,2,3-Trimethyl-N-(2-(2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2H-indazol-6-amine (21).

gave **21** as a white solid (301 mg, 86% yield). Mp: 145–147 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.79 (d, J = 6.0 Hz, 1H), 7.61 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 1.2 Hz, 1H), 6.82

(*dd*, J = 8.8, 1.7 Hz, 1H), 6.00 (*d*, J = 6.0 Hz, 1H), 4.76 (*q*, J = 8.6 Hz, 2H), 4.10 (*s*, 3H), 3.50 (*s*, 3H), 2.61 (*s*, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.57 (*t*, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 164.41, 163.58, 156.10, 147.98, 142.11, 132.31, 123.67 (*q*, J = 277.9 Hz), 121.95, 120.28, 120.04, 114.88, 100.71, 63.06 (*q*, J = 36.0 Hz), 38.26, 37.67, 10.09. MS (ESI): 352.1 [*M*+H]⁺. HRMS (ESI) for C₁₆H₁₇N₅OF₃ [*M*+H]⁺: calc'd: 352.1385; found: 352.1380.

6-Bromo-8-cyclopentyl-5-methyl-2-(2,2,2-trifluoroethoxy)pyrido[2,3-\d]pyrimidin-7(8\H)-one (22).

General procedure 1 with 6-bromo-2–chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave 22 as a white solid (158 mg, 78% yield). Mp: 205–207 °C. ¹H

NMR (400 MHz, CDCl₃) δ (ppm): 8.84 (s, 1H), 6.66–5.64 (*m*, 1H), 4.87 (*q*, *J* = 8.2 Hz, 2H), 2.64 (s, 3H), 2.26–2.20 (*m*, 2H), 2.16–2.02 (*m*, 2H), 1.93–1.88 (*m*, 2H), 1.76–1.59 (*m*, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.52 (*t*, *J* = 8.3 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.78, 158.68, 157.45, 155.92, 143.06, 123.19 (*q*, *J* = 277.9 Hz), 120.23, 110.72, 64.04 (*q*, *J* = 36.6 Hz), 55.49, 28.53, 26.17, 18.56. MS (ESI): 406.0 [*M*+H]⁺. HRMS (ESI) for C₁₅H₁₆N₃O₂F₃⁷⁹Br [*M*+H]⁺: calc'd: 406.0378; found: 406.0374.

2.2. Syntheses of benzenoid precursors and standards.

2.2.1. General procedure 2 for diaryliodonium precursors synthesis.²

Supplementary Figure 4. General procedure 2 for the synthesis of diaryliodonium salts.

Aryl(trimethoxyphenyl)iodonium or aryl(trimethylphenyl)iodonium tosylates were prepared by known literature procedures.² In a closed reaction vessel, iodoarene (1 equiv.) was dissolved in acetonitrile (1 mL/mmol of iodoarene). *p*-Toluenesulfonic acid

monohydrate (1 equiv.) was then added in one portion, followed by *m*CPBA (1 equiv.) in one portion. The reaction mixture was stirred vigorously at 75 °C. After 30 min, the flask was raised from the oil bath and 1,3,5-trimethoxybenzene or 1,3,5-trimethylbenzene (1 equiv.) was added in one portion. The flask was returned to the oil bath and stirring was continued at 75 °C for 5 min (in the case of 1,3,5-trimethylbenzene, the second stage of the reaction was allowed to proceed for 3 h). The reaction was removed from heat and triturated with diethyl ether until precipitation ceased. The precipitate was isolated by vacuum filtration and washed with diethyl ether to give a white or light beige solid. Diaryliodonium salts were isolated in moderate yield. If needed, precursors were purified via recrystallization in a minimal amount of methanol and crystallized by addition of diethyl ether.

2.2.2. General procedure 3 for iodonium ylide precursors synthesis.3

Supplementary Figure 5. General procedure 3 for the synthesis of aryliodonium ylides.

A solution of iodoarene (1 equiv.) in chloroform (1 mL/mmol of iodoarene) was treated with trifluoroacetic acid (1.1 mL/mmol) followed by oxone monopersulfate (1.6 equiv.). The heterogeneous mixture was stirred at RT for 8 h and then concentrated under reduced pressure. The residue was suspended in ethanol (4 mL/mmol) and treated with Meldrum's acid (1 equiv.) and a solution of 10% sodium carbonate in water, which was used to adjust the *p*H to ~10. The reaction was stirred at RT for 3 h and then diluted with water and extracted with DCM. The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was recrystallized in a minimal amount of methanol and diethyl ether to give the corresponding aryliodonium ylide.

2.2.3. General procedure 4 for synthesis of reference compounds.⁴

Supplementary Figure 6. General procedure 4 for the synthesis of 2,2,2-trifluoroethyl aryl ethers.

The iodoarene (1 equiv.), CuI (5 mol%), and *t*-BuONa (1.2 equiv.) were placed in a round-bottomed flask with a magnetic stirrer bar. DMF (1 M) and 2,2,2-trifluoroethanol (2 equiv.) were added under argon. The reaction mixture was stirred at 60 °C for 12 h, then quenched with water, and diluted with DCM (30 mL). The organic layer was washed with brine, dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography to afford the corresponding 2,2,2-trifluoroethyl aryl ether.

2.2.4. General procedure 5 for synthesis of reference compounds.

Supplementary Figure 7. General procedure 5 for the synthesis of 2,2,2-trifluoroethyl aryl ethers.

Hydroxy precursor (1 equiv.), Cs_2CO_3 (2 equiv.) 2-iodo-1,1,1-trifluoroethane (3 equiv.) and DMF (0.2 M) were added under argon to the reaction vessel. The reaction vessel was capped loosely and stirred vigorously at 80 °C for 12 h. The mixture was cooled to RT, poured onto water, and extracted with DCM (2 \times 15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was then purified by silica gel flash chromatography to afford the corresponding 2,2,2-trifluoroethyl aryl ether.

(4-Benzyloxyphenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.27 g, 65% yield). Mp: 212–214 °C. ¹H NMR (400 MHz, DMSO- d_6) δ (ppm): 7.84 (d, J = 9.0 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.44–7.29 (m, 5H), 7.09 (t, J = 9.0 Hz, 4H), 6.45 (s, 2H), 5.14 (s, 2H), 3.94 (s, 6H), 3.86 (s, 3H), 2.28 (s, 3H); 13 C NMR (101 MHz, DMSO- d_6) δ (ppm): 165.98, 160.60, 159.23, 145.83, 137.49, 136.45, 136.17, 128.48, 128.06, 127.99, 127.78, 125.47, 117.96, 105.30, 91.97, 87.57, 69.58, 57.27, 56.11, 20.74. MS (ESI): 477.0 [M–OTs]+. HRMS (ESI) for C₂₂H₂₂O₄I [M–OTs]+: calc'd: 477.0563; found: 477.0564.

1-(Benzyloxy)-4-(2,2,2-trifluoroethoxy)benzene (23).

7.31 (m, 5H), 6.97–6.90 (m, 4H), 5.05 (s, 2H), 4.31 (q, J = 8.2 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.04 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 154.48, 152.03, 137.19, 128.79, 128.19, 127.66, 123.63 (q, J = 278.4 Hz), 116.54, 116.12, 70.77, 67.05 (q, J = 35.3 Hz). (Known compound).⁵

(p-Tolyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide.

Me O O

General procedure 3 on a 6.0 mmol scale gave the title compound as a white solid (630 mg, 29% yield). Mp: dec.135 °C. ¹H NMR (400 MHz, DMSO– d_6) δ (ppm): 7.67 (d, J = 8.2 Hz, 2H), 7.26 (d,

J = 8.2 Hz, 2H), 2.33 (s, 3H), 1.55 (s, 6H); ¹³C NMR (101 MHz, DMSO– d_6) δ (ppm): 162.83, 140.79, 132.64, 131.55, 112.87, 102.63, 58.03, 25.57, 20.69. MS (ESI): 743.0 [2M+Na]⁺. HRMS (ESI) for C₂₆H₂₆O₈I₂Na [2M+Na]⁺: calc'd: 742.9615; found: 742.9614.

1-Methyl-4-(2,2,2-trifluoroethoxy)benzene (24).

General procedure 4 on a 2.0 mmol scale followed by flash chromatography (n-hexane) gave **24** as a colorless oil (201 mg, 53% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.13 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 4.33 (q, J = 8.2 Hz, 2H), 2.32 (s, 3H); 19 F NMR (376 MHz, CDCl₃) δ (ppm): -74.05 (t, J = 8.3 Hz, 3F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 155.61, 132.16, 130.37, 123.66 (q, J = 278.0 Hz), 115.07, 66.32 (q, J = 35.4 Hz), 20.69. (Known compound).

(4-Chlorophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.34 g, 77% yield). Mp: 226–230 $^{\circ}$ CI MeO $^{\circ}$ C. 1 H NMR (400 MHz, DMSO- d_{6}) δ (ppm): 7.91 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.7 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.10 (d, J = 7.9 Hz, 2H), 6.47 (s, 2H), 3.94 (s, 6H), 3.87 (s, 3H), 2.28 (s, 3H); 13 C NMR (101 MHz, DMSO- d_{6}) δ (ppm): 166.27, 159.33, 145.74, 137.56, 136.67, 136.11, 131.49, 128.02, 125.47, 113.92, 92.08, 87.21, 57.35, 56.18, 20.76. MS (ESI): 405.0 [M—OTs] $^{+}$: calc'd: 404.9754; found: 404.9758.

1-Chloro-4-(2,2,2-trifluoroethoxy)benzene (25).

General procedure 4 on a 2.0 mmol scale followed by flash chromatography (n-hexane) gave **25** as a white solid (408 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.28 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 4.32 (q, J = 8.1 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.95 (t, J = 8.1 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 156.19, 129.89, 127.85, 123.38 (q, J = 278.0 Hz), 116.52, 66.33 (q, J = 35.8 Hz). (Known compound).⁷

(2-Bromophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.42 g, 76% yield). Mp: 142–145 °C. ¹H NMR (400 MHz, CD₃CN) δ (ppm): 7.90 (d, J = 7.9 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.46–7.43 (m, 3H), 7.32 (t, J = 7.7 Hz, 1H), 7.11 (d, J = 8.0 Hz, 2H), 6.29 (t s, 2H), 3.87 (t s, 6H), 3.85 (t s, 3H), 2.32 (t s, 3H); ¹³C NMR (101 MHz, CD₃CN) δ (ppm): 168.31, 161.21, 145.17, 140.26, 139.13, 134.71, 134.60, 131.09, 129.46, 127.08, 126.68, 121.12, 93.03, 86.44, 58.04, 57.09, 21.37. MS (ESI): 450.9 [t M—OTs]+: calc'd: 448.9249; found: 48.9254.

1-Bromo-2-(2,2,2-trifluoroethoxy)benzene (26).

General procedure 5 on a 3.0 mmol scale followed by flash chromatography (n-hexane) gave **26** as a colorless oil (246 mg, 32% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.58 (d, J = 7.9 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 6.98–6.94 (m, 2H), 4.40 (q, J = 8.1 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.90 (t, J = 8.0 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 154.40, 134.12, 128.85, 124.44, 123.34 (q, J = 278.4 Hz), 115.48, 113.37, 67.46 (q, J = 35.8 Hz). (Known compound).⁸

1-lodo-4-(2,2,2-trifluoroethoxy)benzene (27).

CF₃ General procedure 5 on a 3.0 mmol scale followed by flash chromatography (n-hexane) gave **27** as a white solid (367 mg, 41% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.61 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.7 Hz, 2H), 4.32 (q, J = 8.1 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.91 (t, J = 8.1 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 157.48, 138.80, 123.35 (q, J = 278.1 Hz), 117.45, 85.26, 66.06 (q, J = 35.9 Hz). (Known compound).

(4-Methylbenzenesulfonate)(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 5.0 mmol scale gave the title compound as a white solid (2.54 g, 71% yield). Mp: 191–192 $^{\circ}$ C. 1 H NMR (400 MHz, DMSO) $^{\circ}$ (ppm): 7.93 ($^{\circ}$ J = 8.9 Hz, 2H), 7.73 ($^{\circ}$ J = 8.3 Hz, 2H), 7.47 ($^{\circ}$ J = 7.9, 6.6 Hz, 4H), 7.12 ($^{\circ}$ J = 17.2, 8.4 Hz, 4H), 6.46 (s, 2H), 3.91 (s, 6H), 3.87 (s, 3H), 2.41 (s, 3H), 2.28 (s, 3H); 13 C NMR (101 MHz, DMSO) $^{\circ}$ (ppm): 166.28, 159.32, 150.84, 146.24, 145.71, 137.60, 136.47, 130.93, 130.38, 128.20, 128.03, 125.48, 125.17, 113.86, 92.10, 87.17, 57.33, 56.17, 21.17, 20.76. MS (ESI): 541.0 [$^{\prime}$ M-OTs] $^{+}$. HRMS (ESI) for C₂₂H₂₂O₆SI [$^{\prime}$ M-OTs] $^{+}$: calc'd: 541.0182; found: 541.0184.

4-(2,2,2-Trifluoroethoxy)phenyl 4-methylbenzenesulfonate (28).

To a round-bottomed flask with a magnetic stirrer bar was added 4-(2,2,2-trifluoroethoxy)phenol (96 mg, 0.5 mmol, 1.0 equiv.), DMAP (122 mg, 1.0 mmol, 2.0 equiv.) and DCM (3 mL) under argon. Tosyl chloride (114 mg, 0.6 mmol, 1.2 equiv.) in DCM (1 mL) was added dropwise at 0 °C and the reaction mixture was stirred at RT for 12 h. After completion of the reaction, the reaction mixture was poured onto water and extracted with DCM (2 × 15 mL). The organic phase was separated, dried over Mg₂SO₄, and concentrated *in vacuo*. The residue was purified by flash chromatography (ethyl acetate/*n*-hexane, 1: 10) to give **28** as a colorless oil (156 mg, 90% yield). Mp: 75–77 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.67 (*d*, *J* = 8.3 Hz, 1H), 7.30 (*d*, *J* = 8.0 Hz, 2H), 6.9. 8–6.87 (*m*, 2H), 6.87–6.76 (*m*, 2H), 4.30 (*q*, *J* = 8.1 Hz, 2H), 2.44 (*s*, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.96 (t, *J* = 8.0 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 156.04, 145.71, 144.51, 132.24, 129.97, 128.66, 123.87, 123.31 (*q*, *J* = 278.0 Hz), 115.87, 66.21 (*q*, *J* = 35.8 Hz), 21.82.

(4-Nitrophenyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide.

General procedure 3 on a 3.0 mmol scale gave the title compound as a white solid (895 mg, 38% yield). Mp: dec. 131 °C.
1
H NMR (400 MHz, DMSO- d_{6}) δ (ppm): 8.28 (d , J = 8.4 Hz, 2H), 8.05 (d , J

= 8.4 Hz, 2H), 1.59 (s, 6H); ¹³C NMR (101 MHz, DMSO- d_6) δ (ppm): 162.93, 148.91, 133.51, 125.63, 122.94, 103.04, 58.45, 25.63. MS (ESI): 804.9 [2M+Na]⁺. HRMS (ESI) for C₂₄H₂₀N₂O₁₂I₂Na [2M+Na]⁺: calc'd: 804.9003; found: 804.9008.

1-Nitro-4-(2,2,2-trifluoroethoxy)benzene (29).

General procedure 4 on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **29** as a pale-yellow solid (408 mg, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.25 (d, J = 8.9 Hz, 2H), 7.04 (d, J = 8.9 Hz, 2H), 4.46 (q, J = 7.8 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.72 (t, J = 8.0 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.96, 143.04, 126.26, 122.99 (q, J = 278.1 Hz), 115.06, 65.98 (q, J = 36.5 Hz). (Known compound).¹⁰

(4-Ethoxycarbonylphenyl)(mesityl)iodonium tosylate.

General procedure 2 on a 5.0 mmol scale gave the title compound as a white solid (1.98 g, 70% yield). Mp: 165–167 eto₂c Me °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.86 (d, J = 8.2 Hz, 2H), 7.75 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 7.8 Hz, 2H), 6.97–6.95 (m, 2H), 4.32 (q, J = 7.1 Hz, 2H), 2.53 (s, 6H), 2.28 (s, 6H), 1.33 (t, J = 7.1 Hz, 3H); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 165.24, 143.54, 142.45, 142.38, 139.50, 133.23, 132.78, 132.14, 129.89, 128.52, 126.02, 122.57, 118.73, 61.69, 27.17, 21.40, 21.21, 14.33. MS (ESI): 395.0 [M-OTs]⁺. HRMS (ESI) for C₁₈H₂₀O₂I [M-OTs]⁺: calc'd: 395.0508; found: 395.0508.

Ethyl 4-(2,2,2-trifluoroethoxy)benzoate (30).

General procedure 4 on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 20) gave **30** as a white solid (412 mg, 83% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.02 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H), 4.67–4.07 (m, 4H), 1.38 (t, J = 7.1 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.90 (t, J = 8.1 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 166.14, 160.85, 131.91, 125.02, 123.30 (t, t = 277.9 Hz), 114.51, 65.72 (t = 36.2 Hz), 61.08 (t = 36.2

(4-Cyanophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate.

Hz, 2H), 7.90 (*d*, J = 8.4 Hz, 2H), 7.47 (*d*, J = 8.0 Hz, 2H), 7.11 (*d*, J = 7.8 Hz, 2H), 6.48 (s, 2H), 3.93 (s, 6H), 3.88 (s, 3H), 2.28 (s, 3H); ¹³C NMR (101 MHz, DMSO-d₆) δ (ppm): 166.49, 159.43, 145.57, 137.68, 134.81, 128.07, 125.48, 120.96, 117.54, 114.09, 92.18, 86.99, 57.40, 56.23, 20.78. MS (ESI): 396.0 [*M*–OTs]⁺. HRMS (ESI) for C₁₆H₁₅NO₃I [*M*–OTs]⁺: calc'd: 396.0097; found: 396.0093.

4-(2,2,2-Trifluoroethoxy)benzonitrile (31).

GF₃ General procedure 4 on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **31** as a white solid (330 mg, 82% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.63 (d, J = 8.2 Hz, 2H), 7.01 (d, J = 8.2 Hz, 2H), 4.41 (q, J = 7.9 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.77 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 160.40, 134.40, 123.05 (q, J = 278.0 Hz), 118.74, 115.67, 106.25, 65.68 (q, J = 36.4 Hz). (Known compound).¹⁰

(3-Cyanophenyl) (2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.13 g, 66% yield). Mp: 212– 214 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.25 (d, J = 8.3 Hz, 1H), 7.91 (s, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.39 (t, J = 8.0 Hz, 1H), 7.06 (d, J = 8.0 Hz, 2H), 6.12 (s, 2H), 3.83 (s, 9H), 2.32 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 167.18, 160.53, 142.86, 139.57, 138.95, 136.79, 134.34, 131.56, 128.66, 126.11, 116.99, 116.12, 114.78, 91.84, 86.06, 57.18, 56.11, 21.47. MS (ESI): 396.0 [M—OTs]+. HRMS (ESI) for C₁₆H₁₅NO₃I [M—OTs]+: calc'd: 396.0097; found: 396.0097.

3-(2,2,2-Trifluoroethoxy)benzonitrile (32).

CF₃ General procedure 4 on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **32** as a white solid (235 mg, 58% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.49–7.40 (m, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.23–7.15 (m, 2H), 4.39 (q, J = 8.0 Hz, 2H); 19 F NMR (376 MHz, CDCl₃) δ (ppm): –73.86 (t, J = 8.1 Hz, 3F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 157.51, 130.95, 126.50, 123.13 (q, J = 278.0 Hz), 120.14, 118.28, 118.23, 113.80, 66.05 (q, J = 36.1 Hz). (Known compound). 11

(3-Chloro-4-(methoxycarbonyl)phenyl)(2,4,6-trimethoxyphenyl) tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.53 g, 81% yield). Mp: MeO_2C MeO OMe 214-216 °C. 1H NMR (400 MHz, CDCl₃) δ (ppm): 8.27 (d, J = 2.3 Hz, 1H), 7.96 (dd, J = 8.7, 2.3 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.7 Hz, 1H), 7.03 (d, J = 7.9 Hz, 2H), 6.11 (s, 2H), 3.87 (s, 3H), 3.84 (s, 6H), 3.82 (s, 3H), 2.30 (s, 3H); ^{13}C NMR (101 MHz, CDCl₃) δ (ppm): 167.11, 164.16, 160.50, 142.91, 139.45, 138.43, 137.50, 137.28, 133.63, 132.08, 128.56, 126.10, 112.96, 91.78, 85.54, 57.11, 56.13, 53.01, 21.46. MS (ESI): 463.0 [M-OTs] $^+$: calc'd: 462.9809; found: 462.9814.

Methyl 2-chloro-5-(2,2,2-trifluoroethoxy)benzoate (33).

General procedure 4 on a 2.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 20) gave **33** as a white solid (230 mg, 43% yield). H NMR (400 MHz, CDCl₃) δ (ppm): 7.38 (s, 1H), 7.37 (d, J = 5.8 Hz, 1H), 7.02 (dd, J = 8.8, 3.2 Hz, 1H), 4.36 (q, J = 8.0 Hz, 2H), 3.92 (s, 3H); HP NMR (376 MHz, CDCl₃) δ (ppm): -73.93 (t, J = 8.1 Hz, 3F); HS NMR (101 MHz, CDCl₃) δ (ppm): 165.63, 155.76, 132.48, 131.03, 127.35, 123.21 (d, d = 278.0 Hz), 120.00, 117.36, 66.28 (q, d = 36.1 Hz), 52.78. (Known compound).

Naphthalen-1-yl(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.23 g, 69% yield). Mp: 189-191 °C. 1 H NMR (400 MHz, DMSO- d_6) δ (ppm): 8.47 (d, J = 6.7 Hz, 1H), 8.28–8.13 (m, 2H), 8.02 (d, J = 8.1 Hz, 1H), 7.87–7.77 (m, 1H), 7.70 (t, J = 7.2 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 6.39 (s, 2H), 3.95 (s, 6H), 3.80 (s, 3H), 2.28 (s, 3H); 13 C NMR (101 MHz, DMSO- d_6) δ (ppm): 165.92, 159.36, 145.83, 137.49, 137.42, 134.01, 132.99, 130.98, 129.21, 129.19, 129.17, 128.00, 127.75, 127.37, 125.47, 119.24, 92.01, 87.00, 57.18, 56.06, 20.75. MS (ESI): 421.0 [M-OTs]+: calc'd: 421.0301; found: 421.0300.

1-(2,2,2-Trifluoroethoxy)naphthalene (2).

General procedure 4 on a 2.0 mmol scale followed by flash of CF₃ chromatography (n-hexane) gave **2** as a white solid (312 mg, 69% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 8.53–8.22 (m, 1H), 7.95–7.77 (m, 1H), 7.58–7.56 (m, 3H), 7.40 (t, t = 8.0 Hz, 1H), 6.79 (t = 7.6 Hz, 1H), 4.53 (t = 8.0 Hz, 2H); t = NMR (376 MHz, CDCl₃) t (ppm): -73.71 (t = 8.0 Hz, 3F); t = NMR (101 MHz, CDCl₃) t (ppm): 153.31, 134.78, 127.72, 127.07, 126.07, 125.58, 123.71 (t = 277.9 Hz), 122.42, 121.98, 105.62, 66.23 (t = 35.8 Hz). (Known compound).

Naphthalen-2-yl(2,4,6-trimethoxyphenyl)iodonium tosylate.

General procedure 2 on a 3.0 mmol scale gave the title compound as a white solid (1.26 g, 71% yield). Mp: 217–220 °C. ¹H NMR (400 MHz, DMSO- d_6) δ (ppm): 8.65 (d, J = 1.3 Hz, 1H), 8.12–8.02 (m, 1H), 8.00 (d, J = 8.9 Hz, 2H), 7.91 (dd, J = 8.8, 1.8 Hz, 1H), 7.71–7.58 (m, 2H), 7.47 (d, J = 8.1 Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 6.46 (s, 2H), 3.97 (s, 6H), 3.85 (s, 3H), 2.27 (s, 3H); ¹³C NMR (101 MHz, DMSO- d_6) δ (ppm): 166.11, 159.39, 145.76, 137.53, 135.16, 133.77, 133.20, 131.13, 129.81, 128.62, 128.15, 128.00, 127.98, 127.70, 125.47, 113.07, 92.07, 87.12, 57.33, 56.13, 20.75. MS (ESI): 421.0 [M-OTs]*: calc'd: 421.0301; found: 421.0302.

2-(2,2,2-Trifluoroethoxy)naphthalene (34).

O CF₃ General procedure 4 on a 2.0 mmol scale followed by flash chromatography (n-hexane) gave **34** as a white solid (253 mg, 56% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.91–7.68 (m, 3H), 7.54 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 7.26 (t, t = 9.0, 2.0 Hz, 1H), 7.18 (t = 8.1 Hz, 3F); t NMR (376 MHz, CDCl₃) δ (ppm): t = 73.73 (t, t = 8.1 Hz, 3F); t C NMR (101 MHz, CDCl₃) δ (ppm): 155.43, 134.31, 130.17, 129.87, 127.95, 127.12, 126.97, 124.72, 123.61 (t = 277.9 Hz), 118.49, 107.69, 65.90 (t = 35.7 Hz). (Known compound).

(Quinolin-6-yl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide.

General procedure 3 on a 5.0 mmol scale gave the title compound as a white solid (640 mg, 32% yield). Mp: dec. 165 °C.

¹H NMR (400 MHz, DMSO- d_6) δ (ppm): 9.01 (dd, J = 4.2, 1.6 Hz, 1H), 8.74–8.37 (m, 2H), 8.27–7.88 (m, 2H), 7.65 (dd, J = 8.4, 4.2 Hz, 1H), 1.57 (s, 6H);

¹³C NMR (101 MHz, DMSO-d₆) δ (ppm): 162.92, 152.56, 147.60, 136.27, 133.41, 132.32, 131.78, 128.81, 122.69, 113.88, 102.80, 58.49, 25.58. (Known compound).³

6-(2,2,2-Trifluoroethoxy)quinoline (35).

General procedure 4 on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **35** as a white solid (86 mg, 38% yield). Mp: 76–78 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.81 (dd, J = 4.2, 1.6 Hz, 1H), 8.20–7.81 (m, 2H), 7.39 (ddd, J = 20.8, 8.8, 3.5 Hz, 2H), 7.07 (d, J = 2.8 Hz, 1H), 4.46 (q, J = 8.0 Hz, 2H); ¹9F NMR (376 MHz, CDCl₃) δ (ppm): -73.73 (t, J = 8.1 Hz, 3F); ¹3C NMR (101 MHz, CDCl₃) δ (ppm): 155.47, 149.11, 145.14, 135.13, 131.74, 129.06, 123.41 (q, J = 277.9 Hz), 121.91, 121.90, 107.23, 66.04 (q, J = 36.0 Hz). MS (ESI): 228.1 [2M+Na]⁺. HRMS (ESI) for C₂₄H₂₀N₂O₁₂I₂Na [2M+Na]⁺: calc'd: 228.0636; found: 228.0636.

(*R*)-5-((4-Chloro-3-(4-((tetrahydrofuran-3-yl)oxy)benzoyl)phenyl) iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide.

General procedure 3 on a 5.0 mmol scale gave the title compound as a pale-yellow solid (860 mg, 30% yield). Mp: dec. 140 °C. ¹H NMR (400 MHz,

CDCl₃) δ (ppm): 7.96–7.76 (m, 2H), 7.68 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 8.6 Hz, 1H), 6.88 (d, J = 8.9 Hz, 2H), 4.99 (dd, J = 5.8, 4.2 Hz, 1H), 4.11–3.93 (m, 3H), 3.89 (td, J = 8.4, 4.3 Hz, 1H), 2.25 (td, J = 14.3, 8.3 Hz, 1H), 2.17–2.03 (m, 1H), 1.63 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 191.07, 163.86, 162.85, 141.85, 135.57, 135.33, 133.36, 133.30, 132.90, 128.35, 115.62, 111.97, 104.95, 78.12, 73.08, 67.34, 56.72, 33.12, 26.02 .

(*R*)-(2-Chloro-5-(2,2,2-trifluoroethoxy)phenyl)(4-((tetrahydrofuran-3-yl)oxy)phenyl)methanone (36).

91–93 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.77 (d, J = 8.8 Hz, 2H), 7.38 (d, J = 8.8 Hz, 1H), 7.01 (dd, J = 8.8, 3.0 Hz, 1H), 6.97–6.80 (m, 3H), 5.00 (td, J = 4.2, 2.2 Hz, 1H), 4.35 (q, J = 8.0 Hz, 2H), 4.21–3.95 (m, 3H), 3.91 (td, J = 8.4, 4.4 Hz, 1H), 2.26 (dtd, J =

14.4, 8.3, 6.2 Hz, 1H), 2.19–2.00 (m, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.85 (t, J = 8.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 193.04, 162.36, 156.05, 140.23, 132.77, 131.40, 129.29, 124.54, 123.21 (q, J = 278.1 Hz), 117.94, 115.35, 115.17, 78.01, 73.15, 67.37, 66.29 (q, J = 36.0 Hz), 33.18. MS (ESI): 401.1 [M+H]⁺. HRMS (ESI) for C₁₉H₁₇O₄F₃Cl [2M+Na]⁺: calc'd: 401.0767; found: 401.0773.

3-(2-Chloro-6-2,2,2-trifluoroethoxy)phenyl)-5-methylisoxazole-4-carbonitrile (37).

To a round bottomed flask equipped with a magnetic stirrer bar was added dry NaH (27 mg, 1.0 mmol, 2 equiv.) and DMF (2 mL, 0.5 M) under argon, and then 2,2,2-trifluoroethanol (100 mg, 1.0 mmol, 2 equiv.) in DMF (1 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon and (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (237 mg, 1.0 mmol, 1 equiv.) in DMF (2 mL) was added dropwise at RT. The reaction flask was capped loosely and stirred vigorously at 80 °C for 2 h. The reaction mixture was then poured onto water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/n-hexane, 1: 4) to give **37** as a colorless oil (235 mg, 74% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.36 (t, t = 8.3 Hz, 1H), 7.18 (t = 8.5 Hz, 1H), 6.86 (t = 8.4 Hz, 1H), 4.32 (t = 7.9 Hz, 2H), 2.63 (t = 8.3 Hz, 1H), NMR (376 MHz, CDCl₃) δ (ppm): t = 73.76 (t = 8.2 Hz, 3F); t C NMR (101 MHz, CDCl₃) δ (ppm): 177.15, 157.33, 156.57, 135.71, 132.73, 124.48, 122.90 (t = 278.3 Hz), 116.23, 111.49, 110.71, 93.77, 66.87 (t = 36.3 Hz), 12.69.

(3-(5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol.

Ataluren (2.84 g, 10 mmol, 1.0 equiv.) was dissolved in THF (20 mL) and BH₃·Me₂S (1.52 g, 20 mmol, 2.0 equiv.) was added dropwise at 0 °C under argon. The mixture was stirred at RT for 12 h and then quenched with methanol, washed with saturated NH₄Cl, and extracted with EtOAc (2 × 20 mL). The organic layer was dried (Mg₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate-*n*-hexane, 1: 2) to give the title compound as a white solid (2.34 g, 87% yield). Mp: 102–104 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.26–8.11 (m, 2H), 8.06 (d, J = 7.4 Hz, 1H), 7.64–7.54 (m, 1H), 7.49 (dt, J = 15.1, 7.6 Hz, 2H), 7.29 (dt, J = 19.4, 7.8 Hz, 2H), 4.76 (s, 2H), 2.49 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –108.25 (m, 1F), ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 172.91 (d, J = 4.4 Hz), 168.74, 160.90 (d, J = 260.5 Hz), 141.97, 134.80 (d, J = 8.7 Hz), 131.08, 129.92, 129.27, 126.99, 126.86, 126.12, 124.87 (d, J = 3.7 Hz), 117.31 (d, J = 21.1 Hz), 112.91 (d, J = 11.5 Hz), 64.93. MS (ESI): 271.1 [M+H]⁺. HRMS (ESI) for C₁₅H₁₂N₂O₂F [M+H]⁺: calc'd: 271.0883; found: 271.0884.

(3-(5-(2-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (38).

To a round bottomed flask equipped with a magnetic stirrer bar was added dry NaH (27 mg, 1.0 mmol, 2 equiv.) and DMF (2 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol (100 mg, 1.0 mmol, 2 equiv.) in DMF (1 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. (3-(5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (135 mg, 1.0 mmol, 1 equiv.) in DMF (2 mL) was then added dropwise at RT. The reaction flask was loosely capped and stirred vigorously at 80 °C for 2 h. The reaction mixture was poured onto water and extracted with DCM (2 ×15 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/n-hexane, 1: 1) to give **38** as a white solid (117 mg, 67% yield). Mp: 100–102 °C.¹H NMR (400 MHz, CD₃CN) δ (ppm): 8.14 (dd, J = 7.8, 1.7 Hz, 2H), 8.10 (s, 1H), 8.00 (dt, J = 6.5, 1.9 Hz, 1H), 7.63 (ddd, J = 8.6, 7.5, 1.7 Hz, 1H), 7.55–7.44 (m, 2H), 7.32–7.13 (m, 1H), 5.04–4.37 (m, 4H), 3.44 (t, t =

5.9 Hz, 1H); ¹⁹F NMR (376 MHz, CD₃CN) δ (ppm): –74.45 (t, J = 8.3 Hz, 3F); ¹³C NMR (101 MHz, CD₃CN) δ (ppm): 175.57, 169.26, 157.05, 144.24, 135.55, 132.57, 130.54, 130.08, 127.95, 126.84, 126.34, 124.80 (q, J = 277.1 Hz), 123.94, 115.83, 115.19, 67.38 (q, J = 35.4 Hz), 64.37. MS (ESI): 351.1 [M+H]⁺. HRMS (ESI) for C₁₇H₁₄N₂O₃F₃ [M+H]⁺: calc'd: 351.0957; found: 351.0963.

2.3. The synthesis of alkyl precursors and standards.

2.3.1. General procedure 6 for precursors synthesis.

Supplementary Figure 8. General procedure 6 for the synthesis of alkyl 4–methylbenzenesulfonates.

To a round-bottomed flask equipped with a magnetic stirrer bar was added the alcohol (RCH₂OH; 1.0 equiv.), DMAP (1.5 equiv.), and DCM (20 mL) under argon. Tosyl chloride (1.2 equiv.) in DCM (3 mL) was then added dropwise at 0 °C. The reaction mixture was then stirred at RT for 12 h, poured onto water, and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography to give the desired alkyl 4-methylbenzenesulfonate in moderate to high yield.

2.3.2. General procedure 7 for synthesis of reference standards.

Supplementary Figure 9. General procedure 7 for the synthesis of 2,2,2-trifluoroethyl alkyl ethers.

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (2 equiv.) and DMF (0.5 M) under argon, followed by 2,2,2-trifluoroethanol (2.0 equiv.) in DMF (1.0 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. An alkyl p-toluenesulfonate or iodoalkane (1 equiv.) in DMF (1 mL) was then added dropwise and the reaction temperature was kept under -10 °C. The reaction flask was loosely capped. The were contents stirred vigorously below -10 °C for 1 h, warmed to RT, and stirred for another 10 h. The reaction mixture was then poured into water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄), filtered and concentrated *in vacuo*.

The residue was purified by silica gel flash chromatography to give the corresponding 2,2,2-trifluoroethyl alkyl ether.

3-(1,3-Dioxoisoindolin-2-yl)propyl 4-methylbenzenesulfonate.

General procedure 6 with 2-(3-hydroxypropyl)isoindoline-1,3-dione on 5.0 mmol followed by flash chromatography (ethyl acetate/n-hexane, 1: 2) gave the title compound as a white solid (1.58 g, 88% yield). Mp: 105–107 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.80 (dt, J = 7.0, 3.5 Hz, 2H), 7.76 (d, J = 8.3 Hz, 2H), 7.73–7.65 (m, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.09 (t, J = 6.3 Hz, 2H), 3.72 (t, J = 7.0 Hz, 2H), 2.42 (s, 3H), 2.04 (quint, J = 6.5 Hz, 2H); t °C NMR (101 MHz, CDCl₃) δ (ppm): 168.23, 145.00, 134.21, 132.99, 132.11, 130.02, 128.11, 123.47, 67.94, 34.76, 28.14, 21.81. MS (ESI): 360.1 [M+H]⁺. HRMS (ESI) for C₁₈H₁₈NO₅S [M+H]⁺: calc'd: 360.0906; found: 360.0903.

2-(3-(2,2,2-Trifluoroethoxy)propyl)isoindoline-1,3-dione (39).

General procedure 7 with 3-(1,3-dioxoisoindolin-2-yl)propyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave **39** as a colorless oil (64 mg, 22% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.84–7.72 (m, 2H), 7.70–7.54 (m, 2H), 3.72 (dt, J = 13.6, 7.7 Hz, 4H), 3.59 (t, J = 5.9 Hz, 2H), 1.92 (t quint, t = 6.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.16 (t, t = 8.6 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 168.59, 134.12, 132.31, 124.11 (t = 279.6 Hz), 123.38, 70.51, 68.68 (t = 34.0 Hz), 35.34, 28.85. MS (ESI): 288.1 [t HRMS (ESI) for C₁₃H₁₃NO₃F₃ [t HRMS) (ESI) for C₁₃H₁₃NO₃F₃ [t = 288.0848; found: 288.0848.

2-(2-(Benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate.

General procedure 6 with 2-[2-(benzyloxy)ethoxy]ethanol on a 5.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 3) gave the title product as a colorless oil (1.61 g, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.79 (d, J = 8.3 Hz, 2H), 7.50–7.00 (m, 7H), 4.52 (s, 2H), 4.27–4.04 (m, 2H), 3.84–3.64 (m, 2H), 3.63–3.41 (m, 2H), 2.41 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 144.92, 138.28, 133.13, 129.95, 128.53, 128.10, 127.85, 127.78, 73.40, 70.94, 69.50, 69.42, 68.82, 21.76. MS (ESI): 351.1 [M+H]⁺. HRMS (ESI) for C₁₈H₂₃O₅S [M+H]⁺: calc'd: 351.1266; found: 351.1266.

((2-(2-(2,2,2-Trifluoroethoxy)ethoxy)ethoxy)methyl)benzene (40).

General procedure 7 with 2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate-n-hexane, 1: 4) gave **40** as a colorless oil (234 mg, 84% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.75–6.75 (m, 5H), 4.56 (s, 2H), 3.90 (q, J = 8.8 Hz, 2H), 3.83–3.73 (m, 2H), 3.73–3.57 (m, 6H); 19 F NMR (376 MHz, CDCl₃) δ (ppm): -74.30 (t, J = 8.8 Hz, 3F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 138.39, 128.54, 127.89, 127.80, 124.23 (q, J = 279.6 Hz), 73.41, 72.13, 70.95, 70.87, 69.57, 68.94 (q, J = 33.9 Hz). MS (ESI): 279.1 [M+H] $^{+}$. HRMS (ESI) for C₁₃H₁₈O₃F₃ [M+H] $^{+}$: calc'd: 279.1208; found: 279.1207.

7,8-Dimethoxy-3-(3-(2,2,2-trifluoroethoxy)propyl)-1*H*-benzo[*d*]azepin-2(3*H*)-one (41).

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (53 mg, 2.0 mmol, 2.0 equiv.) and DMF (4.0 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol

(200 mg, 2.0 mmol, 2 equiv. in 1 mL DMF) at 0 °C. The reaction mixture was stirred for 20 min under argon. 3-(3-lodopropyl)-7,8-dimethoxy-1*H*-benzo[*d*]azepin-2(3*H*)-one (387 mg, 1.0 mmol, 1 equiv.) in DMF (2 mL) was then added dropwise at 0 °C. The reaction flask was capped loosely, and the contents were stirred vigorously at 0 °C for 1 h, warmed to 80 °C, and stirred for another 12 h. The reaction mixture was then poured onto water and extracted with DCM (2 ×15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/*n*-hexane, 1: 4) to give **41** as a colorless oil (172 mg, 48% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.77 (s, 1H), 6.72 (s, 1H), 6.33 (*d*, *J* = 9.1 Hz, 1H), 6.20 (*d*, *J* = 9.1 Hz, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.72 (*q*, *J* = 8.8 Hz, 2H), 3.65 (*t*, *J* = 6.8 Hz, 2H), 3.47 (*t*, *J* = 6.0 Hz, 2H), 3.42 (s, 2H), 1.81 (*quint*, *J* = 6.4 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -74.13 (*t*, *J* = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 167.86, 150.05, 148.22, 128.89, 126.51, 124.92, 124.13 (*q*, *J* = 279.6 Hz), 117.08, 111.35, 109.60, 69.75, 68.45 (*q*, *J* = 33.9 Hz), 56.13, 45.34, 43.37, 28.67. MS (ESI): 360.2 [*M*+H]⁺. HRMS (ESI) for C₁₇H₂₁NO₄F₃ [*M*+H]⁺: calc'd: 360.1423; found: 360.1425.

4-Methyl-2-((2,2,2-trifluoroethoxy)methyl)quinazoline (42).

Ме To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (53 mg, 2.0 mmol, 2.0 equiv.) and DMF (4.0 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol (200 mg, 2.0 mmol, 2.0 equiv.) in DMF (1.0 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. 2-(Chloromethyl)-4-methylquinazoline (193 mg, 1.0 mmol, 1.0 equiv.) in DMF (2.0 mL) was then added dropwise at 0 °C. The flask was capped loosely, and the contents stirred vigorously at 0 °C for 1 h and then 80 °C for 2 h. The reaction mixture was then poured onto water and extracted with DCM (2×15 mL). The organic phase was dried (Mg₂SO₄) and concentrated in vacuo. The residue was purified by flash chromatography (ethyl acetate-n-hexane, 1: 2) to give 42 as a white solid (238 mg, 93%) yield). Mp: 75–77 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.14–7.92 (m, 2H), 7.84 (ddd, J = 8.4, 7.0, 1.3 Hz, 1H), 7.59 (ddd, J = 8.2, 7.0, 1.1 Hz, 2H), 4.98 (s, 2H), 4.13 (q, J = 8.8Hz, 2H), 2.91 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -73.89 (t, J = 8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 169.13, 161.19, 149.78, 134.01, 129.06, 127.72, 125.12, 124.25 (q, J = 279.7 Hz), 123.35, 75.22, 68.58 (q, J = 34.0 Hz), 21.88. MS (ESI): 257.1 [M+H]+. HRMS (ESI) for C₁₂H₁₂N₂OF₃ [M+H]+: calc'd: 257.0902; found: 257.0901.

2-(4-Chloro-2-methylphenoxy)ethan-1-ol.

Me CI 2-Methyl-4-chlorophenoxyacetic acid (2.01 g, 10 mmol, 1 equiv.) was dissolved in THF (20 mL) and BH₃·Me₂S (1.52 g, 20 mmol, 2 equiv.) was added dropwise at 0 °C under argon. The mixture was stirred at RT for 12 h, quenched with methanol, washed with saturated aq. NH₄Cl, and extracted with ethyl acetate (2 × 20 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate-*n*-hexane, 1: 2) to give the title compound as a white solid (1.47 g, 79% yield). Mp: 56–58 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.11–7.02 (m, 2H), 6.72 (d, J = 8.4 Hz, 1H), 4.18–4.00 (m, 2H), 3.98 (d, J = 8.1 Hz, 2H), 2.20 (s, 4H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 155.50, 130.70, 128.88, 126.59, 125.68, 112.54, 69.86, 61.67, 16.28.

2-(4-Chloro-2-methylphenoxy)ethyl 4-methylbenzenesulfonate

Me CI General procedure 6 with 2-(4-chloro-2-'methylphenoxy)ethan-1-ol on a 5.0 mmol followed by flash chromatography (ethyl acetate/n-hexane, 1: 3) gave the title compound as a colorless oil (1.56 g, 92% yield). Mp: 58–60 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.80 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.15–6.92 (m, 2H), 6.60 (d, J = 8.5 Hz, 1H), 4.50–4.27 (m, 2H), 4.25–3.95 (m, 2H), 2.44 (s, 3H), 2.09 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 154.93, 145.22, 133.03, 130.78, 130.08, 129.19, 128.10, 126.50, 126.01, 112.39, 68.26, 65.98, 21.84, 16.13. MS (ESI): 358.1 [M+NH₄]⁺. HRMS (ESI) for C₁₆H₂₁NO₄SCI [M+NH₄]⁺: calc'd: 358.0880; found: 358.0880.

4-Chloro-2-methyl-1-(2-(2,2,2-trifluoroethoxy)ethoxy)benzene (43).

Me CI General procedure 7 with 2-(4-chloro-2-F₃C O methylphenoxy)ethyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 1: 10) gave **43** as a colorless oil (183 mg, 68% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.11 (dt, J = 8.6, 2.3 Hz, 2H), 6.72 (d, J = 8.5 Hz, 1H), 4.12 (dd, J = 5.5, 3.7 Hz, 2H), 4.05–3.83 (m, 4H), 2.21 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.40 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 155.52, 130.77, 129.08, 126.59, 125.79, 124.14 (q, J = 279.7 Hz), 112.46, 71.29, 69.19 (q, J = 33.9 Hz), 68.18, 16.27 .

3-(Benzo[d][1,3]dioxol-5-yl)-2-methylpropan-1-ol.

Helional (2-methyl-3-(3,4-methylenedioxyphenyl)propionaldehyde; HO 1.92 g, 10 mmol, 1 equiv.) was added over a period of 2 min at 0 °C to a suspension of NaBH₄ (0.76 g, 20 mmol, 2 equiv.) in ethanol (200 proof, 20 mL), The reaction mixture was stirred for 6 h at RT, quenched with ice—cold aq. HCl (1 M), and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄) and then concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/*n*-hexane, 1: 4) to give the product as a colorless oil (1.73 g, 89% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.72 (*d*, *J* = 7.9 Hz, 1H), 6.67 (*d*, *J* = 1.6 Hz, 1H), 6.61 (*dd*, *J* = 7.9, 1.6 Hz, 1H), 5.91 (s, 2H), 3.48 (*qd*, *J* = 10.6, 5.9 Hz, 1H), 2.67 (*dd*, *J* = 13.6, 6.4 Hz, 1H), 2.34 (*dd*, *J* = 13.6, 8.0 Hz, 1H), 1.97–1.77 (*m*, 1H), 1.56 (s, 1H), 0.90 (*d*, *J* = 6.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 147.68, 145.83, 134.60, 122.07, 109.64, 108.21, 100.93, 67.69, 39.57, 38.07, 16.58.

3-(Benzo[d][1,3]dioxol-5-yl)-2-methylpropyl 4-methylbenzenesulfonate.

OTs General procedure 6 with 3-(benzo[d][1,3]dioxol-5-yl)-2-methylpropan-1-ol on a 5.0 mmol followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave the title compound as a colorless oil

(1.38 g, 79% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.78 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.1 Hz, 2H), 6.66 (d, J = 7.8 Hz, 1H), 6.59–6.38 (m, 2H), 5.90 (s, 2H), 3.95–3.72 (m, 2H), 2.58 (dd, J = 13.7, 6.7 Hz, 1H), 2.45 (s, 3H), 2.33 (dd, J = 13.7, 7.7 Hz, 1H), 2.00 (td, J = 13.0, 6.7 Hz, 1H), 0.88 (d, J = 6.8 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 147.74, 146.07, 144.93, 133.23, 133.12, 130.03, 128.10, 122.14, 109.52, 108.26, 101.00, 74.20, 38.85, 35.18, 21.83, 16.39. MS (ESI): 371.1 [M+Na]⁺. HRMS (ESI) for C₁₈H₂₀O₅SNa [M+Na]⁺: calc'd: 371.0929; found: 371.0934.

5-(2-Methyl-3-(2,2,2-trifluoroethoxy)propyl)benzo[d][1,3]dioxole (44).

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (53 mg, 2.0 mmol, 2 equiv.) and DMF (4 mL, 0.5 M) under argon followed by adding 2,2,2-trifluoroethanol (200 mg, 2.0 mmol, 2 equiv.) in DMF (1.0 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. 3-(Benzo[d][1,3]dioxol-5-yl)-2-methylpropyl 4-methylbenzenesulfonate (348 mg, 1.0 mmol, 1 equiv.) in DMF (2 mL) was added dropwise at 0 °C, The flask was loosely capped, stirred vigorously at 0 °C for 1 h, and heated at 80 °C for 12 h. The reaction mixture was then poured onto water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. Silica gel flash chromatography (ethyl acetate/n-hexane, 1: 10) of the residue gave 44 as a colorless oil (173 mg, 63% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 6.73 (d, J = 7.9 Hz, 1H), 6.65 (d, J = 1.6 Hz, 1H), 6.60 (dd, J = 7.9, 1.6 Hz, 1H), 5.92 (s, 2H), 3.79 (g, J = 8.8 Hz, 1H), 3.53–3.30 (m, 2H), 2.67 (dd, J = 13.6, 6.4 Hz, 1H), 2.37 (dd, J = 13.6, 7.8 Hz, 1H), 1.99 (dq, J = 12.9, 6.4 Hz, 1H), 0.92 (d, J = 6.8 Hz, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -74.12 (d, J =8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 147.72, 145.92, 134.23, 124.31 (g, J = 279.7 Hz), 122.20, 109.69, 108.23, 100.97, 77.19, 68.74 (q, J = 33.8 Hz), 39.37, 35.81, 16.72.

1-(((2*R*,4*R*)-2-(2,4-Difluorophenyl)-4-((2,2,2-trifluoroethoxy)methyl)tetrahydrofuran-2-yl)methyl)-1*H*-1,2,4-triazole (45).

General procedure 7 with ((3S,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorophenyl)tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/DCM: 3: 1) gave**45**as a

colorless oil (87 mg, 46% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 8.07 (s, 1H), 7.79

(s, 1H), 7.33 (td, J = 8.7, 6.6 Hz, 1H), 6.81 (tdd, J = 11.1, 8.4, 2.5 Hz, 2H), 4.53 (dd, J = 46.3, 14.4 Hz, 2H), 4.20–3.88 (m, 1H), 3.69 (ddd, J = 15.2, 13.0, 7.5 Hz, 3H), 3.40 (dd, J = 8.9, 5.3 Hz, 1H), 3.33–3.21 (m, 1H), 2.67–2.21 (m, 2H), 1.93 (td, J = 11.6, 4.8 Hz, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.14 (t, J = 8.4 Hz, 3F), –109.02 (dd, J = 18.7, 9.6 Hz, 1F), –109.93 – –111.27 (m, 1F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.97 (dd, J = 249.6, 11.9 Hz), 159.16 (dd, J = 247.5, 11.9 Hz), 151.26, 144.74, 128.75 (dd, J = 9.5, 5.5 Hz), 125.47 (dd, J = 13.1, 3.7 Hz), 123.99 (q, J = 279.7 Hz), 111.49 (dd, J = 20.7, 3.5 Hz), 104.79 (t, J = 26.0 Hz), 84.15 (d, J = 4.3 Hz), 73.60, 70.72, 68.68 (q, J = 33.9 Hz), 56.05 (d, J = 4.1 Hz), 39.16, 37.40 (d, J = 3.5 Hz). MS (ESI): 378.1 [M+H]⁺. HRMS (ESI) for C₁₆H₁₇N₃O₂F₅ [M+H]⁺: calc'd: 378.1241; found: 378.1238.

1-(((2*R*,4*R*)-2-(2,4-Dichlorophenyl)-4-((2,2,2-trifluoroethoxy)methyl)-1,3-dioxolan-2-yl)methyl)-1*H*-imidazole (46).

General procedure 7 with ((2*R*,4*S*)-2-((1*H*-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate) gave **46** as a colorless

oil (345 mg, 84% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.53 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.22 (dd, J = 8.4, 2.0 Hz, 1H), 6.98 (s, 1H), 6.94 (s, 1H), 4.41 (dd, J = 49.1, 14.8 Hz, 2H), 4.24–4.07 (m, 1H), 3.94–3.63 (m, 3H), 3.56 (dd, J = 8.4, 5.2 Hz, 1H), 3.27 (dd, J = 10.0, 6.0 Hz, 1H), 3.17 (dd, J = 10.0, 5.5 Hz, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.22 (t, J = 8.4 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 138.91, 136.08, 134.62, 133.09, 131.53, 129.71, 128.67, 127.40, 123.91 (q, J = 279.6 Hz), 121.25, 108.27, 75.19, 72.32, 68.81 (q, J = 34.3 Hz), 67.14, 51.33. MS (ESI): 411.1 [M+H]⁺. HRMS (ESI) for C₁₆H₁₆N₂O₃F₃Cl₂ [M+H]⁺: calc'd: 411.0490; found: 411.0494.

(3-(5-(2-Methoxyphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol.

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (267 mg, 10.0 mmol, 2 equiv.) and DMF (20 mL) under argon, followed by addition of MeOH (2 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. (3-(5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (1.35 g, 5.0 mmol, 1.0 equiv.) in

DMF (3 mL) was then added dropwise at RT. The flask was loosely capped, and the contents stirred vigorously at 80 °C for 12 h. The reaction mixture was then poured onto

water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄) and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/*n*-hexane, 1: 2) to give the title compound as a white solid (901 mg, 64% yield). Mp: 98–100 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.37–7.96 (m, 3H), 7.72–7.38 (m, 3H), 7.22–6.86 (m, 2H), 4.78 (d, J = 5.9 Hz, 2H), 4.00 (s, 3H), 2.06 (t, J = 6.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 175.36, 168.42, 158.73, 141.85, 134.34, 131.86, 129.71, 129.26, 127.54, 126.94, 126.20, 120.98, 113.65, 112.32, 65.13, 56.27. MS (ESI): 283.1 [M+H]⁺. HRMS (ESI) for C₁₆H₁₅N₂O₃ [M+H]⁺: calc'd: 283.1083; found: 283.1078.


3-(3-(Bromomethyl)phenyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole.

5-(2-Methoxyphenyl)-3-(3-((2,2,2-trifluoroethoxy)methyl)phenyl)-1,2,4-oxadiazole (47).

To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (27 mg, 1.0 mmol, 2 equiv.) and DMF (1 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol (100 mg, 1.0 mmol, 2.0 equiv.) in DMF (1 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. 3-(3-(Bromomethyl)phenyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole (173 mg, 0.5 mmol, 1 equiv.) in DMF (2 mL) was then added dropwise at RT. The flask was capped loosely capped, and the contents stirred vigorously at 80 °C for 2 h. The reaction mixture was then poured onto water and

extracted with DCM (2 × 15 mL). The organic phase was separated off, dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/n-hexane, 1: 5) to give **47** as a white solid (147 mg, 81% yield). Mp: 66–68 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.34–7.90 (m, 3H), 7.90–7.43 (m, 3H), 7.20–6.74 (m, 2H), 4.75 (s, 2H), 3.99 (s, 3H), 3.88 (q, J = 8.7 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.82 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 175.42, 168.21, 158.70, 137.50, 134.33, 131.79, 130.46, 129.35, 127.70, 127.54, 127.01, 124.21 (q, J = 279.3 Hz), 120.92, 113.56, 112.28, 73.86, 67.54 (q, J = 34.2 Hz), 56.17. MS (ESI): 365.1 [M+H]⁺. HRMS (ESI) for C₁₈H₁₆N₂O₃F₃ [M+H]⁺: calc'd: 365.1113; found: 365.1117.

2-Cyclopropyl-4-(4-fluorophenyl)-3-((2,2,2-trifluoroethoxy)methyl)quinoline (48).



To a round-bottomed flask equipped with a magnetic stirrer bar was added dry NaH (53 mg, 2.0 mmol, 2 equiv.) and DMF (4 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol (200 mg, 2.0 mmol, 2 equiv.) in DMF (1 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. 3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline (356 mg, 1.0 mmol, 1


equiv.) in DMF (2 mL) was then added dropwise at RT. The flask was capped loosely and stirred vigorously at 80 °C for 2 h. The reaction mixture was then poured onto water and extracted with DCM (2 x 15 mL). The organic phase was separated, dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. Flash chromatography (ethyl acetate/*n*-hexane, 1: 4) of the residue gave **48** as a colorless oil (278 mg, 74% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.97 (*d*, J = 8.4 Hz, 1H), 7.61 (ddd, J = 8.4, 5.6, 2.6 Hz, 1H), 7.38–7.26 (m, 4H), 7.22 (dt, J = 8.7, 2.4 Hz, 2H), 4.67 (s, 2H), 3.75 (q, J = 8.7 Hz, 2H), 2.48 (tt, J = 8.1, 4.9 Hz, 1H), 1.46–1.26 (m, 2H), 1.19–0.89 (m, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.69 (t, J = 8.8 Hz, 3F), –105.26 – –117.40 (m, 1F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.90 (t, t = 247.7 Hz), 162.62, 147.90, 132.29 (t = 3.5 Hz), 131.67 (t = 8.0 Hz), 129.68, 129.21, 126.66, 126.12, 125.93, 125.78, 124.11 (t = 279.7 Hz), 115.61 (t = 21.5 Hz), 69.09, 67.94 (t = 34.2 Hz), 14.73, 9.90. MS (ESI): 376.1 [t HRMS (ESI) for C₂₁H₁₈NOF₄ [t = t + t

2-(1-Benzyl-1*H*-indazol-3-yloxy)ethanol.

Bendazac (2-((1-benzyl-1*H*-indazol-3-yl)oxy)acetic acid; 2.82 g, 10 mmol, 1 equiv.) was dissolved in THF (20 mL) and BH₃·Me₂S (1.52 g, 20 mmol, 2 equiv.) was added dropwise at 0 °C under argon. The mixture was stirred at RT for 12 h and then quenched with MeOH,

washed with saturated aq. NH₄Cl, and extracted with ethyl acetate (2 × 20 mL). The organic layer was dried (Mg₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified with silica gel chromatography (ethyl acetate/n-hexane, 1/3) to give the title compound as a white solid (2.34 g, 87% yield). Mp: 89–91 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.58 (d, J = 8.1 Hz, 1H), 7.29–7.13 (m, 4H), 7.09 (t, J = 7.2 Hz, 3H), 6.96 (t, J = 7.5 Hz, 1H), 5.28 (t, 2H), 4.66–4.28 (t, 2H), 3.92 (t, t = 3.1 Hz, 2H), 3.17 (t, t = 5.3 Hz, 1H); t C NMR (101 MHz, CDCl₃) δ (ppm): 156.13, 141.84, 137.31, 128.83, 127.89, 127.81, 127.30, 120.30, 119.61, 113.00, 109.14, 71.59, 62.49, 52.55. MS (ESI): 269.1 [t HRMS (ESI) for C₁₆H₁₇N₂O₂ [t HH]+: calc'd: 269.1290; found: 269.1290.

2-(1-Benzyl-1*H*-indazol-3-yloxy)ethyl 4-methylbenzenesulfonate.



General procedure 6 with 2-(1-benzyl-1*H*-indazol-3-yloxy)ethanol on a 5.0 mmol followed by flash chromatography (ethyl acetate/n-hexane, 1: 3) gave the title compound as a white solid (1.75 g, 83% yield). Mp: 61–63 °C. 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.68 (d, J

= 8.0 Hz, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.20 (dt, J = 17.2, 8.8 Hz, 4H), 7.07 (dd, J = 14.8, 7.2 Hz, 5H), 6.94 (t, J = 7.5 Hz, 1H), 5.23 (s, 2H), 4.59–4.44 (m, 2H), 4.42–4.30 (m, 2H), 2.23 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 155.06, 144.89, 141.70, 137.45, 133.02, 129.90, 128.79, 128.11, 127.76, 127.67, 127.23, 120.20, 119.46, 112.82, 108.99, 68.34, 66.17, 52.47, 21.73. MS (ESI): 423.1 [M+H]⁺. HRMS (ESI) for C₂₃H₂₃N₂O₄S [M+H]⁺: calc'd: 423.1379; found: 423.1378.

1-Benzyl-3-(2-(2,2,2-trifluoroethoxy)ethoxy)-1*H*-indazole (49).

O CF₃

General procedure 7 with 2-(1-benzyl-1H-indazol-3-yloxy)ethyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave **49** as a colorless oil (178 mg, 51% yield). ¹H NMR (400 MHz, CDCl₃) δ

(ppm): 7.59 (d, J = 8.1 Hz, 1H), 7.40–7.12 (m, 4H), 7.08 (t, J = 7.3 Hz, 3H), 6.95 (t, J = 7.5 Hz, 1H), 5.29 (s, 2H), 4.48 (dd, J = 4.9, 3.8 Hz, 2H), 4.10–3.94 (m, 2H), 3.88 (q, J =

8.7 Hz, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.21 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 155.72, 141.85, 137.58, 128.79, 127.73, 127.69, 127.19, 124.22 (q, J = 279.7 Hz), 120.26, 119.49, 113.08, 109.07, 71.22, 69.03 (q, J = 33.9 Hz), 68.36, 52.52. MS (ESI): 351.1 [M+H]⁺. HRMS (ESI) for C₁₈H₁₈N₂O₂F₃ [M+H]⁺: calc'd: 351.1320; found: 351.1323.

((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5,6-tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methyl 4-methylbenzenesulfonate.

OTs General procedure with ((2R,3R,4S,5R,6S)-3,4,5,6-6 **BnO** tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methanol on a 4.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 3) gave the title compound as a colorless oil (2.34 g, 84% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.68 (d, J = 8.3 Hz, 2H), 7.37–7.13 (m, 20H), 7.07 (dd, J = 7.0, 2.4 Hz, 2H), 4.91 (d, J = 10.9 Hz, 1H), 4.84 - 4.61 (m, 3H), 4.54 (dd, J = 13.8, 12.2 Hz, 2H), 4.48 - 4.29 (m, 3.8)3H), 4.11 (dd, J = 10.6, 4.2 Hz, 1H), 4.06–3.86 (m, 2H), 3.71 (ddd, J = 10.1, 4.1, 1.9 Hz, 1H), 3.46–3.28 (*m*, 2H), 2.31 (s, 3H); 13 C NMR (101 MHz, CDCl₃) δ (ppm); 145.00, 138.82, 138.17, 137.95, 137.10, 133.11, 129.98, 128.63, 128.60, 128.58, 128.19, 128.17, 128.13, 128.10, 128.05, 128.03, 127.82, 95.67, 82.03, 79.93, 77.15, 75.86, 75.23, 73.22, 69.59, 68.97, 68.70, 21.81. MS (ESI): 712.3 [M+NH₄]+. HRMS (ESI) for C₄₁H₄₆NO₈S [M+NH₄]+: calc'd: 712.2944: found: 712.2946.

(2S,3R,4S,5R,6R)-2,3,4,5-tetrakis(benzyloxy)-6-((2,2,2-trifluoroethoxy)methyl)tetrahydro-2*H*-pyran (50).

F₃C General procedure 7 with ((2R,3R,4S,5R,6S)-3,4,5,6tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methyl 4methylbenzenesulfonate on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave **50** as a white solid (240 mg, 77%) yield). Mp: 85–87 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.55–7.27 (m, 20H), 5.08 (d, J = 10.8 Hz, 1H, 4.97 (d, J = 10.9 Hz, 1H), 4.90 (dd, J = 7.2, 3.6 Hz, 2H), 4.74 (d, J = 12.0)Hz, 2H), 4.64 (dd, J = 19.5, 11.4 Hz, 3H), 4.12 (t, J = 9.3 Hz, 1H), 4.02–3.73 (m, 4H), 3.75–3.53 (m, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –73.87 (t, J = 8.7 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 138.93, 138.38, 138.29, 137.25, 128.63, 128.57, 128.12, 128.09, 127.97, 127.77, 124.11 (q, J = 279.7 Hz), 95.81, 82.23, 80.14, 77.42,

75.91, 75.23, 73.23, 71.14, 70.62, 69.49, 69.08 (q, J = 34.1 Hz). MS (ESI): 640.3 [M+H]⁺. HRMS (ESI) for C₃₆H₄₁NO₆F₃ [M+H]⁺: calc'd: 640.2886; found: 640.2892.

5-(5-(Hydroxymethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile

Febuxostat (2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid; 1.58 g, 5.0 mmol, 1 equiv.) was dissolved in THF (20 mL) and BH₃-Me₂S (0.76 g, 10 mmol, 2 equiv.) was added dropwise at 0 °C under argon. The mixture was stirred

at RT for 12 h, quenched with MeOH, washed with saturated aq. NH₄Cl, and extracted with ethyl acetate (2 × 20 mL). The organic layer was dried (Mg₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate/n-hexane, 1: 1) to give the title compound as a white solid (1.15 g, 74% yield). Mp: 106–108 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.02 (d, J = 2.3 Hz, 1H), 7.95 (dd, J = 8.8, 2.3 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 4.78 (s, 2H), 3.84 (d, J = 6.5 Hz, 2H), 2.86 (s, 1H), 2.38 (s, 3H), 2.16 (sept, J = 13.3, 6.7 Hz, 1H), 1.06 (d, J = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.60, 161.89, 150.41, 132.23, 131.77, 131.56, 126.86, 115.87, 112.70, 102.72, 75.74, 56.79, 28.32, 19.22, 15.20. MS (ESI): 303.1 [M+H]⁺. HRMS (ESI) for C₁₆H₁₉N₂O₂S [M+H]⁺: calc'd: 303.1167; found: 303.1172.

5-(5-(Bromomethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile.

NC S Br

5-(5-(Hydroxymethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile (0.91 g, 3.0 mmol, 1 equiv.) was dissolved in

anhydrous DCM (20 mL) and PBr₃ (0.34 mL, 0.97 g, 3.6 mmol, 1.2

N-d equiv.) was added dropwise at 0 °C. The mixture was stirred at RT for 2 h , quenched with saturated aq. NaHCO₃ solution, and extracted with DCM (2 × 15 mL). The organic layer was dried (Mg₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate/*n*-hexane, 1: 3) to give the title compound as a white solid (0.73 g, 67% yield). Mp: 96–98 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 8.09 (*d*, J = 2.2 Hz, 1H), 8.01 (*dd*, J = 8.8, 2.3 Hz, 1H), 6.98 (*d*, J = 8.9 Hz, 1H), 4.70 (s, 2H), 3.88 (*d*, J = 6.5 Hz, 2H), 2.43 (s, 3H), 2.19 (sept, J = 13.3, 6.7 Hz, 1H), 1.08 (*d*, J = 6.7 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 164.24, 162.16, 153.25, 132.29, 131.77, 128.39, 126.67, 115.75, 112.76, 103.01, 75.81, 28.35, 23.86, 19.26, 15.25. MS (ESI): 365.0 [*M*+H]⁺. HRMS (ESI) for C₁₆H₁₈N₂OS⁷⁹Br [*M*+H]⁺: calc'd: 365.0323; found: 365.0329.

2-Isobutoxy-5-(4-methyl-5-((2,2,2-trifluoroethoxy)methyl)thiazol-2-yl)benzonitrile (51).

To a round-bottomed flask with a magnetic stirrer bar was added dry NaH (53 mg, 2.0 mmol, 2 equiv.) and DMF (2 mL, 0.5 M) under argon, followed by 2,2,2-trifluoroethanol (200 mg, 2.0 mmol, 2 equiv.) in DMF (1 mL) at 0 °C. The reaction mixture was stirred for 20 min under argon. 5-(5-(Bromomethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile (183 mg, 1.0 mmol, 1 equiv.) in DMF (2 mL) was then added dropwise at R. The reaction was loosely capped and stirred vigorously at 80 °C for 2 h. The reaction mixture was poured onto water and extracted with DCM. The organic phase was dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. Flash chromatography (ethyl acetate/*n*-hexane, 1: 3) of the residue gave **51** as a white solid (132 mg, 69% yield). Mp: 86–88 °C .¹H NMR (400 MHz, CDCl₃)
$$\delta$$
 (ppm): 8.10 (*d*, J = 2.3 Hz, 1H), 8.02 (*dd*, J = 8.8, 2.3 Hz, 1H), 6.98 (*d*, J = 8.9 Hz, 1H), 4.81 (s, 2H), 4.07–3.52 (*m*, 4H), 2.45 (s, 3H), 2.19 (dp, J = 13.3, 6.7 Hz, 1H), 1.08 (*d*, J = 6.7 Hz, 6H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm):

N-(2,6-Diethylphenyl)-N-(2-propoxyethyl)-2-(2,2,2-trifluoroethoxy)acetamide (52).

for C₁₈H₂₀N₂O₂F₃S [*M*+H]⁺: calc'd: 385.1198; found: 385.1203.

-73.72 (t, J = 9.2 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 164.69, 162.10, 152.74,

132.32, 131.78, 126.78, 126.54, 124.08 (q, J = 279.3 Hz), 115.80, 112.74, 102.97, 75.80,


 $67.02 (q, J = 34.3 \text{ Hz}), 65.45, 28.36, 19.25, 15.36. \text{ MS (ESI)}: 385.1 [M+H]^+. HRMS (ESI)$

To a round-bottomed flask equipped with a magnetic stirrer bar was added Cs₂CO₃ (652 mg, 2.0 mmol, 2 equiv.) and DMF (4 mL) under argon. The reaction mixture was stirred for 5 min. Pretilachlor (2-chloro-*N*-(2,6-diethylphenyl)-*N*-(2-propoxyethyl)acetamide; 312 mg, 1.0 mmol, 1 equiv.) was then

added under argon. The reaction mixture was stirred vigorously at RT for 12 h, poured onto water, and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. The residue was purified by flash chromatography (ethyl acetate/n-hexane, 1: 10) to afford the product as a colorless oil (301 mg, 80% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.25 (t, t = 7.7 Hz, 1H), 7.13 (t = 7.7 Hz, 2H), 3.90 (t = 8.8 Hz, 2H), 3.74–3.64 (t = 7.4 Hz, 3H), 3.53 (t = 6.1 Hz, 2H), 3.25 (t = 6.7 Hz, 2H), 2.64–2.30 (t = 7.4 Hz, 3H), 1.18 (t = 7.5 Hz, 6H), 0.78 (t = 7.4 Hz, 3H);

¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): -74.33 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 169.44, 141.54, 137.20, 129.26, 126.99, 124.01 (q, J = 279.6 Hz), 72.85, 69.53, 68.53 (q, J = 34.2 Hz), 67.52, 49.69, 23.37, 22.95, 14.28, 10.63. MS (ESI): 376.2 [M+H]⁺. HRMS (ESI) for C₁₉H₂₉NO₃F₃ [M+H]⁺: calc'd: 376.2100; found: 376.2107.


3-(4,5-Diphenyloxazol-2-yl)propan-1-ol.



Oxaprozin (3-(4,5-diphenyloxazol-2-yl)propanoic acid; 2.93 g, 10 mmol, 1 equiv.) was dissolved in THF (20 mL) and BH₃-Me₂S (1.52 g, 20 mmol, 2 equiv.) was added dropwise at 0 °C under argon. The mixture was stirred at RT for 12 h,

quenched with MeOH, and washed with saturated aq. NH₄Cl. The aqueous phase was further extracted with ethyl acetate (2 × 15 mL). The combined organic phase was dried (Mg₂SO₄), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate/n-hexane, 1: 2) to give the title compound as a white solid (2.01 g, 72% yield). Mp: 98–100 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.60 (*dd*, J = 20.6, 7.1 Hz, 4H), 7.43–7.28 (m, 6H), 3.80 (t, J = 5.6 Hz, 2H), 3.11 (t s, 1H), 2.99 (t = 7.1 Hz, 2H), 2.19–2.02 (t s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 163.72, 145.51, 135.01, 132.48, 129.14, 128.85, 128.77, 128.67, 128.29, 128.06, 126.67, 62.21, 29.66, 25.58. MS (ESI): 280.1 [t HRMS (ESI) for C₁₈H₁₈NO₂ [t HH]+: calc'd: 280.1338; found: 280.1337.

3-(4,5-Diphenyloxazol-2-yl)propyl 4-methylbenzenesulfonate.



General procedure 6 from 3-(4,5-diphenyloxazol-2-yl)propan-1-ol on a 5.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 2) gave the title compound as a colorless oil (1.93 g, 89% yield). 1 H NMR (400 MHz, CDCl₃) δ

(ppm): 7.81 (*d*, J = 8.2 Hz, 2H), 7.59 (*dd*, J = 16.0, 7.1 Hz, 4H), 7.43–7.32 (*m*, 6H), 7.30 (*d*, J = 8.2 Hz, 2H), 4.25 (*t*, J = 6.1 Hz, 2H), 2.93 (*t*, J = 7.3 Hz, 2H), 2.39 (s, 3H), 2.25 (*p*, J = 6.7 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.91, 145.55, 145.01, 135.22, 133.06, 132.59, 130.04, 129.09, 128.86, 128.75, 128.69, 128.28, 128.09, 128.04, 126.62, 69.34, 26.30, 24.27, 21.79. MS (ESI): 434.1 [*M*+H]⁺. HRMS (ESI) for C₂₅H₂₄NO₄S [*M*+H]⁺: calc'd: 434.1426; found: 434.1431.


4,5-Diphenyl-2-(3-(2,2,2-trifluoroethoxy)propyl)oxazole (53).

$$O$$
 O
 CF_3

General procedure 7 with 3-(4,5-diphenyloxazol-2-yl)propyl 4-methylbenzenesulfonate on a 1.0 mmol scale followed by flash chromatography (ethyl acetate/*n*-hexane, 1: 4) gave **53** as a colorless oil (280 mg, 78%)

yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.62 (*dd*, *J* = 25.1, 6.9 Hz, 4H), 7.45–7.28 (*m*, 6H), 3.85 (*q*, *J* = 8.7 Hz, 2H), 3.77 (*t*, *J* = 6.1 Hz, 2H), 2.98 (*t*, *J* = 7.5 Hz, 2H), 2.50–1.99 (*m*, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.15 (*t*, *J* = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 162.95, 145.45, 135.28, 132.76, 129.26, 128.82, 128.75, 128.58, 128.21, 128.09, 126.62, 124.21 (*q*, *J* = 279.6 Hz), 71.70, 68.58 (*q*, *J* = 34.0 Hz), 27.16, 24.83. MS (ESI): 362.1 [*M*+H]⁺. HRMS (ESI) for C₂₀H₁₉NO₂F₃ [*M*+H]⁺: calc'd: 362.1368; found: 362.1370.

(Z)-2-(4-(1,2-Diphenylbuta-1,3-dien-1-yl)phenoxy)ethan-1-ol.




(1.35 g, 12 mmol, 2 equiv.) was added at 0 °C and the reaction mixture was stirred at RT for 12 h. The reaction mixture was then poured onto water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (ethyl acetate/*n*-hexane, 1: 4) to give the title compound as a white solid (1.95 g, 95% yield). Mp: 114–116 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.41–7.08 (m, 10H), 6.83–6.64 (m, 3H), 6.61–6.49 (m, 2H), 5.12 (dd, J = 10.7, 1.7 Hz, 1H), 4.90 (dd, J = 17.3, 1.7 Hz, 1H), 3.93 (dd, J = 5.1, 3.7 Hz, 2H), 3.89–3.65 (m, 2H), 2.05 (t, J = 6.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 157.06, 142.72, 141.91, 140.35, 138.76, 138.54, 135.74, 132.41, 131.59, 131.14, 128.13, 128.06, 127.37, 126.65, 117.71, 113.52, 69.06, 61.59. MS (ESI): 343.2 [M+H]†. HRMS (ESI) for C₂₄H₂₃O₂ [M+H]†: calc'd: 343.1698; found: 343.1704.

(Z)-2-(4-(1,2-Diphenylbuta-1,3-dien-1-yl)phenoxy)ethyl 4-methylbenzenesulfonate.

General procedure 6 with (Z)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethan-1-ol on a 5.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 4) gave the title compound as a pale–yellow solid (1.93 g, 78% yield). Mp: 52–54 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.76 (d, J = 8.0 Hz,

2H), 7.45–7.01 (m, 12H), 6.90–6.55 (m, 3H), 6.41 (d, J = 8.4 Hz, 2H), 5.11 (d, J = 10.8 Hz, 1H), 4.89 (d, J = 17.2 Hz, 1H), 4.49–4.13 (m, 2H), 3.97–3.99 (m, 2H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 156.41, 145.06, 142.60, 141.77, 140.23, 138.66, 138.59, 135.94, 132.98, 132.30, 131.53, 131.07, 129.99, 128.14, 128.11, 128.03, 127.36, 126.66, 117.77, 113.48, 68.26, 65.26, 21.79. MS (ESI): 514.2 [M+NH₄]⁺. HRMS (ESI) for C₃₁H₃₂NO₄S [M+ NH₄]⁺: calc'd: 514.2052; found: 514.2045.

(Z)-(1-(4-(2-(2,2,2-trifluoroethoxy)ethoxy)phenyl)buta-1,3-diene-1,2-di-yl)dibenzene (54).



General procedure 7 with (Z)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethyl 4-methylbenzenesulfonate on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 20) gave **54** as a colorless oil (84 mg, 40% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.41–7.01 (m, 10H), 6.86–

6.64 (m, 3H), 6.60–6.44 (m, 2H), 5.12 (dd, J = 10.7, 1.7 Hz, 1H), 4.90 (dd, J = 17.3, 1.7 Hz, 1H), 4.01 (dd, J = 5.5, 3.6 Hz, 2H), 3.96–3.73 (m, 4H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.27 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 156.95, 142.74, 141.94, 140.36, 138.77, 138.59, 135.81, 132.41, 131.62, 131.16, 128.15, 128.07, 127.38, 126.67, 124.14 (q, J = 279.8 Hz), 117.72, 113.58, 71.24, 69.11 (q, J = 34.1 Hz), 67.36 . MS (ESI): 425.2 [M+H]⁺. HRMS (ESI) for C₂₆H₂₄O₂F₃ [M+H]⁺: calc'd: 425.1728; found: 425.1728.

(E)-2-(2-(4-(3,5-Dimethoxystyryl)phenoxy)ethoxy)ethanol.

Pterostilbene (4-[(1*E*)-2-(3,5-dimethoxyphenyl)ethenyl]phenol; 2.56 g, 10.0 mmol, 1 equiv.), Cs₂CO₃ (4.89 g, 15.0 mmol, 1.5 equiv.) and DMF (30 mL) were

added to a round-bottomed flask equipped with a magnetic stirrer bar under argon. The

reaction mixture was stirred at 60 °C for 12 h. The reaction mixture was then poured onto water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated *in vacuo*. The residue was purified by flash chromatography (ethyl acetate/*n*-hexane, 2: 1) to give the title compound as a colorless oil (1.41 g, 41% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.43 (*d*, *J* = 8.7 Hz, 2H), 7.10–6.76 (*m*, 4H), 6.65 (*d*, *J* = 2.2 Hz, 2H), 6.38 (*t*, *J* = 2.2 Hz, 1H), 4.24–4.09 (*m*, 2H), 3.87 (*dd*, *J* = 5.4, 4.0 Hz, 2H), 3.82 (s, 6H), 3.80–3.74 (*m*, 2H), 3.70–3.64 (*m*, 2H), 2.33 (*t*, *J* = 6.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.13, 158.62, 139.81, 130.43, 128.81, 127.99, 126.92, 114.99, 104.52, 99.82, 72.79, 69.82, 67.62, 61.95, 55.52. MS (ESI): 345.2 [*M*+H]⁺: HRMS (ESI) for C₂₀H₂₅O₅ [*M*+H]⁺: calc'd: 345.1702; Found: 345.1708.

(E)-2-(2-(4-(3,5-Dimethoxystyryl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate

General procedure 6 with (E)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethoxy)ethanol on a 4.0 mmol followed by flash chromatography (ethyl acetate/n-hexane, 1: 1) gave the title

compound as a colorless oil (1.62 g, 81% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.80 (d, J = 8.3 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 7.12–6.81 (m, 4H), 6.65 (d, J = 2.2 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 4.28–4.15 (m, 2H), 4.14–3.97 (m, 2H), 3.83 (t, 6H), 3.82–3.73 (t, 4H), 2.41 (t, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.16, 158.63, 145.01, 139.82, 133.15, 130.41, 130.00, 128.84, 128.17, 127.98, 126.93, 114.99, 104.54, 99.84, 70.05, 69.44, 69.10, 67.62, 55.55, 21.81. MS (ESI): 499.2 [t HRMS (ESI) for C₂₇H₃₁O₇S [t t t t calc'd: 499.1790; found: 499.1786.

(*E*)-1,3-Dimethoxy-5-(4-(2-(2-(2,2,2-trifluoroethoxy)ethoxy)ethoxy)styryl)benzene (55).

General procedure 7 with (*E*)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate on a 0.5 mmol scale followed by flash chromatography

(ethyl acetate/*n*-hexane, 1: 2) gave **55** as a colorless oil (185 mg, 87% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.44 (*d*, *J* = 8.7 Hz, 2H), 6.96 (*dt*, *J* = 13.1, 10.3 Hz, 4H), 6.66 (*d*, *J* = 2.2 Hz, 2H), 6.39 (*t*, *J* = 2.2 Hz, 1H), 4.24–4.09 (*m*, 2H), 3.92 (*q*, *J* = 8.8 Hz, 2H), 3.87 (*dd*, *J* = 5.4, 4.1 Hz, 2H), 3.84–3.79 (*m*, 8H), 3.79–3.72 (*m*, 2H); ¹⁹F NMR (376 MHz,

CDCl₃) δ (ppm): -74.23 (t, J = 8.8 Hz, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 161.15, 158.72, 139.84, 130.34, 128.86, 127.97, 126.86, 124.22 (q, J = 279.6 Hz), 115.00, 104.52, 99.81, 72.14, 71.06, 70.04, 68.98 (q, J = 33.9 Hz), 67.61, 55.51.

(R)-3-fluoro-4-(4-(1-hydroxypropan-2-yloxy)phenoxy)benzonitrile.

To a round-bottomed flask equipped with a magnetic stirrer bar was added CaCl2 (666 mg, 6.0 mmol, 1 equiv.) and ethanol (200 proof, 30 mL), followed by NaBH₄ (681 mg, 18 mmol, 3 equiv.) at 0 °C. The reaction mixture was stirred for 10 min. Butyl (R)-2-(4-(4-cyano-2fluorophenoxy)phenoxy)propanoate (2.14 g, 6.0 mmol, 1 equiv.) was then added and the reaction mixture was stirred at 60 °C for 3 h. The reaction mixture was guenched with water and extracted with DCM (2 × 15 mL). The organic phase was dried (Mg₂SO₄), filtered, and concentrated in vacuo. The residue was purified by flash chromatography (ethyl acetate/n-hexane, 1: 2) to give the title compound as a white solid (1.21 g, 70%) yield). Mp: 86–88 °C. ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.44 (dd, J = 10.2, 1.9 Hz, 1H), 7.36-7.28 (m, 1H), 7.04-6.91 (m, 4H), 6.87 (t, J = 8.3 Hz, 1H), 4.46 (m, , 1H), 3.91-3.56(m, 2H), 2.19 (s, 1H), 1.28 (d, J = 6.2 Hz, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): – 130.13 (t, J = 8.9 Hz, 1F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 155.37, 152.24 (d, J =303.6 Hz), 151.04 (d, J = 41.2 Hz), 148.34, 129.52 (d, J = 4.1 Hz), 121.30, 120.70 (d, J = 21.2 Hz), 118.59 (d, J = 1.8 Hz), 117.85 (d, J = 2.5 Hz), 117.75, 106.05 (d, J = 8.2 Hz), 75.72, 66.35, 15.95.

(R)-2-(4-(4-Cyano-2-fluorophenoxy)phenoxy)propyl 4-methylbenzenesulfonate.

2.4 Hz), 117.80, 106.20 (d, J = 8.1 Hz), 72.50, 71.89, 21.83, 16.68. MS (ESI): 459.1 [$M+NH_4$]+. HRMS (ESI) for C₂₃H₂₄N₂O₅FS [$M+NH_4$]+: calc'd: 459.1390; found: 459.1398.

(*R*)-3-fluoro-4-(4-(1-(2,2,2-trifluoroethoxy)propan-2-yloxy)phenoxy)benzonitrile (56).

methylbenzenesulfonate on a 0.5 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 10) gave **56** as a colorless oil (78 mg, 42% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.44 (dd, J = 10.2, 1.9 Hz, 1H), 7.39–7.30 (m, 1H), 7.08–6.92 (m, 4H), 6.87 (t, J = 8.3 Hz, 1H), 4.64–4.35 (m, 1H), 4.09–3.86 (m, 2H), 3.84–3.69 (m, 2H), 1.33 (d, J = 6.3 Hz, 3H); 19 F NMR (376 MHz, CDCl₃) δ (ppm): –74.30 (t, J = 9.1 Hz, 3F); –130.21 (d, J = 9.7 Hz, 1F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 155.37, 152.27 (d, J = 302.7 Hz), 151.07 (d, J = 40.1 Hz), 148.41, 129.53 (d, J = 4.0 Hz), 124.11 (d, J = 279.8 Hz), 121.30, 120.70 (d, J = 21.2 Hz), 118.61 (d, J = 1.6 Hz), 117.88 (d, J = 2.4 Hz), 117.82, 106.09 (d, J = 8.1 Hz), 75.82, 74.29, 69.18 (d, J = 34.2 Hz), 16.67 .

2.4. Synthesis of PS13 analogue 57 and precursor for radiolabeling.

2-(1,5-Bis(4-methoxyphenyl)-1*H*-1,2,4-triazol-3-yloxy)ethanol.

MeO N-NOOH

1,5-Bis(4-methoxyphenyl)-1*H*-1,2,4-triazol-3-ol (1.49 g, 5.0 mmol, 1 equiv.), 2-bromoethanol (1.25 g, 10 mmol, 2 equiv.) and Cs₂CO₃ (3.26 g, 10 mmol, 2 equiv.) were added to a round-bottomed flask equipped with a magnetic stirrer bar. The flask was thrice evacuated and backfilled with pure

argon. DMF (20 mL) was added from a syringe and the mixture was stirred for 12 h at 80 $^{\circ}$ C under argon. Water (30 mL) was added. The mixture was extracted with DCM (2 × 15 mL), washed with brine, dried (Mg₂SO₄), and concentrated under reduced pressure. The residue was purified by flash chromatography (ethyl acetate/*n*-hexane, 3: 1) to give the title compound (1.23 g, 72% yield) as a white solid. Mp: 104–106 $^{\circ}$ C. 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.38–7.26 (*m*, 2H), 7.25–7.12 (m, 2H), 6.95–6.80 (*m*, 2H), 6.80–6.67 (*m*, 2H), 4.50–4.28 (*m*, 2H), 3.90 (*d*, *J* = 3.3 Hz, 2H), 3.77 (s, 3H), 3.73 (s, 3H), 3.11 (s, 1H); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 167.66, 161.08, 159.91, 153.22, 131.40, 130.43,

127.26, 120.03, 114.76, 114.11, 71.74, 62.03, 55.74, 55.49. MS (ESI): 274.0 [*M*+H]⁺. HRMS (ESI) for C₁₈H₂₀N₃O₄ [*M*+H]⁺: calc'd: 342.1454; found: 342.1457.

2-(1,5-Bis(4-methoxyphenyl)-1*H*-1,2,4-triazol-3-yloxy)ethyl 4-methylbenzenesulfonate.


General procedure 6 with 2-(1,5-bis(4-methoxyphenyl)-1H-1,2,4-triazol-3-yloxy)ethanol on a 3.0 mmol scale followed by flash chromatography (ethyl acetate/n-hexane, 1: 1) gave the title compound as a colorless oil (1.39 g, 93% yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.82 (d, J = 8.3

Hz, 2H), 7.43–7.35 (m, 2H), 7.32 (d, J = 8.0 Hz, 2H), 7.25–7.17 (m, 2H), 6.96–6.86 (m, 2H), 6.86–6.76 (m, 2H), 4.52 (dd, J = 5.6, 3.8 Hz, 2H), 4.41 (dd, J = 5.5, 3.8 Hz, 2H), 3.84 (s, 3H), 3.80 (s, 3H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 167.10, 161.14, 159.98, 153.35, 145.12, 133.07, 131.50, 130.48, 130.11, 128.32, 127.28, 120.18, 114.83, 114.16, 68.00, 66.85, 55.83, 55.57, 21.91. MS (ESI): 496.1 [M+H]⁺. HRMS (ESI) for C₂₅H₂₆N₃O₆S [M+H]⁺: calc'd: 496.1542; found: 496.1537.

General procedure 8.

Supplementary Figure 10. General procedure 8 for the synthesis of PS13 analogues.

1,5-Bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy)ethoxy)-1*H*-1,2,4-triazole.



The synthesis of this compound exemplifies general procedure 8, as follows. To a round-bottomed flask equipped with a magnetic stirrer bar was added paraformaldehyde (15 mg, 0.5 mmol, 3.0 equiv.) and *t*-BuOK (56 mg, 0.5 mmol, 3.0 equiv.), and then DMF (3

1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1,1- d_2)ethoxy)-1H-1,2,4-triazole.

General procedure 8 with paraformaldehyde- d_2 ((CD₂O)_n) instead of paraformaldehyde followed by flash chromatography (ethyl acetate/n-hexane, 1: 2) gave the title compound as a colorless oil (35 mg, 48% yield). ¹H NMR (400 MHz, CDCl₃) δ (ppm): 7.51–7.37 (m, 2H), 7.37–

7.14 (m, 2H), 7.01–6.86 (m, 2H), 6.86–6.74 (m, 2H), 4.59–4.43 (m, 2H), 4.10–3.94 (m, 2H), 3.84 (s, 3H), 3.80 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ (ppm): –74.49 (s, 3F); ¹³C NMR (101 MHz, CDCl₃) δ (ppm): 167.47, 161.06, 159.91, 153.36, 131.53, 130.46, 127.29, 124.17 (q, J = 279.6 Hz), 120.21, 114.77, 114.10, 70.97, 69.12, 55.76, 55.50. MS (ESI): 426.2 [M+H]⁺. HRMS (ESI) for C₂₀¹H₁₉²H₂N₃O₄F₃ [M+H]^{+:} calc'd: 426.1610; found: 426.1604.

1,5-Bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1-¹³C)ethoxy)-1*H*-1,2,4-triazole.

General procedure 8 with [13 C]paraformaldehyde ((13 CH₂O)_n) instead of paraformaldehyde followed by flash chromatography (ethyl acetate/n-hexane, 1: 2) to give the title compound as a colorless oil (40 mg, 56%)

yield). 1 H NMR (400 MHz, CDCl₃) δ (ppm): 7.50–7.36 (m, 2H), 7.35–7.16 (m, 2H), 7.00–6.87 (m, 2H), 6.87–6.67 (m, 2H), 4.65–4.45 (m, 2H), 4.17 (q, J = 8.7 Hz, 1H), 4.08–3.96 (m, 2H), 3.84–3.78 (m, 7H); 19 F NMR (376 MHz, CDCl₃) δ (ppm): –68.59 to –81.62 (m, 3F); 13 C NMR (101 MHz, CDCl₃) δ (ppm): 167.48, 161.05, 159.90, 153.36, 131.53, 130.46, 127.29, 120.22, 114.77, 114.09, 71.04, 69.20 (q, J = 34.2 Hz), 55.76, 55.50. MS (ESI): 425.2 [M+H] $^+$. HRMS (ESI) for 12 C₁₉ 13 C₁H₂₁N₃O₄F₃ [M+H] $^+$: calc'd: 425.1518; found: 425.1515.

3. General HPLC methods

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex).

The detection wavelength used for HPLC measurements was 254 nm.

Radioactivity was measured using an in-line Flow-Count PMT radioactivity detector (Eckert & Ziegler)).

3.1. HPLC condition A

Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min

0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B

3.2. HPLC condition B

Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min

0-1 min: 30% B

1-5 min: 30% to 50% B

5-10 min: 50% to 90% B

10-12 min: 90% B

3.3. HPLC condition C

Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min

0-1 min: 30% B

1-15 min: 30% to 80% B

3.4. HPLC condition D

Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min

0–1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B

3.5. HPLC condition E

Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min

0-5 min: 30% B

5–10 min: 30% to 50% B 10–12 min: 50% to 90% B

4. Syntheses of [11C]fluoroform and [18F]fluoroform

4.1. General procedure for the preparation of [11C]fluoroform 13

Supplementary Figure 11. The preparation of [11C]fluoroform from [11C]methane.

4.1.1. The preparation of [11C]methane.


[11 C]Methane was produced by the 14 N(p, α) 11 C nuclear reaction by irradiation of nitrogen gas (164 psi) containing hydrogen (10%) with a proton beam (16.5 MeV; 5–45 μ A) generated with a PETtrace 200 cyclotron (GE Healthcare) for 3 to 10 min.

4.1.2. The preparation of [11C]fluoroform.

The apparatus for [11C]fluoroform synthesis is shown in Supplementary Figure 12. [11C]Methane (3.7–5.5 GBq) was trapped by passing gas from the irradiated cyclotron

target through both cooled U-traps and out into a bag for the safe collection of the nitrogen-hydrogen gas mixture and any untrapped radioactivity. When radioactivity in the cooled Porapak [¹¹C]methane trap had maximized, as indicated by a nearby radiation detector, the liquid argon coolant was removed. The trap was then allowed to warm to RT under a controlled helium flow (20 mL/min) to direct and pass [¹¹C]methane through a heated CoF₃ column, through the cooled HF trap, and into the cooled [¹¹C]fluoroform collection trap. This transfer generally took about 15 min. Then [¹¹C]fluoroform trap was put in warm water (60 °C) for another 35-45 s to release [¹¹C]fluoroform into a vial containing DMF (0.8 mL) at –40 °C. The yield of [¹¹C]fluoroform from [¹¹C]methane was usually 35–55% accompanied by 10–50% [¹¹C]fluoromethane. This solution was used for further reactions. The yields of the reaction products are based on the [¹¹C]fluoroform and calculated by decay-correction to the beginning of HPLC analysis. We confirmed that all the radioactivity injected onto the HPLC column was fully recovered.


4.1.3. HPLC analysis of [11C]fluoroform.



Supplementary Figure 12. Analytical HPLC chromatogram for [¹¹C]fluoroform in collection solvent. [¹¹C]Fluoroform solution in DMF (0.8 mL) was analyzed with HPLC condition A. HPLC yields of [¹¹C]fluoroform were around 50–85% and the byproduct of this production was [¹¹C]fluoromethane.

4.2. General procedure for the preparation of [18F]fluoroform.14

Supplementary Figure 13. The preparation of [18F]fluoroform from difluoroiodomethane.




Supplementary Figure 14. Apparatus for [18F]fluoroform synthesis from difluoroiodomethane.

4.2.1. Preparation of [18F]fluoroform.

The apparatus for [18 F]fluoroform synthesis is depicted in Supplementary Figure 15. [18 F]Fluoride ion was produced on a cyclotron (PETtrace; GE Healthcare) according to the 18 O(p,n) 18 F reaction by irradiating 18 O-enriched water (3 mL, 98 atom%) with a beam of protons (35 MeV; 35-45 μ A) for at least 45 min. [18 F]Fluoroforrm was synthesized within a fully automated apparatus (TRACERlab TM FX2 NFX2N; GE Healthcare). Thus, [18 F]fluoride ion (3.72–11.1 GBq) in [18 O]water (200–400 μ L) and a solution (100 μ L) containing K₂CO₃ (3.4 μ mol) plus K 2.2.2 (13.6 μ mol) were loaded into a glass vial. MeCN (2 mL) was added, and the solvent was azeotropically removed at 80–100 °C under a stream of nitrogen gas that was vented to vacuum. This step was repeated after a second addition of MeCN (2 mL). A solution of difluoroiodomethane (8.0 mg, 45 μ mol) in anhydrous acetonitrile (1.0 mL) was then added to the dried [18 F]fluoride-K₂CO₃/K 2.2.2 complex, sealed, and heated at 35 °C for 10 min. [18 F]Fluoroform was flushed out of the vial with helium (20 mL/min) and into the [18 F]fluoroform trap. The transfer generally required 5 min. Then the [18 F]fluoroform trap was put in warm water (60 °C) for another

35 s to release [¹⁸F]fluoroform into a vial containing DMF (0.8 mL) and finally [¹⁸F]fluoroform solvent (35–65% yield from dried [¹⁸F]fluoride). The solution in the vial was used for further reactions.

4.2.2. HPLC analysis of [18F]fluoroform.



Supplementary Figure 15. Analytical HPLC chromatogram for [¹⁸F]fluoroform in collection solvent. [¹⁸F]Fluoroform in DMF (0.8 mL) was analyzed using HPLC condition A. HPLC yields of [¹⁸F]fluoroform were quantitative (>99% yield).

5. General procedure for producing [11C/18F]2,2,2-trifluoroethanol.

5.1. Optimization of the preparation of [11C]2,2,2-trifluoroethanol.

Procedure

To a 10-mL vial contained within a glovebox was added *t*-BuOK and paraformaldehyde, followed by DMF (6 mL). The *t*-BuOK-paraformaldehyde mixture in DMF was kept in the glovebox until further use i.e., just before adding to [11 C]fluoroform (\sim 30 min). A V-vial (1 mL) containing the DMF reagent mixture (200 μ L) was closed with a septum-sealed cap and removed from the glovebox. [11 C]Fluoroform (37–296 MBq) in DMF (50–300 μ L) was added to the vial, mixed by shaking, and left at RT for *t* min. The reaction was quenched by addition of water (100 μ L). Then the reaction mixture was analyzed with radio-HPLC using HPLC condition A. Results are shown in Supplementary Table 2.

Supplementary Table 2. Optimization of the preparation of [11C]2,2,2-trifluoroethanol from [11C]fluoroform.

Entry	n [(CH ₂ O) _n]: n [t-BuOK]	n [^t BuOK] (μmol)	t (min)	Radiochemical yield (%) ^a
1	1: 3	50	2	$\textbf{84}\pm\textbf{10}$
2	1: 3	50	3	88 ± 1
3	1: 3	50	4	94 ± 0
4	1: 3	50	5	95 ± 1
5	1: 1	50	4	97 ± 2
6	1: 2	50	4	> 99 (n > 5)
7	1: 4	50	4	73 ± 0
8	1: 2	40	4	96 ± 0
9	1: 2	30	4	91 ± 1


^a Decay-corrected. n = 2 unless otherwise stated.

5.2. General procedure for the preparation of [11C]2,2,2-trifluoroethanol and [18F]2,2,2-trifluoroethanol.

5.2.1. General procedure A.


To a 10-mL vial within a glovebox was added *t*-BuOK (112.2 mg, 1.0 mmol) and paraformaldehyde ((CH₂O)_n; 15.0 mg, 0.5 mmol), followed by DMF (6 mL). The DMF mixture of *t*-BuOK-(CH₂O)_n was stored in the glovebox for about 30 min. A V-vial (1 mL) containing of DMF reagent mixture (200 μ L) was closed with a septum-sealed cap and removed from the glovebox. [¹¹C]Fluoroform or [¹8F]fluoroform (37–296 MBq) in DMF (50–300 μ L) was added to the vial, mixed by shaking, and left at RT for 4 min. The reaction was quenched with water (100 μ L) and then the mixture analyzed by HPLC. The corresponding products, ¹¹CF₃CH₂OH or CF₂¹8FCH₂OH, were formed in high yields (more than 95% in most cases).

5.2.2. HPLC analysis for [11C]2,2,2-trifluoroethanol.



Supplementary Figure 16. Analytical HPLC chromatogram for crude [¹¹C]2,2,2-trifluoroethanol reaction mixture. [¹¹C]2,2,2-trifluoroethanol was synthesized according to general procedure 1 and analyzed with HPLC condition A. HPLC yields of 2,2,2-trifluoroethanol were high (>99%) based on consuming [¹¹C]fluoroform (in most cases within 4 min).

5.2.3. HPLC analysis for [18F]2,2,2-trifluoroethanol.



Supplementary Figure 17. Analytical HPLC chromatogram for crude [¹¹C]2,2,2-trifluoroethanol. Reaction mixture. [¹¹C]2,2,2-trifluoroethanol was synthesized according to general procedure 1 and analyzed with HPLC condition A. HPLC yields of [¹¹C]2,2,2-trifluoroethanol. were high (> 95%) (in most cases within 4 min).

5.3. General procedure for the preparation of [11C/18F]2,2,2-trifluoroethanol isotopologues.

Supplementary Figure 18. The preparation of [11C/18F]2,2,2-trifluoroethanol isotopologues from radiolabeled fluoroform and isotopically labeled paraformaldehyde.

General procedure 1 was used for preparing ¹¹CF₃CD₂OH, CF₂¹⁸FCD₂OH, ¹¹CF₃¹³CH₂OH and CF₂¹⁸F¹³CH₂OH from the appropriately isotopically labeled paraformaldehyde. Deuterated paraformaldehyde (CD₂O)_n was used for the preparations of ¹¹CF₃CD₂OH and CF₂¹⁸FCD₂OH. [¹³C]Paraformaldehyde ((¹³CH₂O))_n was used for the preparations of ¹¹CF₃¹³CH₂OH and CF₂¹⁸F¹³CH₂OH. The different [¹¹C/¹⁸F]2,2,2-trifluoroethanol isotopologues were obtained in high yields (> 95% within 4 min).

6. General procedure for radio-2,2,2-trifluoroethoxylation.

6.1 The preparation of ¹¹C- or ¹⁸F- labeled 2,2,2-trifluoroethyl heterocyclic ethers.

General procedure B.

Supplementary Figure 19. The preparation of radiolabeled 2,2,2-trifluoroethyl heterocyclic ethers.

To a 10-mL vial within a glovebox, was added *t*-BuOK (112.2 mg, 1.0 mmol) and (CH₂O)_n (15.0 mg, 0.5 mmol), followed by DMF (6 mL). The *t*-BuOK-(CH₂O)_n mixture in DMF was kept in the glovebox until further use (~ 30 min). A V-vial (1 mL) containing this reagent mixture in DMF (200 μ L) was closed with a septum-sealed cap, removed from the glovebox, and taken to the hot-cell for further reaction. [¹¹C]Fluoroform or [¹8F]fluoroform (37–296 MBq) in DMF (50–300 μ L) was added to the vial, mixed by shaking, and left at RT for 4 min. A DMF solution of heterocyclic precursor (50 μ mol, 200 μ L) was added to

the reaction vial and the reaction mixture was allowed to react at RT for another 1 min. The reaction was quenched with water (100 μ L) and the reaction mixture was analyzed with radio-HPLC.

6.2. Optimization of the preparation of ¹¹C- or ¹⁸F- labeled 2,2,2-trifluoroethyl aryl ethers.

6.2.1. Optimization.

Supplementary Table 3. Optimization of the preparation of [11C]1–(2,2,2-trifluoroethoxy)naphthalene.

Entry	substrate (μmol)	T (°C)	Radiochemical yield (%) ^a
1	55	rt	65 ± 7
2	55	60	$87 \pm 4 \ (n = 3)$
3	55	80	85 ± 1
4	55	100	85 ± 0
5	30	60	49 ± 9
6	15	60	<1

^a Decay-corrected, n = 2 unless otherwise statted

6.2.2. General procedure C.

Supplementary Figure 20. The preparation of radiolabeled 2,2,2-trifluoroethyl aryl ethers.

Within a glovebox, to a 10 mL vial was added *t*-BuOK (112.2 mg, 1.0 mmol) and (CH₂O)_n (15.0 mg, 0.5 mmol), followed by DMF (6 mL). The *t*-BuOK-(CH₂O)_n mixture in DMF was kept in the glovebox until further use (~ 30 min). A V-vial (1 mL) containing this reagent mixture in DMF (200 μ L) was closed with a septum-sealed cap, removed from the glovebox, and taken to hot cell for further reaction. [¹¹C]Fluoroform or [¹⁸F]fluoroform (37–296 MBq) in DMF (50–300 μ L) was added to the vial, mixed by shaking, and left at RT for

4 min. A DMF solution of benzenoid precursor, TMP iodonium salt or iodonium ylide (55 μ mol, in 200 μ L) was,added to the vial and the reaction mixture was heated at 60 °C for 3 min. The reaction was then quenched with water (100 μ L) and the reaction mixture was analyzed with radio-HPLC.

6.3. Optimization of the preparation of ¹¹C- or ¹⁸F- labeled 2,2,2-trifluoroethyl alkyl ethers.

6.3.1. Optimization.

Supplementary Table 4. Optimization of the preparation of a ¹¹C-labeled 2,2,2-trifluoroethyl alkyl ether.

H¹¹CF₃
$$\xrightarrow{\text{(CH}_2O)_n}$$
 ^tBuOK $\xrightarrow{\text{P}}$ $\xrightarrow{\text{DMF}}$ 4 min $\xrightarrow{\text{T}}$ 3 min $\xrightarrow{\text{F}}$ $\xrightarrow{\text{N}}$ $\xrightarrow{\text$

Entry	<i>n</i> [¹BuOK] (μmol)	T (°C)	Radiochemical yield (%) ^a
1	55	rt	52 ± 2
2	55	40	$\textbf{72} \pm \textbf{3}$
3	55	60	$89 \pm 6 \ (n = 3)$
4	55	80	80 ± 9
5	30	60	15 ± 1
6	15	60	2 ± 1

^a Decay-corrected. n = 2 unless otherwise stated

6.3.2. General procedure D.

Supplementary Figure 21. The preparation of radiolabeled 2,2,2-trifluoroethyl alkyl ethers.

To a 10-mL vial within a glovebox, was added *t*-BuOK (112.2 mg, 1.0 mmol) and (CH₂O)_n (15.0 mg, 0.5 mmol), followed by DMF (6 mL). The *t*-BuOK-(CH₂O)_n mixture in DMF was kept in the glovebox until further use (~ 30 min). A V-vial (1 mL) containing this reagent mixture in DMF (200 μ L) was closed with a septum-sealed cap, removed from the glovebox, and taken to a hot-cell for further reaction. [¹¹C]Fluoroform or [¹⁸F]fluoroform (37–296 MBq) in DMF (50–300 μ L) was added to the vial, mixed by shaking, and left at

RT for 4 min. A DMF solution (200 μ L) of alkyl precursor (55 μ mol) was added and the reaction mixture heated at 60 °C for another 3 min. The reaction was quenched with water (100 μ L) and the reaction mixture analyzed with radio-HPLC.


6.4. The preparation of radiolabeled PS13 analogues.

$$p$$
-An N -N p -

Supplementary Figure 22. The preparation of radiolabeled PS13 analogues. These followed general procedure D using different isotopic paraformaldehydes. For the preparation of d_2 -labled products, $(CD_2O)_n$ was used instead of $(CH_2O)_n$. For the preparation of ^{13}C -labeled products, $(^{13}CH_2O)_n$ was used instead of $(CH_2O)_n$. All the radioactive product identities were confirmed by LC-MS analysis of non–radioactive carrier after complete decay.


6.5. Determination of the molar activity for [11C]1.

The molar activity of [¹¹C]**1** was measured by HPLC determination of mass of carrier in a sample of analyte of known radioactivity amount from a calibrated UV absorbance response curve for reference **1**. The standard mass calibration curve for **1** [Y axis = UV area, X axis = mass (ng)] was created from the UV-absorbance at 254 nm from HPLC analyses of solutions of **1** with known dilutions. For a molar activity determination, [¹¹C]**1** from the labeling reaction was purified by HPLC and collected.



Supplementary Figure 23. Calibration curve for 2-(2,2,2-trifluoroethoxy)pyrimidine **1** to determine molar activity.


A known activity of radiochemically pure [11 C]1 was analyzed with HPLC using the same conditions used for creating the calibration curve. The standard curve was used to calculate mass and moles of carrier in [11 C]1. Starting with about 10 GBq of cyclotron-produced [11 C]methane, produced from a 10 μ A × 10 min cyclotron irradiation, [11 C]1 was obtained with a molar activity of 60 GBq/ μ mol, corrected to the end of radionuclide production.



Supplementary Figure 24. Analytical HPLC chromatogram for QC injection of [11C]1.

6.6. Determination of the molar activity for [18F]1.

A known activity of radiochemically pure [18 F]1 was analyzed with HPLC using the same conditions used for creating the calibration curve (Supplementary Figure 24). The standard curve was used to calculate mass and moles of carrier in [18 F]1. Starting with about 200 mCi [18 F]Fluoride ion, [18 F]1 was obtained with a molar activity of 1.3 GBq/ μ mol, corrected to the end of radionuclide production. The molar activity is consistent with the literature reported. 14



Supplementary Figure 25. Analytical HPLC chromatogram for QC injection of [18F]1.

7. HPLC analysis of ¹¹C- and ¹⁸F- labeled products.

7.1. HPLC analysis of ¹¹C-labeled compounds.

HPLC analysis of [11C]1

Prepared following general procedure B and analyzed using HPLC condition C.

HPLC condition C


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate = 2 mL/min

0-1 min: 30% B


1-15 min: 30% to 80% B



Supplementary Figure 26. Analytical HPLC chromatogram for 1.



Supplementary Figure 27. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 28. Analytical HPLC chromatogram for [11C]1 collected from the above HPLC analysis when co–injected with 1.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.607	88		
2	5.606	89	90 ± 2	83
3	5.701	92		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 29. Analytical HPLC chromatogram for 2.



Supplementary Figure 30. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 31. Analytical HPLC chromatogram for [11C]**2** collected from the above HPLC analysis when co–injected with **2.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	7.088	89		
2	7.118	89	87 ± 4	73
3	7.023	83		

Prepared following general procedure B and analyzed using HPLC condition B.

HPLC condition B

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1–5 min: 30% to 50% B 5–10 min: 50% to 90% B


10-12 min: 90% B



Supplementary Figure 32. Analytical HPLC chromatogram for 3.



Supplementary Figure 33. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 34. Analytical HPLC chromatogram for [11C]**3** collected from the above HPLC analysis when co–injected with **3**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
	(min)	(%)	(%)	(%)
1	7.966	20		
2	7.967	37	28 ± 9	22
3	7.964	26		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 35. Analytical HPLC chromatogram for 4.



Supplementary Figure 36. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 37. Analytical HPLC chromatogram for [11C]4 collected from the above HPLC analysis when co–injected with 4.

Run	Retention time	Yield (decay corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	6.727	92		
2	6.716	95	94 ± 2	86
3	6.720	95		

Prepared following general procedure B and analyzed using HPLC condition B.

HPLC condition B

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1–5 min: 30% to 50% B 5–10 min: 50% to 90% B


10-12 min: 90% B



Supplementary Figure 38. Analytical HPLC chromatogram for 5.



Supplementary Figure 39. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 40. Analytical HPLC chromatogram for [11C]5 collected from the above HPLC analysis when co–injected with 5.

Run	Retention time (min)	Yield (decay corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.564	81	(70)	(70)
2	9.577	88	86 ± 5	77
3	9.555	90		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 41. Analytical HPLC chromatogram for 6.



Supplementary Figure 42. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 43. Analytical HPLC chromatogram for [11C]6 collected from the above HPLC analysis when co–injected with 6.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuii	(min)	(%)	(%)	(%)
1	8.966	88		
2	9.057	87	87 ± 1	86
3	9.049	87		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 44. Analytical HPLC chromatogram for **7.**



Supplementary Figure 45. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 46. Analytical HPLC chromatogram for [11C]**7** collected from the above HPLC analysis when co–injected with **7.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Run	(min)	(%)	(%)	(%)
1	7.011	41		
2	7.013	44	45 ± 5	31
3	7.009	50		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 47. Analytical HPLC chromatogram for 8.



Supplementary Figure 48. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 49. Analytical HPLC chromatogram for [11C]8 collected from the above HPLC analysis when co–injected with 8.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Run	(min)	(%)	(%)	(%)
1	6.891	78		
2	6.932	85	80 ± 5	82
3	6.940	76		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 50. Analytical HPLC chromatogram for 9.



Supplementary Figure 51. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 52. Analytical HPLC chromatogram for [11C]**9** collected from the above HPLC analysis when co–injected with **9**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	6.442	45		
2	6.405	48	46 ± 2	41
3	6.068	44		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 53. Analytical HPLC chromatogram for 10.



Supplementary Figure 54. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 55. Analytical HPLC chromatogram for [11C]10 collected from the above HPLC analysis when co–injected with 10.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuii	(min)	(%)	(%)	(%)
1	7.309	88		
2	7.314	95	92 ± 4	77
3	7.381	93		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 56. Analytical HPLC chromatogram for 11.



Supplementary Figure 57. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 58. Analytical HPLC chromatogram for [¹¹C]11 collected from the above HPLC analysis when co–injected with 11.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	5.185	28		
2	5.172	49	41 ± 12	41
3	5.173	47		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 59. Analytical HPLC chromatogram for 12.



Supplementary Figure 60. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 61. Analytical HPLC chromatogram for [¹¹C]**12** collected from the above HPLC analysis when co–injected with **12**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
IXUII	(min)	(%)	(%)	(%)
1	6.062	21		
2	6.056	25	21 ± 4	20
3	6.057	17		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 62. Analytical HPLC chromatogram for 13.



Supplementary Figure 63. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 64. Analytical HPLC chromatogram for [¹¹C]**13** collected from the above the HPLC analysis when co–injected with **13**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
IXUII	(min)	(%)	(%)	(%)
1	8.014	54		
2	8.011	54	53 ± 1	42
3	8.015	52		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 65. Analytical HPLC chromatogram for 14.



Supplementary Figure 66. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 67. Analytical HPLC chromatogram for [¹¹C]**14** collected from the above HPLC analysis when co–injected with **14.**

Dun	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Run	(min)	(%)	(%)	(%)
1	6.607	37		
2	6.608	34	35 ± 2	29
3	6.499	35		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 68. Analytical HPLC chromatogram for 15.



Supplementary Figure 69. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 70. Analytical HPLC chromatogram for [¹¹C]**15** collected from the above HPLC analysis when co–injected with **15.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	6.759	37		
2	6.763	40	43 ± 8	33
3	6.761	52		

Prepared following general procedure B and analyzed using HPLC condition B.

HPLC condition B

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1–5 min: 30% to 50% B 5–10 min: 50% to 90% B


10-12 min: 90% B



Supplementary Figure 71. Analytical HPLC chromatogram for 16.



Supplementary Figure 72. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 73. Analytical HPLC chromatogram for [¹¹C]**16** collected from the above HPLC analysis when co–injected with **16.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)	l
1	7.252	47	\ /	` ,	ì
2	7.227	55	51 ± 4	38	Ì
3	7.221	50			ı

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 74. Analytical HPLC chromatogram for 17.



Supplementary Figure 75. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 76. Analytical HPLC chromatogram for [¹¹C]**17** collected from the above HPLC analysis when co–injected with **17.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	7.291	37		
2	7.252	37	34 ± 6	31
3	7.246	27		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 77. Analytical HPLC chromatogram for 18.



Supplementary Figure 78. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 79. Analytical HPLC chromatogram for [¹¹C]**18** collected from the above HPLC analysis when co–injected with **18.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.372	61	, ,	, , ,
2	5.470	58	57 ± 5	48
3	5.470	52		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 80. Analytical HPLC chromatogram for 19.



Supplementary Figure 81. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 82. Analytical HPLC chromatogram for [¹¹C]**19** collected from the above HPLC analysis when co–injected with **19.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	4.932	70		
2	4.935	71	68 ± 4	56
3	4.518	63		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 83. Analytical HPLC chromatogram for 20.



Supplementary Figure 84. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 85. Analytical HPLC chromatogram for [11C]**20** collected from the above HPLC analysis when co–injected with **20.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	9.278	79		
2	9.277	72	74 ± 4	61
3	9.273	72		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 86. Analytical HPLC chromatogram for 21.



Supplementary Figure 87. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 88. Analytical HPLC chromatogram for [¹¹C]**21** collected from the above HPLC analysis when co–injected with **21.**

Run	,	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)	
	(min)	(70)	(70)	(70)	1
1	5.146	75			ĺ
2	5.149	72	73 ± 2	64	
3	5.146	71			ĺ

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 89. Analytical HPLC chromatogram for 22.



Supplementary Figure 90. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 91. Analytical HPLC chromatogram for [¹¹C]**22** collected from the above HPLC analysis when co–injected with **22**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
IXUII	(min)	(%)	(%)	(%)
1	7.104	65		
2	7.111	75	67 ± 7	73
3	7.104	62		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 92. Analytical HPLC chromatogram for 23.



Supplementary Figure 93. Analytical HPLC chromatogram for reaction mixture.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)
1	7.044	14	
2	7.052	13	12 ± 2
3	7.052	10	

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 94. Analytical HPLC chromatogram for 24.



Supplementary Figure 95. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 96. Analytical HPLC chromatogram for [11C]**24** collected from the above HPLC analysis when co–injected with **24.**

Run		Yield (decay-corrected)	•	,	
	(min)	(%)	(%)	(%)	l
1	6.560	44			
2	6.560	36	36 ± 9	35	
3	6.495	27			

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 97. Analytical HPLC chromatogram for 25.



Supplementary Figure 98. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 99. Analytical HPLC chromatogram for [¹¹C]**25** collected from the above HPLC analysis when co–injected with **25.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	6.591	49		
2	6.591	50	49 ± 1	47
3	6.594	48		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 100. Analytical HPLC chromatogram for 26.



Supplementary Figure 101. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 102. Analytical HPLC chromatogram for [11C]**26** collected from the above HPLC analysis when co–injected with **26.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.481	56	. ,	` ,
2	6.488	46	50 ± 5	38
3	6.485	49		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 103. Analytical HPLC chromatogram for 27.



Supplementary Figure 104. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 105. Analytical HPLC chromatogram for [11C]**27** collected from the above HPLC analysis when co–injected with **27.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	•	
IXUII	(min)	(%)	(%)	(%)	
1	6.837	48			
2	6.845	49	47 ± 3	42	
3	6.842	44			l

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 106. Analytical HPLC chromatogram for 28.



Supplementary Figure 107. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 108. Analytical HPLC chromatogram for [11C]**28** collected from the above HPLC analysis when co–injected with **28.**

Run		Yield (decay-corrected)	•	,	
	(min)	(%)	(%)	(%)	
1	6.730	34			
2	6.654	32	33 ± 1	25	
3	6.622	33			

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 109. Analytical HPLC chromatogram for **29.**



Supplementary Figure 110. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 111. Analytical HPLC chromatogram for [11C]**29** collected from the above HPLC analysis when co–injected with **29**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	5.807	71		
2	5.817	72	71 ± 1	57
3	5.820	71		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 112. Analytical HPLC chromatogram for **30.**



Supplementary Figure 113. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 114. Analytical HPLC chromatogram for [11C]**30** collected from the above HPLC analysis when co–injected with **30**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield	1
ixuii	(min)	(%)	(%)	(%)	ì
1	6.285	86			l
2	6.281	86	86 ± 1	74	ì
3	6.450	85			ı

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 115. Analytical HPLC chromatogram for **31.**



Supplementary Figure 116. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 117. Analytical HPLC chromatogram for [¹¹C]**31** collected from the above HPLC analysis when co-injected with **31.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.518	77		
2	5.512	81	80 ± 3	73
3	5.550	82		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 118. Analytical HPLC chromatogram for 32.



Supplementary Figure 119. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 120. Analytical HPLC chromatogram for [¹¹C]**32** collected from the above HPLC analysis when co–injected with **32.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.579	22		
2	5.576	21	22 ± 1	23
3	5.570	22		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 121. Analytical HPLC chromatogram for **33.**



Supplementary Figure 122. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 123. Analytical HPLC chromatogram for [11C]**33** collected from the above HPLC analysis when co–injected with **33.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	6.144	33		
2	6.147	32	32 ± 2	30
3	6.148	30		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 124. Analytical HPLC chromatogram for 34.



Supplementary Figure 125. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 126. Analytical HPLC chromatogram for [11C]**34** collected from the above HPLC analysis when co–injected with **34.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)	
1	6.827	69	, ,	·	
2	6.809	64	68 ± 4	69	l
3	6.899	71			l

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 127. Analytical HPLC chromatogram for 35.



Supplementary Figure 128. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 129. Analytical HPLC chromatogram for [11C]**35** collected from the above HPLC analysis when co–injected with **35.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	5.024	75		
2	5.027	73	73 ± 2	67
3	5.027	71		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 130. Analytical HPLC chromatogram for 36.



Supplementary Figure 131. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 132. Analytical HPLC chromatogram for [¹¹C]**36** collected from the above HPLC analysis when co–injected with **36.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
IXUII	(min)	(%)	(%)	(%)
1	6.621	46		
2	6.617	46	47 ± 2	42
3	6.623	49		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 133. Analytical HPLC chromatogram for **37.**



Supplementary Figure 134. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 135. Analytical HPLC chromatogram for [11C]**37** collected from the above HPLC analysis when co–injected with **37.**

	Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
		(min)	(%)	(%)	(%)
	1	5.985	49		
	2	6.082	33	44 ± 10	36
ĺ	3	6.076	51		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 136. Analytical HPLC chromatogram for **38.**



Supplementary Figure 137. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 138. Analytical HPLC chromatogram for [11C]**38** collected from the above HPLC analysis when co–injected with **38.**

	Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield	
	ixuii	(min)	(%)	(%)	Isolated yield (%) 57	
	1	5.649	60			
	2	5.737	61	60 ± 1	57	
	3	5.756	60			l

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 139. Analytical HPLC chromatogram for 39.



Supplementary Figure 140. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 141. Analytical HPLC chromatogram for [11C]**39** collected from the above HPLC analysis when co–injected with **39**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	5.656	34		
2	5.655	31	31 ± 3	26
3	5.646	29		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 142. Analytical HPLC chromatogram for **40.**



Supplementary Figure 143. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 144. Analytical HPLC chromatogram for [11C]**40** collected from the above HPLC analysis when co–injected with **40**.

	Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
		(min)	(%)	(%)	(%)
	1	6.023	90		
	2	6.028	92	89 ± 4	78
ĺ	3	6.046	85		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 145. Analytical HPLC chromatogram for 41.



Supplementary Figure 146. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 147. Analytical HPLC chromatogram for [11C]**41** collected from the above HPLC analysis when co–injected with **41.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	5.136	46		
2	5.134	44	45 ± 1	41
3	5.133	44		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 148. Analytical HPLC chromatogram for 42.



Supplementary Figure 149. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 150. Analytical HPLC chromatogram for [11C]**42** collected from the above HPLC analysis when co–injected with **42.**

Run		Yield (decay-corrected)	_		
IXAII	(min)	(%)	(%)	(%)	
1	4.782	57			
2	4.782	54	53 ± 4	60	
3	4.786	49			

H¹¹CF₃
$$\xrightarrow{\text{(CH}_2O)_m}$$
 ^tBuOK [¹¹CF₃CH₂OK] $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{OO}}$ OTS $\xrightarrow{\text{Me}}$ $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{F}_3^{11}C}$ $\xrightarrow{\text{CI}}$ $\xrightarrow{\text{CI$

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 151. Analytical HPLC chromatogram for 43.



Supplementary Figure 152. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 153. Analytical HPLC chromatogram for [11C]**43** collected from the above HPLC analysis when co–injected with **43.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)	
1	7.127	86	, ,	` ,	
2	7.128	85	85 ± 1	74	
3	7.132	85			

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 154. Analytical HPLC chromatogram for 44.



Supplementary Figure 155. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 156. Analytical HPLC chromatogram for [11C]**44** collected from the above HPLC analysis when co–injected with **44.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	6.912	60		
2	6.866	51	53 ± 7	44
3	6.854	47		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 157. Analytical HPLC chromatogram for 45.



Supplementary Figure 158. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 159. Analytical HPLC chromatogram for [11C]**45** collected from the above HPLC analysis when co–injected with **45.**

	Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
1	Tuii	(min)	(%)	(%)	(%)
	1	5.443	91		
	2	5.528	93	89 ± 6	90
	3	5.459	82		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 160. Analytical HPLC chromatogram for 46.



Supplementary Figure 161. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 162. Analytical HPLC chromatogram for [11C]**46** collected from the above HPLC analysis when co–injected with **46.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuii	(min)	(%)	(%)	(%)
1	6.252	50		
2	6.305	58	56 ± 5	52
3	6.286	59		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 163. Analytical HPLC chromatogram for 47.



Supplementary Figure 164. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 165. Analytical HPLC chromatogram for [¹¹C]**47** collected from the above HPLC analysis when co–injected with **47.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	7.117	71		
2	7.117	72	71 ± 1	64
3	7.110	70		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 166. Analytical HPLC chromatogram for 48.



Supplementary Figure 167. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 168. Analytical HPLC chromatogram for [11C]**48** collected from the above HPLC analysis when co–injected with **48.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	7.988	84		
2	8.118	85	85 ± 2	81
3	8.111	87		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 169. Analytical HPLC chromatogram for 49.



Supplementary Figure 170. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 171. Analytical HPLC chromatogram for [11C]**49** collected from the HPLC analysis when co–injected with **49.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	7.025	87		
2	7.028	87	86 ± 1	84
3	7.028	85		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 172. Analytical HPLC chromatogram for **50.**



Supplementary Figure 173. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 174. Analytical HPLC chromatogram for [11C]**50** collected from the above HPLC analysis when co–injected with **50.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kun	(min)	(%)	(%)	(%)
1	8.800	82		
2	8.787	81	82 ± 1	77
3	8.790	82		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 175. Analytical HPLC chromatogram for 51.



Supplementary Figure 176. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 177. Analytical HPLC chromatogram for [¹¹C]**51** collected from the above HPLC analysis when co–injected with **51.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuii	(min)	(%)	(%)	(%)
1	7.370	86		
2	7.482	83	85 ± 2	88
3	7.489	85		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 178. Analytical HPLC chromatogram for **52.**



Supplementary Figure 179. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 180. Analytical HPLC chromatogram for [11C]**52** collected from the above HPLC analysis when co–injected with **52.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuii	(min)	(%)	(%)	(%)
1	7.506	70		
2	7.608	76	73 ± 3	58
3	7.585	73		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 181. Analytical HPLC chromatogram for 53.



Supplementary Figure 182. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 183. Analytical HPLC chromatogram for [11C]**53** collected from the above HPLC analysis when co–injected with **53.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Run	(min)	(%)	(%)	(%)
1	7.615	35		
2	7.621	35	34 ± 2	23
3	7.615	32		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 184. Analytical HPLC chromatogram for 54.



Supplementary Figure 185. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 186. Analytical HPLC chromatogram for [¹¹C]**54** collected from the above HPLC analysis when co–injected with **54.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	8.533	91		
2	8.537	93	93 ± 2	81
3	8.544	95		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 187. Analytical HPLC chromatogram for 55.



Supplementary Figure 188. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 189. Analytical HPLC chromatogram for [11C]**55** collected from the above HPLC analysis when co–injected with **55.**

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
Kuli	(min)	(%)	(%)	(%)
1	7.102	84		
2	7.041	89	87 ± 3	83
3	7.147	89		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B


6-12 min: 95% B



Supplementary Figure 190. Analytical HPLC chromatogram for 56.



Supplementary Figure 191. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 192. Analytical HPLC chromatogram for [¹¹C]**56** collected from the above HPLC analysis when co–injected with **56.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.913	50		
2	6.913	51	51 ± 1	52
3	6.914	52		

7.2. HPLC analysis of ¹⁸F-labeled compounds.

HPLC analysis of [18F]1

Prepared following general procedure B and analyzed using HPLC condition C.

HPLC condition C


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate = 2 mL/min

0-1 min: 30% B

1-15 min: 30% to 80% B



Supplementary Figure 193. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 194. Analytical HPLC chromatogram for 1.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.818	82		
2	5.824	91	88 ± 5	79
3	5.804	91		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 195. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 196. Analytical HPLC chromatogram for [18F]4 collected from the above HPLC analysis when co–injected with 4.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.767	94		
2	6.775	98	96 ± 2	83
3	6.773	95		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 197. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 198. Analytical HPLC chromatogram for [18F]6 collected from the above HPLC analysis when co–injected with 6.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	8.912	88		
2	9.033	92	91 ± 2	83
3	9.047	92		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 199. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 200. Analytical HPLC chromatogram for [18F]**8** collected from the above HPLC analysis when co–injected with **8**.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.964	92		
2	6.956	96	94 ± 2	85
3	6.953	94		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 201. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 202. Analytical HPLC chromatogram for [18F]**13** collected from the above HPLC analysis when co–injected with **13**.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.826	83		
2	7.833	83	82 ± 2	77
3	7.836	80		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 203. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 204. Analytical HPLC chromatogram for [18F]**15** collected from the above HPLC analysis when co–injected with **15.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.683	54		
2	6.662	54	56 ± 4	57
3	6.652	60		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 205. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 206. Analytical HPLC chromatogram for [18F]**17** collected from the above HPLC analysis when co–injected with **17.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.214	58		
2	7.229	54	56 ± 2	44
3	7.220	57		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 207. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 208. Analytical HPLC chromatogram for [18F]18 collected from the above HPLC analysis when co–injected with 18.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.437	63		
2	5.436	64	64 ± 1	56
3	5.413	64		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 209. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 210. Analytical HPLC chromatogram for [18F]**19** collected from the above HPLC analysis when co–injected with **19**.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	4.946	72		
2	4.948	79	77 ± 5	80
3	4.946	81		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 211. Analytical HPLC chromatogram for reaction mixture



Supplementary Figure 212. Analytical HPLC chromatogram for [18F]**20** collected from the above HPLC analysis when co–injected with **20.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.248	61		
2	9.201	67	66 ± 4	45
3	9.252	69		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 213. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 214. Analytical HPLC chromatogram for [18F]**21** collected from the above HPLC analysis when co–injected with **21.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.240	75		
2	5.228	63	69 ± 6	67
3	5.233	69		

$$HCF_{2}^{18}F \xrightarrow{(CH_{2}O)_{n}, {}^{t}BuOK} DMF, RT, 4 min$$

$$[CF_{2}^{18}FCH_{2}OK] \xrightarrow{RT, 1 min} I^{18}FF_{2}C \xrightarrow{O} N \xrightarrow{N} N \xrightarrow{N} O$$

$$RT, 1 min \qquad [I^{18}F]_{22}$$

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 215. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 216. Analytical HPLC chromatogram for [18F]**22** collected from the above HPLC analysis when co–injected with **22.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.986	54		
2	6.774	63	61 ± 6	65
3	7.056	66		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 217. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 218. Analytical HPLC chromatogram for [18F]**27** collected from the above HPLC analysis when co–injected with **27.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.908	52		
2	6.939	48	49 ± 3	43
3	6.908	47		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 219. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 220. Analytical HPLC chromatogram for [18F]**33** collected from the above HPLC analysis when co–injected with **33**.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.480	76		
2	5.532	65	69 ± 6	58
3	5.475	67		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 221. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 222. Analytical HPLC chromatogram for [18F]**35** collected from the above HPLC analysis when co–injected with **35.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.075	73		
2	5.131	66	68 ± 4	55
3	5.078	66		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 223. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 224. Analytical HPLC chromatogram for [18F]**36** collected from the above HPLC analysis when co–injected with **36.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.586	25		
2	6.554	27	27 ± 2	21
3	6.527	29		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 225. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 226. Analytical HPLC chromatogram for [18F]**37** collected from the above HPLC analysis when co–injected with **37.**

Run		Yield (decay-corrected)	•	,
	(min)	(%)	(%)	(%)
1	6.075	51		
2	6.144	51	52 ± 2	51
3	6.064	54		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 227. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 228. Analytical HPLC chromatogram for [18F]**38** collected from the above HPLC analysis when co-injected with **38.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.773	55		
2	6.865	52	53 ± 2	48
3	5.772	53		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 229. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 230. Analytical HPLC chromatogram for [18F]**44** collected from the above HPLC analysis when co–injected with **44.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.990	84		
2	6.984	82	83 ± 1	79
3	6.904	84		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 231. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 232. Analytical HPLC chromatogram for [18F]**45** collected from the above HPLC analysis when co–injected with **45.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	5.498	87		
2	5.503	88	87 ± 1	79
3	5.455	86		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 233. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 234. Analytical HPLC chromatogram for [18F]**46** collected from the above HPLC analysis when co–injected with **46.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.345	35		
2	6.337	36	36 ± 1	31
3	6.236	37		

$$HCF_{2}^{18}F \xrightarrow{\text{(CH}_{2}O)_{m}, {}^{t}BuOK} DMF, RT, 4 min$$

$$[CF_{2}^{18}FCH_{2}OK] \xrightarrow{\text{60 °C}, 3 min}$$

$$[CF_{2}^{18}FCH_{2}OK] \xrightarrow{\text{18}FCH_{2}OK} DMF, RT, 4 min$$

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 235. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 236. Analytical HPLC chromatogram for [18F]**49** collected from the above HPLC analysis when co–injected with **49.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.099	86		
2	7.051	94	90 ± 4	75
3	6.979	91		

$$HCF_{2}^{18}F \xrightarrow{(CH_{2}O)_{n}, {}^{t}BuOK} DMF, RT, 4 min$$

$$[CF_{2}^{18}FCH_{2}OK] \xrightarrow{BnO} DBn \\ \hline 0 CF_{2}^{18}FCH_{2}OK]$$

$$[CF_{2}^{18}FCH_{2}OK] \xrightarrow{BnO} DBn \\ \hline 0 CF_{2}^{18}FCH_{2}OK]$$

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 237. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 238. Analytical HPLC chromatogram for [18F]**50** collected from the above HPLC analysis when co–injected with **50**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	8.857	82		
2	8.837	82	84 ± 3	76
3	8.844	87		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 239. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 240. Analytical HPLC chromatogram for [18F]**51** collected from the above HPLC analysis when co–injected with **51.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.472	64	, ,	, ,
2	7.472	91	83 ± 16	80
3	7.467	93		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 241. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 242. Analytical HPLC chromatogram for [18F]**52** collected from the above HPLC analysis when co–injected with **52.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.558	80		
2	7.530	73	75 ± 5	70
3	7.516	71		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate: 2 mL/min


0-1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 243. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 244. Analytical HPLC chromatogram for [18F]**53** collected from the above HPLC analysis when co–injected with **53.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.621	15		
2	7.620	15	15 ± 1	13
3	7.622	14		

Prepared following general procedure B and analyzed using HPLC condition A. HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 245. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 246. Analytical HPLC chromatogram for [18F]**54** collected from the above HPLC analysis when co–injected with **54.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	8.452	95		
2	8.456	95	95 ± 1	86
3	8.449	94		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 247. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 248. Analytical HPLC chromatogram for [18F]55 collected from the above HPLC analysis when co–injected with 55.

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	7.102	91		
2	7.096	96	94 ± 3	90
3	7.100	96		

Prepared following general procedure B and analyzed using HPLC condition A.

HPLC condition A


Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)

Solvent A: H₂O, Solvent B: MeCN


Flow rate: 2 mL/min 0–1 min: 40% B

1–3 min: 40% to 60% B 3–6 min: 60% to 95% B

6-12 min: 95% B



Supplementary Figure 249. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 250. Analytical HPLC chromatogram for [18F]**56** collected from the above HPLC analysis when co–injected with **56.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	6.883	56		
2	6.882	57	56 ± 1	49
3	6.886	56		

7.3. HPLC and LCMS analysis of PS13 analogues. HPLC analysis of [11C]57

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B


5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 251. Analytical HPLC chromatogram for 57.



Supplementary Figure 252. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 253. Analytical HPLC chromatogram for [¹¹C]**57** collected from above HPLC analysis when co–injected with **57**.

Run	Retention time	Yield (decay-corrected)	Mean yield ± SD	Isolated yield
IXuII	(min)	(%)	(%)	(%)
1	9.676	87		
2	9.628	87	88 ± 2	74
3	9.742	90		

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 254. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 255. Analytical HPLC chromatogram for [18F]**57** collected from HPLC analysis when co–injected with **57.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.722	86		
2	9.709	85	84 ± 2	70
3	9.696	82		

[²H/¹¹C]57

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 256. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 257. Analytical HPLC chromatogram for [²H/¹¹C]**57** collected from the above HPLC analysis when co-injected with **57.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.680	83		
2	9.687	82	82 ± 2	79
3	9.698	80		

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 258. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 259. Analytical HPLC chromatogram for [²H/¹⁸F]**57** collected from the above HPLC analysis when co-injected with **57.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.642	80		
2	9.645	90	86 ± 5	81
3	9.649	87		

H¹¹CF₃ (13CH₂O)_m, ^tBuOK (11CF₃13CH₂OK) MeO (11CF₃13C

[¹³C/¹¹C]57

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 260. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 261. Analytical HPLC chromatogram for [¹³C/¹¹C]**57** collected from the HPLC analysis when co-injected with **57.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.653	93		
2	9.652	92	92 ± 1	81
3	9.667	92		

Prepared following general procedure B and analyzed using HPLC condition D.

HPLC condition D

Column: Luna C18(2) (10 μ m, 250 × 4.6 mm; i.d. Phenomenex)


Solvent A: H₂O, Solvent B: MeCN

Flow rate = 2 mL/min


0-1 min: 30% B

1-5 min: 30% to 50% B

5–10 min: 90% B 10–15 min: 90% B



Supplementary Figure 262. Analytical HPLC chromatogram for reaction mixture.



Supplementary Figure 263. Analytical HPLC chromatogram for [¹³C/¹⁸F]**57** collected from the above HPLC analysis when co–injected with **57.**

Run	Retention time (min)	Yield (decay-corrected) (%)	Mean yield ± SD (%)	Isolated yield (%)
1	9.645	85	(73)	(70)
2	9.654	83	84 ± 1	73
3	9.655	83		

Supplementary Abbreviations

DCC, N,N'-dicyclohexylcarbodiimide

DCM, dichloromethane

DMAP, 4-dimethylaminopyridine

DMF, dimethylformamide

DMSO, dimethyl sulfoxide

ESI, electrospray ionization

HPLC, high performance liquid chromatography

K 2.2.2, 2.2.2. cryptand (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane)

mCPBA, meta chloroperbenzoic acid

Meldrum's acid, 2,2-dimethyl-1,3-dioxane-4,6-dione

Mesyl, mesityl (2,4,6-trimethylphenyl)


NIDDK, National Institute of Diabetes, Digestive and Kidney Diseases

NIMH, National Institute of Mental Health


RT, room temperature

THF, tetrahydrofuran


Supplementary NMR spectra




Supplementary Figure 264. ¹H NMR spectrum of compound 1 (400 MHz, CDCl₃)




Supplementary Figure 265. ¹⁹F NMR spectrum of compound 1 (376 MHz, CDCl₃)




Supplementary Figure 266. ¹³C NMR spectrum of compound 1 (101 MHz, CDCl₃)




Supplementary Figure 267. ¹H NMR spectrum of **Naphthalen-1-yl(2,4,6-trimethoxyphenyl)iodonium tosylate** (400 MHz, CDCl₃)




Supplementary Figure 268. ¹³C NMR spectrum of Naphthalen-1-yl(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 269. ¹H NMR spectrum of compound 2 (400 MHz, CDCl₃)




Supplementary Figure 270. ¹⁹F NMR spectrum of compound 2 (376 MHz, CDCl₃)




Supplementary Figure 271. ¹³C NMR spectrum of compound 2 (101 MHz, CDCl₃)




Supplementary Figure 272. ¹H NMR spectrum of compound 3 (400 MHz, CDCl₃)




Supplementary Figure 273. ¹⁹F NMR spectrum of compound 3 (376 MHz, CDCl₃)




Supplementary Figure 274. ¹³C NMR spectrum of compound 3 (101 MHz, CDCl₃)




Supplementary Figure 275. ¹H NMR spectrum of compound 4 (400 MHz, CDCl₃)




Supplementary Figure 276. ¹⁹F NMR spectrum of compound 4 (376 MHz, CDCl₃)




Supplementary Figure 277. ¹³C NMR spectrum of compound 4 (101 MHz, CDCl₃)




Supplementary Figure 278. ¹H NMR spectrum of compound 5 (400 MHz, CDCl₃)




Supplementary Figure 279. ¹⁹F NMR spectrum of compound 5 (376 MHz, CDCl₃)




Supplementary Figure 280. ¹³C NMR spectrum of compound 5 (101 MHz, CDCl₃)




Supplementary Figure 281. ¹H NMR spectrum of compound 6 (400 MHz, CDCl₃)




Supplementary Figure 282. ¹⁹F NMR spectrum of compound 6 (376 MHz, CDCl₃)




Supplementary Figure 283. ¹³C NMR spectrum of compound 6 (101 MHz, CDCl₃)




Supplementary Figure 284. ¹H NMR spectrum of compound 7 (400 MHz, CDCl₃)




Supplementary Figure 285. ¹⁹F NMR spectrum of compound **7** (376 MHz, CDCl₃)




Supplementary Figure 286. ¹³C NMR spectrum of compound 7 (101 MHz, CDCl₃)




Supplementary Figure 287. ¹H NMR spectrum of compound 8 (400 MHz, CDCl₃)




Supplementary Figure 288. ¹⁹F NMR spectrum of compound 8 (376 MHz, CDCl₃)




Supplementary Figure 289. ¹³C NMR spectrum of compound 8 (101 MHz, CDCl₃)




Supplementary Figure 290. ¹H NMR spectrum of compound 9 (400 MHz, CDCl₃)




Supplementary Figure 291. ¹⁹F NMR spectrum of compound 9 (376 MHz, CDCl₃)




Supplementary Figure 292. ¹³C NMR spectrum of compound 9 (101 MHz, CDCl₃)




Supplementary Figure 293. ¹H NMR spectrum of compound 10 (400 MHz, CDCl₃)




Supplementary Figure 294. ¹⁹F NMR spectrum of compound 10 (376 MHz, CDCl₃)




Supplementary Figure 295. ¹³C NMR spectrum of compound 10 (101 MHz, CDCl₃)




Supplementary Figure 296. ¹H NMR spectrum of compound 11 (400 MHz, CDCl₃)




Supplementary Figure 297. ¹⁹F NMR spectrum of compound 11 (376 MHz, CDCl₃)




Supplementary Figure 298. ¹³C NMR spectrum of compound 11 (101 MHz, CDCl₃)




Supplementary Figure 299. ¹H NMR spectrum of compound 12 (400 MHz, CDCl₃)




Supplementary Figure 300. ¹⁹F NMR spectrum of compound 12 (376 MHz, CDCl₃)




Supplementary Figure 301. ¹³C NMR spectrum of compound 12 (101 MHz, CDCl₃)




Supplementary Figure 302. ¹H NMR spectrum of compound 13 (400 MHz, CDCl₃)




Supplementary Figure 303. ¹⁹F NMR spectrum of compound 13 (376 MHz, CDCl₃)




Supplementary Figure 304. ¹³C NMR spectrum of compound 13 (101 MHz, CDCl₃)




Supplementary Figure 305. ¹H NMR spectrum of compound 14 (400 MHz, CDCl₃)




Supplementary Figure 306. ¹⁹F NMR spectrum of compound 14 (376 MHz, CDCl₃)




Supplementary Figure 307. ¹³C NMR spectrum of compound 14 (101 MHz, CDCl₃)




Supplementary Figure 308. ¹H NMR spectrum of **4-chloro-1-isobutyl-1***H***-imidazo[4,5-***c***]quinoline** (400 MHz, CDCl₃)




Supplementary Figure 309. ¹³C NMR spectrum of **4-chloro-1-isobutyl-1***H***-imidazo[4,5-c]quinoline** (101 MHz, CDCl₃)




Supplementary Figure 310. ¹H NMR spectrum of compound 15 (400 MHz, CDCl₃)




Supplementary Figure 311. ¹⁹F NMR spectrum of compound 15 (376 MHz, CDCl₃)




Supplementary Figure 312. ¹³C NMR spectrum of compound 15 (101 MHz, CDCl₃)




Supplementary Figure 313. ¹H NMR spectrum of compound 16 (400 MHz, CDCl₃)




Supplementary Figure 314. ^{19}F NMR spectrum of compound 16 (376 MHz, CDCl₃)




Supplementary Figure 315. ¹³C NMR spectrum of compound 16 (101 MHz, CDCl₃)




Supplementary Figure 316. ¹H NMR spectrum of *tert*-butyl 3,6-dichloropicolinate (400 MHz, CDCl₃)




Supplementary Figure 317. ¹³C NMR spectrum of tert-butyl 3,6-dichloropicolinate (101 MHz, CDCl₃)




Supplementary Figure 318. ¹H NMR spectrum of compound 17 (400 MHz, CDCl₃)




Supplementary Figure 319. 19F NMR spectrum of compound 17 (376 MHz, CDCl₃)




Supplementary Figure 320. ¹³C NMR spectrum of compound 17 (101 MHz, CDCl₃)




Supplementary Figure 321. 1 H NMR spectrum of 6-bromo-2-methyl-3,4'-bipyridine-5-carbonitrile (400 MHz, CDCl₃)




Supplementary Figure 322. ¹³C NMR spectrum of **6-bromo-2-methyl-3,4'-bipyridine-5-carbonitrile** (101 MHz, CDCl₃)




Supplementary Figure 323. ¹H NMR spectrum of compound 18 (400 MHz, CDCI₃)




Supplementary Figure 324. ¹⁹F NMR spectrum of compound 18 (376 MHz, CDCl₃)




Supplementary Figure 325. ¹³C NMR spectrum of compound 18 (101 MHz, CDCl₃)




Supplementary Figure 326. ¹H NMR spectrum of compound 19 (400 MHz, CDCl₃)




Supplementary Figure 327. ¹⁹F NMR spectrum of compound 19 (376 MHz, CDCl₃)




Supplementary Figure 328. ¹³C NMR spectrum of compound 19 (101 MHz, CDCl₃)




Supplementary Figure 329. 1H NMR spectrum of 2-fluoro-5-(3-((5-(4-fluorophenyl))thiophen-2-yl)methyl)-4-methylphenyl)pyridine (400 MHz, CDCl₃)




Supplementary Figure 330. ¹⁹F NMR spectrum of **2-fluoro-5-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)pyridine** (376 MHz, CDCl₃)




Supplementary Figure 331. ¹³C NMR spectrum of **2-fluoro-5-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)pyridine** (101 MHz, CDCl₃)




Supplementary Figure 332. ¹H NMR spectrum of compound 20 (400 MHz, CDCl₃)




Supplementary Figure 333. ¹⁹F NMR spectrum of compound 20 (376 MHz, CDCl₃)





Supplementary Figure 334. ¹³C NMR spectrum of compound 20 (101 MHz, CDCl₃)




Supplementary Figure 335. ¹H NMR spectrum of compound 21 (400 MHz, CDCl₃)









Supplementary Figure 337. ¹³C NMR spectrum of compound 21 (101 MHz, CDCl₃)




Supplementary Figure 338. ¹H NMR spectrum of compound 22 (400 MHz, CDCl₃)




Supplementary Figure 339. ¹⁹F NMR spectrum of compound 22 (376 MHz, CDCl₃)




Supplementary Figure 340. ¹³C NMR spectrum of compound 22 (101 MHz, CDCl₃)




Supplementary Figure 341. ¹H NMR spectrum of (4-benzyloxyphenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 342. ¹³C NMR spectrum of **(4-benzyloxyphenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate** (101 MHz, CDCl₃)




Supplementary Figure 343. ¹H NMR spectrum of compound 23 (400 MHz, CDCl₃)




Supplementary Figure 344. ¹⁹F NMR spectrum of compound 23 (376 MHz, CDCl₃)




Supplementary Figure 345. ¹³C NMR spectrum of compound 23 (101 MHz, CDCl₃)




Supplementary Figure 346. 1 H NMR spectrum of (p-tolyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (4 00 MHz, CDCl $_3$)




Supplementary Figure 347. 13 C NMR spectrum of (*p*-tolyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (101 MHz, CDCl₃)




Supplementary Figure 348. ¹H NMR spectrum of compound 24 (400 MHz, CDCl₃)




Supplementary Figure 349. 19F NMR spectrum of compound 24 (376 MHz, CDCl₃)




Supplementary Figure 350. ¹³C NMR spectrum of compound 24 (101 MHz, CDCl₃)




Supplementary Figure 351. 1H NMR spectrum of (4-chlorophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 352. ¹³C NMR spectrum of (4-chlorophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 353. ¹H NMR spectrum of compound 25 (400 MHz, CDCl₃)




Supplementary Figure 354. ¹⁹F NMR spectrum of compound 25 (376 MHz, CDCl₃)




Supplementary Figure 355. ¹³C NMR spectrum of compound 25 (101 MHz, CDCl₃)




Supplementary Figure 356. ¹H NMR spectrum of (2-bromophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 357. ¹³C NMR spectrum of (2-bromophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 358. ¹H NMR spectrum of compound 26 (400 MHz, CDCl₃)




Supplementary Figure 359. ¹⁹F NMR spectrum of compound 26 (376 MHz, CDCl₃)




Supplementary Figure 360. ¹³C NMR spectrum of compound 26 (101 MHz, CDCl₃)




Supplementary Figure 361. ¹H NMR spectrum of compound 27 (400 MHz, CDCl₃)




Supplementary Figure 362. ¹⁹F NMR spectrum of compound 27 (376 MHz, CDCl₃)




Supplementary Figure 363. ¹³C NMR spectrum of compound 27 (101 MHz, CDCl₃)




Supplementary Figure 364. ¹H NMR spectrum of (4-methylbenzenesulfonate)(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 365. ¹³C NMR spectrum of (4-methylbenzenesulfonate)(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 366. ¹H NMR spectrum of compound 28 (400 MHz, CDCl₃)




Supplementary Figure 367. ¹⁹F NMR spectrum of compound 28 (376 MHz, CDCl₃)




Supplementary Figure 368. ¹³C NMR spectrum of compound 28 (101 MHz, CDCl₃)




Supplementary Figure 369. ¹H NMR spectrum of **4-nitrophenyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide** (400 MHz, CDCl₃)




Supplementary Figure 370. ¹³C NMR spectrum of **4-nitrophenyl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide** (101 MHz, CDCl₃)




Supplementary Figure 371. ¹H NMR spectrum of compound 29 (400 MHz, CDCl₃)




Supplementary Figure 372. ¹⁹F NMR spectrum of compound 29 (376 MHz, CDCl₃)




Supplementary Figure 373. ¹³C NMR spectrum of compound 29 (101 MHz, CDCl₃)




Supplementary Figure 374. ¹H NMR spectrum of **(4-ethoxycarbonylphenyl)(mesityl)iodonium tosylate** (400 MHz, CDCl₃)




Supplementary Figure 375. ¹³C NMR spectrum of **(4-ethoxycarbonylphenyl)(mesityl)iodonium tosylate** (101 MHz, CDCl₃)




Supplementary Figure 376. ¹H NMR spectrum of compound 30 (400 MHz, CDCl₃)




Supplementary Figure 377. ¹⁹F NMR spectrum of compound 30 (376 MHz, CDCl₃)




Supplementary Figure 378. ¹³C NMR spectrum of compound 30 (101 MHz, CDCl₃)




Supplementary Figure 379. 1H NMR spectrum of (4-Cyanophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 380. ¹³C NMR spectrum of (4-Cyanophenyl)(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 381. ¹H NMR spectrum of compound 31 (400 MHz, CDCl₃)




Supplementary Figure 382. ¹⁹F NMR spectrum of compound 31 (376 MHz, CDCl₃)




Supplementary Figure 383. ¹³C NMR spectrum of compound 31 (101 MHz, CDCl₃)




Supplementary Figure 384. ¹H NMR spectrum of (3-cyanophenyl) (2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 385. ¹³C NMR spectrum of (3-cyanophenyl) (2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)




Supplementary Figure 386. ¹H NMR spectrum of compound 32 (400 MHz, CDCl₃)




Supplementary Figure 387. ¹⁹F NMR spectrum of compound 32 (376 MHz, CDCl₃)




Supplementary Figure 388. ¹³C NMR spectrum of compound 32 (101 MHz, CDCl₃)




Supplementary Figure 389. 1H NMR spectrum of (3-chloro-4-(methoxycarbonyl)phenyl)(2,4,6-trimethoxyphenyl) tosylate (400 MHz, CDCl₃)




Supplementary Figure 390. 13 C NMR spectrum of (3-chloro-4-(methoxycarbonyl)phenyl)(2,4,6-trimethoxyphenyl) tosylate (101 MHz, CDCl₃)




Supplementary Figure 391. ¹H NMR spectrum of compound 33 (400 MHz, CDCl₃)




Supplementary Figure 392. ¹⁹F NMR spectrum of compound 33 (376 MHz, CDCl₃)



Supplementary Figure 393. ¹³C NMR spectrum of compound 33 (101 MHz, CDCl₃)




Supplementary Figure 394. ¹H NMR spectrum of naphthalen-2-yl(2,4,6-trimethoxyphenyl)iodonium tosylate (400 MHz, CDCl₃)




Supplementary Figure 395. ¹³C NMR spectrum of naphthalen-2-yl(2,4,6-trimethoxyphenyl)iodonium tosylate (101 MHz, CDCl₃)







Supplementary Figure 396. ¹H NMR spectrum of compound 34 (400 MHz, CDCl₃)




Supplementary Figure 397. ¹⁹F NMR spectrum of compound 34 (376 MHz, CDCl₃)




Supplementary Figure 398. ¹³C NMR spectrum of compound 34 (101 MHz, CDCl₃)




Supplementary Figure 399. ¹H NMR spectrum of (quinolin-6-yl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (400 MHz, CDCl₃)




Supplementary Figure 400. ¹³C NMR spectrum of (quinolin-6-yl)iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (101 MHz, CDCl₃)




Supplementary Figure 401. ¹H NMR spectrum of compound 35 (400 MHz, CDCl₃)




Supplementary Figure 402. ¹⁹F NMR spectrum of compound 35 (376 MHz, CDCl₃)




Supplementary Figure 403. ¹³C NMR spectrum of compound 35 (101 MHz, CDCl₃)




Supplementary Figure 404. ¹H NMR spectrum of (*R*)-5-((4-Chloro-3-(4-((tetrahydrofuran-3-yl)oxy)benzoyl)phenyl) iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (400 MHz, CDCl₃)




Supplementary Figure 405. ¹³C NMR spectrum of (*R*)-5-((4-Chloro-3-(4-((tetrahydrofuran-3-yl)oxy)benzoyl)phenyl) iodonium-(2,2-dimethyl-1,3-dioxane-4,6-dione)ylide (101 MHz, CDCl₃)




Supplementary Figure 406. ¹H NMR spectrum of compound 36 (400 MHz, CDCl₃)




Supplementary Figure 407. ¹⁹F NMR spectrum of compound 36 (376 MHz, CDCl₃)




Supplementary Figure 408. ¹³C NMR spectrum of compound 36 (101 MHz, CDCl₃)




Supplementary Figure 409. ¹H NMR spectrum of compound 37 (400 MHz, CDCl₃)




Supplementary Figure 410. ¹⁹F NMR spectrum of compound 37 (376 MHz, CDCl₃)




Supplementary Figure 411. ¹³C NMR spectrum of compound 37 (101 MHz, CDCl₃)




Supplementary Figure 412. ¹H NMR spectrum of **(3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol** (400 MHz, CDCl₃)




Supplementary Figure 413. ¹⁹F NMR spectrum of **(3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol** (376 MHz, CDCl₃)




Supplementary Figure 414. 13 C NMR spectrum of (3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (101 MHz, CDCl₃)




Supplementary Figure 415. ¹H NMR spectrum of compound 38 (400 MHz, CDCI₃)




Supplementary Figure 416. ¹⁹F NMR spectrum of compound 38 (376 MHz, CDCl₃)




Supplementary Figure 417. ¹³C NMR spectrum of compound 38 (101 MHz, CDCl₃)




Supplementary Figure 418. ¹H NMR spectrum of **3-(1,3-dioxoisoindolin-2-yl)propyl 4-methylbenzenesulfonate** (400 MHz, CDCl₃)




Supplementary Figure 419. 13 C NMR spectrum of 3-(1,3-dioxoisoindolin-2-yl)propyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 420. ¹H NMR spectrum of compound 39 (400 MHz, CDCl₃)




Supplementary Figure 421. ¹⁹F NMR spectrum of compound 39 (376 MHz, CDCl₃)




Supplementary Figure 422. ¹³C NMR spectrum of compound 39 (101 MHz, CDCl₃)




Supplementary Figure 423. ¹H NMR spectrum of **2-(2-(benzyloxy)ethoxy)ethyl 4 methylbenzenesulfonate** (400 MHz, CDCI₃)




Supplementary Figure 424. 13 C NMR spectrum of 2-(2-(benzyloxy)ethoxy)ethyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 425. ¹H NMR spectrum of compound 40 (400 MHz, CDCI₃)




Supplementary Figure 426. ¹⁹F NMR spectrum of compound 40 (376 MHz, CDCl₃)




Supplementary Figure 427. ¹³C NMR spectrum of compound 40 (101 MHz, CDCl₃)




Supplementary Figure 428. ¹H NMR spectrum of compound 41 (400 MHz, CDCl₃)




Supplementary Figure 429. ¹⁹F NMR spectrum of compound 41 (376 MHz, CDCl₃)




Supplementary Figure 430. ¹³C NMR spectrum of compound 41 (101 MHz, CDCl₃)




Supplementary Figure 431. ¹H NMR spectrum of compound 42 (400 MHz, CDCl₃)




Supplementary Figure 432. ¹⁹F NMR spectrum of compound 42 (376 MHz, CDCl₃)




Supplementary Figure 433. ¹³C NMR spectrum of compound 42 (101 MHz, CDCl₃)




Supplementary Figure 434. 1H NMR spectrum of 2-(4-chloro-2-methylphenoxy)ethan-1-ol (400 MHz, CDCl₃)




Supplementary Figure 435. 13 C NMR spectrum of 2-(4-chloro-2-methylphenoxy)ethan-1-ol (101 MHz, CDCl₃)




Supplementary Figure 436. ¹H NMR spectrum of **2-(4-chloro-2-methylphenoxy)ethyl 4-methylbenzenesulfonate** (400 MHz, CDCl₃)




Supplementary Figure 437. 13 C NMR spectrum of 2-(4-chloro-2-methylphenoxy)ethyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 438. ¹H NMR spectrum of compound 43 (400 MHz, CDCl₃)




Supplementary Figure 439. ¹⁹F NMR spectrum of compound 43 (376 MHz, CDCl₃)




Supplementary Figure 440. ¹³C NMR spectrum of compound 43 (101 MHz, CDCl₃)




Supplementary Figure 441. 1 H NMR spectrum of 3-(benzo[d][1,3]dioxol-5-yl)-2-methylpropan-1-ol (400 MHz, CDCl₃)




Supplementary Figure 442. ¹³C NMR spectrum of **3-(benzo[***d***][1,3]dioxol-5-yl)-2-methylpropan-1-ol** (101 MHz, CDCl₃)




Supplementary Figure 443. 1H NMR spectrum of 3-(benzo[d][1,3]dioxol-5-yl)-2-methylpropyl 4-methylbenzenesulfonate (400 MHz, CDCl₃)




Supplementary Figure 444. ¹³C NMR spectrum of **3-(benzo[d][1,3]dioxol-5-yl)-2-methylpropyl** 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 445. ¹H NMR spectrum of compound 44 (400 MHz, CDCI₃)




Supplementary Figure 446. ¹⁹F NMR spectrum of compound 44 (376 MHz, CDCl₃)




Supplementary Figure 447. ¹³C NMR spectrum of compound 44 (101 MHz, CDCl₃)




Supplementary Figure 448. ¹H NMR spectrum of compound 45 (400 MHz, CDCl₃)




Supplementary Figure 449. ¹⁹F NMR spectrum of compound 45 (376 MHz, CDCl₃)




Supplementary Figure 450. ¹³C NMR spectrum of compound 45 (101 MHz, CDCl₃)




Supplementary Figure 451. ¹H NMR spectrum of compound 46 (400 MHz, CDCl₃)




Supplementary Figure 452. ¹⁹F NMR spectrum of compound 46 (376 MHz, CDCl₃)




Supplementary Figure 453. ¹³C NMR spectrum of compound 46 (101 MHz, CDCl₃)




Supplementary Figure 454. ¹H NMR spectrum of **(3-(5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol** (400 MHz, CDCl₃)




Supplementary Figure 455. ¹³C NMR spectrum of (3-(5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl)phenyl)methanol (101 MHz, CDCl₃)




Supplementary Figure 456. ¹H NMR spectrum of **3-(3-(bromomethyl)phenyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole** (400 MHz, CDCl₃)




Supplementary Figure 457. ¹³C NMR spectrum of **3-(3-(bromomethyl)phenyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole** (101 MHz, CDCl₃)




Supplementary Figure 458. ¹H NMR spectrum of compound 47 (400 MHz, CDCl₃)




Supplementary Figure 459. ¹⁹F NMR spectrum of compound 47 (376 MHz, CDCl₃)




Supplementary Figure 460. ¹³C NMR spectrum of compound 47 (101 MHz, CDCl₃)




Supplementary Figure 461. ¹H NMR spectrum of compound 48 (400 MHz, CDCl₃)




Supplementary Figure 462. ¹⁹F NMR spectrum of compound 48 (376 MHz, CDCl₃)




Supplementary Figure 463. ¹³C NMR spectrum of compound 48 (101 MHz, CDCl₃)




Supplementary Figure 464. 1 H NMR spectrum of 2-(1-benzyl-1*H*-indazol-3-yloxy)ethanol (400 MHz, CDCl₃)




Supplementary Figure 465. 13 C NMR spectrum of 2-(1-benzyl-1*H*-indazol-3-yloxy)ethanol (101 MHz, CDCl₃)




Supplementary Figure 466. ¹H NMR spectrum of **2-(1-benzyl-1***H***-indazol-3-yloxy)ethyl 4-methylbenzenesulfonate** (400 MHz, CDCl₃)




Supplementary Figure 467. 13 C NMR spectrum of 2-(1-benzyl-1*H*-indazol-3-yloxy)ethyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 468. ¹H NMR spectrum of compound 49 (400 MHz, CDCl₃)




Supplementary Figure 469. ¹⁹F NMR spectrum of compound 49 (376 MHz, CDCl₃)




Supplementary Figure 470. ¹³C NMR spectrum of compound 49 (101 MHz, CDCl₃)




Supplementary Figure 471. ¹H NMR spectrum of ((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5,6-tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methyl 4-methylbenzenesulfonate (400 MHz, CDCl₃)




Supplementary Figure 472. ¹³C NMR spectrum of ((2*R*,3*R*,4*S*,5*R*,6*S*)-3,4,5,6-tetrakis(benzyloxy)tetrahydro-2*H*-pyran-2-yl)methyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 473. ¹H NMR spectrum of compound 50 (400 MHz, CDCl₃)




Supplementary Figure 474. ¹⁹F NMR spectrum of compound 50 (376 MHz, CDCl₃)




Supplementary Figure 475. ¹³C NMR spectrum of compound 50 (101 MHz, CDCl₃)




Supplementary Figure 476. ¹H NMR spectrum of **5-(5-(hydroxymethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile** (400 MHz, CDCl₃)




Supplementary Figure 477. ¹³C NMR spectrum of **5-(5-(hydroxymethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile** (101 MHz, CDCl₃)




Supplementary Figure 478. ¹H NMR spectrum of **5-(5-(bromomethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile** (400 MHz, CDCl₃)




Supplementary Figure 479. 13 C NMR spectrum of 5-(5-(bromomethyl)-4-methylthiazol-2-yl)-2-isobutoxybenzonitrile (101 MHz, CDCl₃)




Supplementary Figure 480. ¹H NMR spectrum of compound 51 (400 MHz, CDCl₃)




Supplementary Figure 481. 19F NMR spectrum of compound 51 (376 MHz, CDCl₃)




Supplementary Figure 482. ¹³C NMR spectrum of compound 51 (101 MHz, CDCl₃)




Supplementary Figure 483. ¹H NMR spectrum of compound 52 (400 MHz, CDCl₃)




Supplementary Figure 484. ^{19}F NMR spectrum of compound 52 (376 MHz, CDCl₃)




Supplementary Figure 485. ¹³C NMR spectrum of compound 52 (101 MHz, CDCl₃)




Supplementary Figure 486. 1 H NMR spectrum of 3-(4,5-diphenyloxazol-2-yl)propan-1-ol (400 MHz, CDCl₃)




Supplementary Figure 487. 13 C NMR spectrum of 3-(4,5-diphenyloxazol-2-yl)propan-1-ol (101 MHz, CDCl₃)




Supplementary Figure 488. ¹H NMR spectrum of **3-(4,5-diphenyloxazol-2-yl)propyl 4-methylbenzenesulfonate** (400 MHz, CDCl₃)




Supplementary Figure 489. 13 C NMR spectrum of 3-(4,5-diphenyloxazol-2-yl)propyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 490. ¹H NMR spectrum of compound 53 (400 MHz, CDCl₃)




Supplementary Figure 491. ¹⁹F NMR spectrum of compound 53 (376 MHz, CDCl₃)




Supplementary Figure 492. ¹³C NMR spectrum of compound 53 (101 MHz, CDCl₃)




Supplementary Figure 493. 1H NMR spectrum of (*Z*)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethan-1-ol (400 MHz, CDCl₃)




Supplementary Figure 494. ¹³C NMR spectrum of **(Z)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethan-1-ol** (101 MHz, CDCl₃)




Supplementary Figure 495. ¹H NMR spectrum of (*Z*)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethyl 4-methylbenzenesulfonate (400 MHz, CDCl₃)




Supplementary Figure 496. ¹³C NMR spectrum of (*Z*)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)ethyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 497. ¹H NMR spectrum of compound 54 (400 MHz, CDCl₃)




Supplementary Figure 498. ¹⁹F NMR spectrum of compound 54 (376 MHz, CDCl₃)




Supplementary Figure 499. ¹³C NMR spectrum of compound 54 (101 MHz, CDCl₃)




Supplementary Figure 500. ¹H NMR spectrum of **(E)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethanol** (400 MHz, CDCl₃)




Supplementary Figure 501. ¹³C NMR spectrum of **(E)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethoxy)ethanol** (101 MHz, CDCl₃)




Supplementary Figure 502. ¹H NMR spectrum of (*E*)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (400 MHz, CDCl₃)




Supplementary Figure 503. ¹³C NMR spectrum of (*E*)-2-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 504. ¹H NMR spectrum of compound 55 (400 MHz, CDCl₃)




Supplementary Figure 505. ¹⁹F NMR spectrum of compound 55 (376 MHz, CDCl₃)




Supplementary Figure 506. ¹³C NMR spectrum of compound 55 (101 MHz, CDCl₃)




Supplementary Figure 507. 1H NMR spectrum of (R)-3-fluoro-4-(4-(1-hydroxypropan-2-yloxy)phenoxy)benzonitrile (4H 00 MHz, CDCI $_3$)




Supplementary Figure 508. 19 F NMR spectrum of (*R*)-3-fluoro-4-(4-(1-hydroxypropan-2-yloxy)phenoxy)benzonitrile (376 MHz, CDCl₃)




Supplementary Figure 509. 13 C NMR spectrum of (*R*)-3-fluoro-4-(4-(1-hydroxypropan-2-yloxy)phenoxy)benzonitrile (101 MHz, CDCl₃)




Supplementary Figure 510. ¹H NMR spectrum of (*R*)-2-(4-(4-Cyano-2-fluorophenoxy)phenoxy)propyl 4-methylbenzenesulfonate (400 MHz, CDCl₃)




Supplementary Figure 511. ¹⁹F NMR spectrum of (*R*)-2-(4-(4-Cyano-2-fluorophenoxy)phenoxy)propyl 4-methylbenzenesulfonate (376 MHz, CDCl₃)




Supplementary Figure 512. ¹³C NMR spectrum of (*R*)-2-(4-(4-Cyano-2-fluorophenoxy)phenoxy)propyl 4-methylbenzenesulfonate (101 MHz, CDCl₃)




Supplementary Figure 513. ¹H NMR spectrum of compound 56 (400 MHz, CDCl₃)




Supplementary Figure 514. 19F NMR spectrum of compound 56 (376 MHz, CDCl₃)




Supplementary Figure 515. ¹³C NMR spectrum of compound 56 (101 MHz, CDCl₃)




Supplementary Figure 516. ¹H NMR spectrum of **2-(1,5-bis(4-methoxyphenyl)-1***H***-1,2,4-triazol-3-yloxy)ethanol** (400 MHz, CDCl₃)




Supplementary Figure 517. 13 C NMR spectrum of 2-(1,5-bis(4-methoxyphenyl)-1*H*-1,2,4-triazol-3-yloxy)ethanol (101 MHz, CDCl₃)




Supplementary Figure 518. ¹H NMR spectrum of **2-(1,5-bis(4-methoxyphenyl)-1***H***-1,2,4-triazol-3-yloxy)ethyl 4-methylbenzenesulfonate** (400 MHz, CDCl₃)




Supplementary Figure 519. ¹³C NMR spectrum of **2-(1,5-bis(4-methoxyphenyl)-1***H***-1,2,4-triazol-3-yloxy)ethyl 4-methylbenzenesulfonate** (101 MHz, CDCl₃)




Supplementary Figure 520. ¹H NMR spectrum of compound 57 (400 MHz, CDCl₃)




Supplementary Figure 521. ¹⁹F NMR spectrum of compound 57 (376 MHz, CDCl₃)




Supplementary Figure 522. ¹³C NMR spectrum of compound 57 (101 MHz, CDCl₃)




Supplementary Figure 523. 1 H NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1,1- d_2)ethoxy)-1H-1,2,4-triazole (400 MHz, CDCl₃)




Supplementary Figure 524. ^{19}F NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1,1- d_2)ethoxy)-1H-1,2,4-triazole (376 MHz, CDCl₃)




Supplementary Figure 525. 13 C NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1,1- d_2)ethoxy)-1H-1,2,4-triazole (101 MHz, CDCl₃)



Supplementary Figure 526. ¹H NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1-¹³C)ethoxy)-1*H*-1,2,4-triazole (400 MHz, CDCl₃)



Supplementary Figure 527. 19 F NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1- 13 C)ethoxy)-1*H*-1,2,4-triazole (376 MHz, CDCl₃)



Supplementary Figure 528. 13 C NMR spectrum of 1,5-bis(4-methoxyphenyl)-3-(2-(2,2,2-trifluoroethoxy-1- 13 C)ethoxy)-1H-1,2,4-triazole (101 MHz, CDCl₃)

Supplementary References

- 1. Andrew, G., Brian, M., Gabriel, M. B., Kiran, R. & Marion, W. *U.S. Patent* 62677903, (2018).
- 2. Nilova, A., Metze, B. & Stuart, D. R. Aryl(TMP)iodonium tosylate reagents as a strategic entry point to diverse aryl intermediates: selective access to arynes. *Org. Lett.* **23**, *4813* (2021).
- 3. Rotstein, B. H., Wang, Lu., Liu, R. Y., Patteson, J., Kwan, E. E., Vasdev, N. & Liang, S. H. Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(iii) ylides. *Chem. Sci.* **7**, *4407* (2016).
- Chen, Z. X., Jiang, Y. W., Zhang, L., Guo, Y. L. & Ma, D. W. Oxalic diamides and tert-butoxide: two types of ligands enabling practical access to alkyl aryl ethers via Cu-catalyzed coupling reaction *J. Am. Chem. Soc.* 141, 3541 (2019).
- Yang, Q. L. & Njardarson, J. T. Base mediated deprotection strategies for trifluoroethyl (TFE) ethers, a new alcohol protecting group. *Tetrahedron Lett.* 54, 7080 (2013).
- 6. Kamal, A., Pratap, T. B., Ramana, K. V., Ramana, A. V. & Babu, A. H. Facile and efficient synthesis of fluoroalkyl aryl ethers. *Tetrahedron Lett.* **43**, 7353 (2002).
- 7. Tan, X. Q., Liu, Z. L., Shen, H. G., Zhang, P., Zhang, Z. Z. & Li, C. Z. Trifluoromethylation of alkyl radicals in aqueous solution. *J. Am. Chem. Soc.* **139**, 12430 (2017).
- Chiu, G., Li, S. J., Connolly, P. J., Pulito, V., Liu, J. C. & Middleton, S. A. (Phenylpiperidinyl)cyclohexylsulfonamides: development of α_{1a/1d}-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS). *Bioorg. Med. Chem. Lett.* 17, 3930 (2007).
- 9. Zhang, K., Xu, X. H. & Qing, F. L. Copper-catalyzed oxidative trifluoroethoxylation of aryl boronic acids with CF₃CH₂OH. *J. Fluorine Chem.* **196**, 24 (2017).
- 10. Huang, R. L., Huang, Y. J., Lin, X. X., Rong, M. G. & Weng, Z. Q. Well-defined copper(I) fluoroalkoxide complexes for trifluoroethoxylation of aryl and heteroaryl bromides. *Angew. Chem. Int. Ed.* **54**, *5736* (2015).

- 11. Idoux, J. P., Madenwald, M. L., Garcia, B. S., Chu, D. L. & Gupton, J. T. Aromatic fluoroalkoxylation via direct displacement of a nitro or fluoro group. *J. Org. Chem.* 50, 1876 (1985).
- 12. Scott D. L., Richard, N., Kim, H., Dylan, K. & Erika Mathes, L. *U.S. Patent* 16376349, (2019).
- 13. Haskali, M. B. & Pike, V. W. [¹¹C]Fluoroform, a breakthrough for versatile labeling of PET radiotracer trifluoromethyl groups in high molar activity. *Chem. Eur. J.* **23**, *8156* (2017).
- 14. van der Born, D., Sewing, C., Herscheid, J. D. M., Windhorst, A. D., Orru, R. V. & Vugts, D. J. A universal procedure for the [18F]trifluoromethylation of aryl iodides and aryl boronic acids with highly improved specific activity. *Angew. Chem. Int. Ed.* **53**, *11046* (2014).